Modified DNASE enzymes and their therapeutic uses

Modified DNase1-like 3 enzymes with specific modifications address the limitations of existing DNases by enhancing stability and activity, effectively degrading NETs and preventing vascular occlusion.

JP7577314B2Active Publication Date: 2024-11-05NEUTROLIS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2020531567
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-12-28
Filing Date
2018-08-20
Publication Date
2024-11-05
Estimated Expiration
2038-08-20

AI Technical Summary

Technical Problem

Existing DNase enzymes, such as DNase1 and DNase1-like 3, have suboptimal physical, enzymatic, and pharmacokinetic properties for therapeutic use, particularly in degrading neutrophil extracellular traps (NETs), which can lead to uncontrolled inflammation and vascular occlusion.

Method used

Modified DNase1-like 3 (D1L3) variants with specific amino acid changes, such as glycosylation, inactivation of nuclear localization signals, and C-terminal tail deletions, enhance protein stability, protease resistance, and bioavailability, enabling effective NET degradation.

Benefits of technology

The modified D1L3 variants demonstrate improved DNA and chromatin degradation activities, increased circulation half-life, and enhanced therapeutic efficacy in preventing or treating vascular occlusion and other NET-related conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577314000033
    Figure 0007577314000033
  • Figure 0007577314000034
    Figure 0007577314000034
  • Figure 0007577314000035
    Figure 0007577314000035
Patent Text Reader

Abstract

The present invention provides modified DNase proteins (including DNase 1-like 3 and DNase 1) useful in treating conditions characterized by the accumulation and / or release of neutrophil extracellular traps (NETs). In some aspects, the present invention provides compositions and methods for preventing or treating NET-related vascular occlusion. As demonstrated herein, NETs are involved in a non-canonical mechanism of vascular occlusion and are fibrin- or platelet-independent. [Selected Figure] Figure 1A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Priority This application claims the benefit of and priority to U.S. Application No. 62 / 611,166, filed December 28, 2017, and U.S. Application No. 62 / 547,220, filed August 18, 2017. [Background technology]

[0002] Inflammation is an essential host response to control invading microorganisms and heal damaged tissues. Uncontrolled and persistent inflammation causes tissue damage in excessive inflammatory diseases. Neutrophils are the primary leukocytes in acute inflammation. During infection, neutrophils generate neutrophil extracellular traps (NETs), lattices of DNA filaments decorated with toxic histones and enzymes that immobilize and neutralize bacteria. The relevance of NETs in host protection is illustrated by the fact that extracellular DNase functions as a virulence factor for several pathogenic bacteria. However, inappropriately released NETs can harm host cells due to their cytotoxic, proinflammatory, and thrombotic activities. Indeed, NETs are frequently associated with inflammatory or ischemic organ injury, and therapeutic infusion of DNase has limited host damage in various animal models.

[0003] Extracellular trap (ET) formation is not limited to neutrophils, as other leukocytes, namely monocytes, macrophages, basophils, eosinophils, and mast cells, also release ET. Furthermore, cancer cells, including acute promyelocytic leukemia (APL) cells, and damaged endothelial cells can expose DNA filaments with ET-like characteristics.

[0004] How the host degrades NETs in vivo to limit tissue damage during inflammatory episodes is poorly understood. DNase1 (D1) in serum has been shown to digest the DNA backbone of NETs in vitro. Other extracellular DNases have been identified, such as circulating DNase1-like 3 (D1L3), that can digest extracellular particulate-associated chromatin.

[0005] D1 and D1L3, together with DNase1-like 1 (D1L1) and DNase1-like 2 (D1L2), form the DNase1 protein family, a group of homologous secreted DNase enzymes that are expressed in humans and are potential drug candidates for NET-related diseases. However, the physical, enzymatic and pharmacokinetic properties of these enzymes are not ideal for therapy.

[0006] The present invention provides modified DNases, including DNase 1-like 3 and DNase 1, for therapies including preventing or treating vascular occlusion that may result from the release of NETs during acute inflammatory episodes. Summary of the Invention

[0007] The present invention provides modified DNase proteins (including DNase 1-like 3 and DNase 1) useful in treating conditions characterized by the accumulation and / or release of neutrophil extracellular traps (NETs). In some aspects, the present invention provides compositions and methods for preventing or treating NET-related vascular occlusion. As shown herein, NETs are involved in a non-canonical mechanism of vascular occlusion and are fibrin and platelet independent.

[0008] In some aspects, the invention provides DNase 1-like 3 (D1L3) variants that have been modified to have physical, pharmacodynamic, and / or enzymatic properties that are more suitable for treatment, e.g., to reduce or prevent NET accumulation in a subject. In some embodiments, the D1L3 enzyme has manufacturing advantages, providing for the production of recombinant enzyme suitable for therapeutic use. In various embodiments, the invention provides recombinant D1L3 variants with one or more amino acid changes that result in one or more glycosylations, inactivation of the nuclear localization signal, and / or deletion of all or part of the C-terminal tail.

[0009] In various embodiments, the D1L3 protein variants have increased protein stability, increased resistance to inhibition by proteases, increased bioavailability, and substantially the same or better DNA and / or chromatin and / or NET degrading activity (in vitro or in vivo) compared to wild-type D1L3 protein. In various embodiments, the D1L3 variants include one or more of the following properties compared to wild-type D1L3 (e.g., SEQ ID NO: 2): equivalent or substantially equivalent (or higher) protein-free DNA (naked DNA) degrading activity, equivalent or substantially equivalent (or higher) chromosomal DNA (chromatin) degrading activity, protease resistance, increased circulating half-life, and higher production levels in in vitro expression systems (e.g., Chinese hamster ovary cells and / or Pichia pastoris).

[0010] In some embodiments, the D1L3 variant comprises one or more block substitutions from human DNase 1 (SEQ ID NO:1), described herein as building block substitutions.

[0011] In some aspects, the invention provides modified DNase1 (D1) variants to have physical, pharmacodynamic, and / or enzymatic properties that make them more suitable for therapy, for example, to reduce or prevent NET accumulation in a subject. In some embodiments, the D1 enzyme has manufacturing advantages and provides for the production of recombinant enzymes suitable for therapeutic use. In various embodiments, the modified D1 variants have an amino acid sequence that is at least 80% identical to the mature enzyme of the amino acid sequence of SEQ ID NO:1 and includes one or more amino acid substitutions, additions (including insertions), or deletions that result in one or more of a mutant DNA binding site, a mutant chromatin binding site, a mutant actin binding site, a mutant glycosylation site, the addition of a nuclear localization signal (e.g., similarity or identity to NLS1 or NLS2 of D1L3), and / or a C-terminal domain similar or identical to the C-terminal tail of D1L3.

[0012] In various embodiments, the D1 variants are engineered to include one or more of the following characteristics relative to the wild-type enzyme: similar or higher protein-free DNA (naked DNA) degrading activity, higher chromosomal DNA (chromatin) degrading activity, similar or improved protease resistance, actin resistance, similar or improved penetration from blood into urine and / or bile, and higher production levels in in vitro expression systems (e.g., Chinese hamster ovary cells and / or Pichia pastoris).

[0013] The D1 variants described herein may have a combination of point mutations, including the addition of cationic residues, and / or may contain one or more block substitutions from D1L3 (SEQ ID NO: 2). Such block substitutions are described herein and are referred to as "building block substitutions."

[0014] In some aspects, the invention provides pharmaceutical compositions comprising D1L3 and / or D1 variants, or a polynucleotide or vector encoding same, and a pharma- ceutically acceptable carrier. In various embodiments, the compositions are formulated for parenteral or pulmonary administration. In some embodiments, the compositions are formulated for intravenous, intraarterial, intraperitoneal, intraarticular, intramuscular, topical, or subcutaneous administration. In some embodiments, the compositions comprise both D1L3 and D1, each of which is optionally a modified variant as described herein. In some embodiments, the compositions comprise chimeric proteins comprising block sequences from both D1 and D1L3. Exemplary block substitutions between D1 and D1L3 are shown in FIG. 31.

[0015] In yet other aspects, the present invention provides a process for DNase enzyme modification by generating chimeric sequences. For example, in these aspects, the method includes providing a protein-protein alignment of donor and recipient DNase enzymes; identifying variable amino acid sequences ("building blocks") for transfer. One or more variable amino acids are adjacent to one or more conserved amino acids of the donor and recipient DNase enzymes (upstream and downstream of the building blocks). These building blocks can be exchanged between the recipient and donor proteins. The chimeric enzyme is then recombinantly produced.

[0016] In yet another aspect, the invention provides a method for producing a pharmaceutical composition for reducing or preventing the accumulation of neutrophil extracellular traps (NETs). In these embodiments, the invention uses genetically modified mice that are deficient in D1 and D1L3 activity, and heterologous expression of G-CSF polynucleotides (e.g., in hepatocytes), or induction of sustained endogenous G-CSF expression (e.g., by repeated administration of a microbial compound). The mouse models accumulate NETs and rapidly develop NET-associated vascular occlusion. In these embodiments, the invention includes administering a candidate NET inhibitor or candidate DNase enzyme (including a D1L3 or D1 variant according to the present disclosure) to the genetically modified mice to select a NET inhibitor or DNase enzyme that reduces the accumulation of NETs. The selected inhibitor or enzyme is formulated for administration to a human patient.

[0017] In some aspects, the present invention provides a method for treating a subject in need of neutrophil extracellular trap (NET) degradation. The method comprises administering a therapeutically effective amount of D1L3 and / or D1, and / or variants thereof according to the present disclosure. D1L3 or D1 variants may be administered as a pharmaceutical composition comprising recombinant protein, or in some embodiments, DNA or RNA encoding, or in some embodiments, a vector comprising same.

[0018] In various embodiments, the invention relates to the treatment of diseases or conditions characterized by the presence or accumulation of NETs, ​​such as chronic neutrophilia (e.g., elevated neutrophil counts), neutrophil aggregation and leukostasis, thrombosis and vascular occlusion (e.g., sickle cell disease), ischemia-reperfusion injury (e.g., intestinal volvulus, testicular torsion, limb ischemia-reperfusion, vital organ ischemia-reperfusion, organ transplant), surgical and traumatic tissue injury, acute or chronic inflammatory responses or conditions, autoimmune diseases (e.g., systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis, vasculitis, systemic sclerosis), cardiovascular diseases (e.g., myocardial infarction, stroke, atherosclerosis, venous thromboembolism including thrombolytic therapy), metabolic diseases (e.g., diabetes), systemic inflammation (e.g., systemic inflammatory responses, These include, but are not limited to, inflammatory diseases of the airways (e.g., cystic fibrosis, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), smoking-related lung injury, transfusion-associated acute lung injury (TRALI), acute respiratory distress syndrome (ARDS), and asthma, atelectasis, bronchitis, empyema), renal inflammatory diseases (acute and chronic kidney disease, including acute kidney injury (AKI) and chronic kidney disease (CKD), inflammatory diseases associated with transplanted tissues (e.g., graft-versus-host disease), and diseases associated with cancer (e.g., leukemia, tumor metastasis, and solid tumors).

[0019] In some embodiments, the subject has or is at risk of having ductal blockage in the ductal system.Non-limiting examples of ductal systems or organs or tissues that contain ductal systems include bile duct, lacrimal duct, lactiferous duct, cystic duct, hepatic duct, ejaculatory duct, parotid duct, submandibular duct, greater sublingual duct, Bartholin's duct, aqueduct of the cerebral aqueduct, pancreas, mammary gland, vas deferens, ureter, bladder, gallbladder, and liver.Thus, the present invention is useful for treating subjects with pancreatitis, cholangitis, conjunctivitis, mastitis, dry eye disease, blockage of the ductus deferens, or kidney disease.

[0020] In other embodiments, the subject has or is at risk of NETs accumulating on endothelial surfaces (e.g., post-surgical adhesions), skin (e.g., wounds / scars, ulcers), or synovial joints (e.g., gout, arthritis). For example, NETs contribute to post-surgical adhesions, for example, after invasive medical procedures. The present invention can be administered during surgery to prevent or inhibit the formation of post-surgical adhesions. In some cases, D1, D1L3 (including variants thereof), or a combination of D1 and D1L3 (or variants thereof) as outlined herein can be administered topically to the skin to prevent or treat wounds and / or scars. In other examples, D1, D1L3, or variants, or combinations thereof as outlined herein can be administered to synovial joints to prevent or treat gout and arthritis.

[0021] In some embodiments, the subject has or is at risk for having a vascular obstruction involving a NET.

[0022] In various embodiments, the present invention relates to the treatment of diseases treatable with DNase enzymes, including D1 and streptodornase, such as thrombosis, stroke, sepsis, lung injury, atherosclerosis, viral infections, sickle cell disease, myocardial infarction, ear infections, wound healing, liver injury, endocarditis, liver infections, pancreatitis, primary graft failure, limb ischemia-reperfusion injury, kidney injury, blood clotting, alum-induced inflammation, hepatorenal injury, pleural effusion, hemothorax, intrabiliary clots, post-pneumonic anemia, ulcers, ear, nose and throat conditions, and oral infections. , minor injuries, sinusitis, post-operative rhinoplasty, infertility, bladder catheters, wound irrigation, skin reaction tests, pneumococcal meningitis, gout, leg ulcers, cystic fibrosis, Kartegener's syndrome, asthma, lobar atelectasis, chronic bronchitis, bronchiectasis, lupus, primary ciliary dyskinesia, bronchiolitis, empyema, pleural infections, cancer, dry eye disease, lower respiratory tract infections, chronic hematomas, Alzheimer's disease, and obstructive pulmonary disease.

[0023] In yet other embodiments, the present invention provides methods for recombinant production of D1 or D1L3, or variants thereof, using non-mammalian expression systems, such as Pichia pastoris, which in some embodiments encodes a DNase enzyme with a native signal peptide that allows for secretion from the host cell.

[0024] Other objects, embodiments and advantages of the present invention will become apparent from the following detailed description. Item 1 A DNase1-like 3 (D1L3) variant comprising an amino acid sequence at least 80% identical to the enzyme defined by SEQ ID NO:2 and having, compared to SEQ ID NO:2, one or more modifications selected from: a mutated DNA binding site or a mutated chromatin binding site, a glycosylation site, inactivation of the nuclear localization signal, and deletion of all or part of the C-terminal tail. Section 2 The D1L3 variant of item 1, wherein the D1L3 protein variant has increased protein stability, increased protease resistance, increased bioavailability, increased half-life in circulation, higher production levels in an in vitro expression system, and / or substantially equal or better DNA and / or chromatin and / or NET degradation activity compared to the wild-type D1L3 protein of SEQ ID NO:2. Section 3 The D1L3 variant of paragraph 1, wherein the variant is fused or conjugated to a protein or carrier moiety. Section 4 The D1L3 variant of claim 1, wherein the variant comprises one or more glycosylation consensus sequences of NX(T / S). Section 5 5. The D1L3 variant of item 4, wherein the glycosylation consensus sequence contains a D38N substitution and an N40T or N40S substitution, and / or an A127N substitution and a V129T or V129S substitution relative to the corresponding amino acid positions of SEQ ID NO:2. Section 6 The D1L3 variant of item 1, wherein the variant comprises an inactivating nuclear localization signal (NLS). Section 7 Item 7. The D1L3 variant of item 6, which inactivates the NLS by deletion of all or part of NLS1 and / or NLS2 of SEQ ID NO:2. Section 8 7. The D1L3 variant of item 6, which inactivates the NLS by substitution and / or deletion of amino acids in NLS1 and / or NLS2. Section 9 The D1L3 variant of item 8, wherein NLS2 of SEQ ID NO:2 is deleted. Section 10 The D1L3 variant of item 1, comprising a deletion of all or part of the C-terminal tail defined by SEQ ID NO: 33 and / or a substitution of an amino acid in the C-terminal tail. Section 11 Item 11. The D1L3 variant of any one of items 1 to 10, wherein the variant has at least one building block substitution from DNase1 (D1). Section 12 The variants are: M1_A20delinsMRGMKLLGALLALAALLQGAVS, M21_S25delinsLKIAA, V28_S30delinsIQT, E33_S34delinsET, Q36_I45delinsMSNATLVSYI, K47_K50delinsQILS, C52Y, I54_M58delinsIALVQ, I60_K61delinsVR, S63_I70delinsSHLTAVGK, M72_K74delinsLDN, R77_T84delins nsQDAPDT, N86H, V88_I89delinsVV, S91_R92delinsEP, N96_T97delinsNS, Q101R, A103L, L105V, K107_L110delinsRPDQ, V113_S116delinsAV DS, H118Y, H120D, Y122_A127delinsGCEPCGN, V129T, S131N, 135F_136VdelinsAI, W138R, Q140_H143delinsFSRF, A145_D148delinsAVKD, V150 A, I152A, T156_T157delinsAA, E159_S161delinsGDA, K163A, E167A, V169_E170delinsYD, T173L, K176_R178delinsQEK, K180_A181delinsGL , N183_F186delinsDVML, P198_A201delinsRPSQ, K203_N204delinsSS, R208W, D210S, R212T, V214Q, G218P, Q220_E221delinsSA, V225_S228de 12. The D1L3 variant of clause 11, having one or more building block substitutions selected from linsATP, N230H, L238_R239delinsVA, Q241_S246delinsMLLRGA, K250D, N252_V254delinsALP, D256N, K259_A260delinsAA, K262G, T264_E267delinsSDQL, L269_V271delinsQAI, F275Y, F279_K280delinsVM, and Q282_S305delinsK. Item 13 12. The D1L3 variant of claim 11, comprising the following amino acid modifications with respect to SEQ ID NO:2: F275Y / F279_K280delinsVM / Q282_S305delinsK. Section 14 The D1L3 variant of clause 11, comprising the following amino acid modification with respect to SEQ ID NO:2: Q36_I45delinsMSNATLVSYI. Section 15 12. The D1L3 variant of claim 11, comprising the following amino acid modifications with respect to SEQ ID NO:2: Y122_A127delinsGCEPCGN / V129T / S131N. Item 16 Item 12. The D1L3 variant of item 11, comprising two or three modifications selected from F275Y / F279_K280delinsVM / Q282_S305delinsK, Q36_I45delinsMSNATLVSYI, and Y122_A127delinsGCEPCGN / V129T / S131N with respect to SEQ ID NO:2. Item 17 A DNase enzyme comprising an amino acid sequence at least 80% identical to the enzyme of the amino acid sequence of SEQ ID NO:2 and comprising at least one building block substitution derived from human DNase1. Section 18 18. The DNase enzyme of clause 17, wherein the enzyme comprises the building block substitutions F275Y / F279_K280delinsVM / Q282_S305delinsK and optionally comprises the amino acid sequence of SEQ ID NO:17. Section 19 18. The DNase enzyme according to clause 17, wherein the enzyme comprises the following modifications with respect to SEQ ID NO: 2: Q36_I45delinsMSNATLVSYI / Y122_A127delinsGCEPCGN / V129T / S131N, and optionally has the amino acid sequence of SEQ ID NO: 19 or SEQ ID NO: 20. Section 20 1. A DNase enzyme comprising an amino acid sequence that is at least 80% identical to the enzyme of SEQ ID NO:2, wherein the enzyme has an asparagine substitution at the positions corresponding to positions 38 and / or 127 of SEQ ID NO:2, and wherein the asparagine at N38 and / or N127 is glycosylated. Section 21 21. An isolated polynucleotide encoding the D1L3 variant according to any one of items 1 to 20. Section 22 22. A vector comprising the polynucleotide according to Item 21. Section 23 A host cell comprising the vector according to item 22. Section 24 A pharmaceutical composition comprising the D1L3 variant according to any one of items 1 to 20, the polynucleotide according to item 21, or the vector according to item 22, and a pharma- ceutically acceptable carrier. Section 25 25. The pharmaceutical composition of claim 24, comprising a D1L3 variant formulated for topical, parenteral or pulmonary administration. Section 26 25. The pharmaceutical composition according to paragraph 24, formulated for intradermal, intramuscular, intraperitoneal, intraarticular, intravenous, subcutaneous, intraarterial, oral, sublingual, pulmonary, or transdermal administration. Section 27 27. The pharmaceutical composition according to any one of Items 24 to 26, comprising a D1L3 variant produced in a non-mammalian expression system. Section 28 25. The pharmaceutical composition of claim 24, wherein the non-mammalian expression system is Pichia pastoris. Section 29 29. The pharmaceutical composition of claim 28, wherein the Pichia pastoris encodes a D1L3 variant comprising the signal peptide of wild-type human D1L3 of SEQ ID NO:2. Section 30 30. The pharmaceutical composition according to any one of items 24 to 29, further comprising a DNase1 protein or a variant thereof, an isolated polynucleotide encoding a DNase1 protein or a variant thereof, or a vector comprising the isolated polynucleotide. Section 31 Item 31. The pharmaceutical composition according to Item 30, comprising a D1L3 variant and a DNase1 protein or a variant thereof in a ratio (m / m) of 100:1 to 1:100. Section 32 Item 32. The pharmaceutical composition according to item 31, wherein the ratio is 10:1 to 1:10, and optionally about 1:1. Item 33 A DNase1 (D1) variant comprising an amino acid sequence at least 80% identical to the enzyme of SEQ ID NO:1, and having one or more modifications with respect to SEQ ID NO:1 selected from: one or more mutated DNA binding sites or mutated chromatin binding sites, a mutated actin binding site, a mutated glycosylation site, the addition of a nuclear localization signal, the addition of a C-terminal tail having at least 50% sequence identity to the C-terminal tail of the wild-type D1L3 protein of SEQ ID NO:2; and / or an N- or C-terminal fusion to a half-life extending moiety. Section 34 In SEQ ID NO: 1, 1M_S22delinsMSRELAPLLLLLLSIHSALA, L23_A27delinsMRICS, I30_T32delinsVRS, E35_T36delinsES, M38_I47delinsQEDKNAMDVI, Q49_S52delinsKVIK, Y54C, I56_Q60delinsIILVM, V62_R63delinsIK, S65_K72delinsSNNRICPI, L74_N76delinsMEK, Q79_T84delinsRNSRRGIT , H86N, V88_V89delinsVI, E91_P92delinsSR, N96_S97delinsNT, R101Q, L103A, V105L, R107_Q110delinsKEKL, A113_S116delinsVKRS, Y118H, D 120H, G122_N128delinsYQDGDA, T130S, N132S, A136_I137delinsFV, R139W, F141_F144delinsQSPH, E146_E149delinsAVKD, A151V, V153I, A157 _A158delinsTT, G160_A162delinsETS, A164K, A168E, Y170_D171delinsVE, L174T, Q177_K179delinsKHR, G181_L182delinsKA, D184_L187del insNFIF, R199_Q202delinsPKKA, S204_S205delinsKN, W209R, S211D, T213R, Q215V, P219G, S221_A222delinsQE, A226_P228delinsVKKS, H230N 34. The D1 variant of claim 33, comprising one or more building block substitutions selected from among V238_A239delinsLR, M241_A246delinsQEIVSS, D250K, A252_P254delinsNSV, N256D, A259_A260delinsKA, G262K, S264_L267delinsTEEE, Q269_I271delinsLDV, Y275F, V279_M280delinsFK, and K282delinsQSSRAFTNSKKSVTLRKKTKSKRS. Section 35 35. The D1 variant of claim 34, comprising the following modification with respect to SEQ ID NO:1: Q79_T84delinsRNSRRGIT. Section 36 35. The D1 variant of clause 34, comprising the following modifications with respect to SEQ ID NO: 1: H86N / V88_V89delinsVI / E91_P92delinsSR. Section 37 The D1 variant of clause 34, comprising the following modification with respect to SEQ ID NO:1: A136_I137delinsFV. Section 38 The following modifications with respect to SEQ ID NO:1: The D1 variant of clause 34, comprising R199_Q202delinsPKKA / S204_S205delinsKN / W209R / S211D / T213R / Q215V / P219G / S221_A222delinsQE. Item 39 The D1 variant of clause 34, comprising the following modification with respect to SEQ ID NO: 1: A226_P228delinsVKKS. Section 40 The following modifications with respect to SEQ ID NO:1: The D1 variant of clause 34, comprising Y275F / V279_M280delinsFK / K282delinsQSSRAFTNSKKSVTLRKKTKSKRS. Section 41 1. A DNase enzyme comprising an amino acid sequence that is at least 80% identical to the enzyme of SEQ ID NO:1 and comprising a substitution, insertion, or addition of one or more arginine and / or lysine residues, wherein said DNase enzyme has increased chromatin degrading activity compared to the enzyme of SEQ ID NO:1. Section 42 42. The DNase enzyme of claim 41, wherein the one or more arginine and / or lysine residues are amino acid substitutions selected from substitutions at positions corresponding to positions 31, 41, 49, 52, 68, 76, 79, 81, 92, 109, 114, 115, 164, 177, 181, 200, 201, 204, 209, 213, 227, 239, 250, 259, 262, and 280 of SEQ ID NO:1. Section 43 42. The DNase enzyme according to claim 41, comprising substitutions and / or insertions of two or more arginine and / or lysine residues. Section 44 44. The DNase enzyme according to claim 43, comprising substitutions and / or insertions of three or more arginine and / or lysine residues. Section 45 Item 45. The DNase enzyme according to any one of Items 41 to 44, comprising arginine or lysine at one or more positions corresponding to positions 31, 49, 76, 92, 109, 164, 177, 201, 204, and 213 of SEQ ID NO:1. Section 46 42. The DNase enzyme of claim 41, comprising arginine or lysine at positions corresponding to positions 31, 49, 79, and 209 of SEQ ID NO:1. Section 47 42. The DNase enzyme according to claim 41, comprising arginine or lysine at positions corresponding to positions 31, 49, 79, 177, 209, 262 of SEQ ID NO:1. Section 48 42. The DNase enzyme of claim 41, comprising a lysine or arginine residue at positions corresponding to positions 31 and 227 of SEQ ID NO:1. Section 49 42. The DNase enzyme of claim 41, wherein the enzyme has a lysine or arginine at the position corresponding to position 164 of SEQ ID NO:1. Section 50 50. The DNase enzyme according to any one of clauses 41 to 49, which comprises an amino acid substitution at position 136 with respect to SEQ ID NO: 1, optionally A136F. Section 51 43. The DNase enzyme of claim 42, comprising one or more amino acid modifications selected from Q31R, A41K, Q49R, S52K, T68R, N76K, Q79R, D80_A81insR, A81R, P92R, D109K, V114K, D115R, A164K, Q177K, G181K, P200K, S201K, S204R, W209R, T213R, A226_T227insK, T227K, A239R, D250K, A259K, G262K, and K280M, and optionally having a modification that results in actin resistance, wherein the modification that results in actin resistance is optionally A136F with respect to SEQ ID NO: 1. Section 52 43. The DNase enzyme of claim 42, wherein if the enzyme comprises a Q31R or T227K substitution, the enzyme comprises at least two amino acid modifications selected from Q31R, A41K, Q49R, S52K, T68R, N76K, Q79R, D80_A81insR, A81R, P92R, D109K, V114K, D115R, A164K, Q177K, G181K, P200K, S201K, S204R, W209R, T213R, A226_T227insK, T227K, A239R, D250K, A259K, G262K, and K280M. Section 53 53. The DNase enzyme of clause 52, comprising the amino acid substitutions Q31R and T227K with respect to SEQ ID NO:1. Section 54 52. The DNase enzyme of clause 51, comprising the amino acid substitution A164K with respect to SEQ ID NO:1. Section 55 46. ​​The DNase enzyme of claim 45, comprising one or more amino acid substitutions selected from Q31R, Q49K, N76K, Q79R, P92R, D109K, A164K, Q177K, P200K, S201K, S204R, T213R, and G262K. Section 56 56. The DNase enzyme of clause 55, comprising the following amino acid substitutions: Q31R, Q49K, Q79R, A164K, and W209R. Section 57 56. The DNase enzyme of clause 55, comprising the following amino acid substitutions: Q31R, Q49K, Q79R, A136F, Q177K, W209R, G262K. Section 58 49. The DNase enzyme of clause 48, comprising the following amino acid substitutions: Q31R, T227K, and A136F. Section 59 50. The DNase enzyme of clause 49, comprising the following amino acid substitutions: A164K and A136F. Section 60 60. The DNase enzyme according to any one of claims 41 to 59, wherein the enzyme comprises a glycosylation consensus sequence comprising an N40S substitution and / or an N128S substitution with respect to SEQ ID NO:1. Section 61 61. The DNase enzyme of clause 60, comprising the amino acid substitutions Q31R, N40S, A136F, N128S, and T227K with respect to SEQ ID NO:1. Section 62 62. The DNase enzyme of any one of claims 41 to 61, wherein the enzyme is at least 90% identical to the enzyme of SEQ ID NO:1, or at least about 95% identical to the enzyme of SEQ ID NO:1, or at least about 97% identical to the enzyme of SEQ ID NO:1. Section 63 1. A DNase enzyme having an amino acid sequence that is at least 80% identical to the enzyme of SEQ ID NO:1 and comprising at least one building block substitution from the amino acid sequence of SEQ ID NO:2, wherein said DNase enzyme has increased chromatin degrading activity compared to the DNase enzyme of SEQ ID NO:1. Section 64 64. The DNase enzyme of Clause 63, wherein the enzyme comprises at least two adjacent building block substitutions from SEQ ID NO:2. Section 65 64. The DNase enzyme of Clause 63, wherein the enzyme comprises the building block substitution Q79_T84delinsRNSRRGIT and optionally comprises the amino acid sequence of SEQ ID NO:10. Section 66 65. The DNase enzyme of Clause 64, wherein the enzyme comprises the building block substitutions H86N / V88_V89delinsVI / E91_P92delinsSR and optionally comprises the amino acid sequence of SEQ ID NO:11. Section 67 64. The DNase enzyme of Clause 63, wherein the enzyme comprises the building block substitution A136_I137delinsFV and optionally comprises the amino acid sequence of SEQ ID NO:12. Section 68 65. The DNase enzyme of Clause 64, wherein the enzyme comprises the building block substitutions R199_Q202delinsPKKA / S204_S205delinsKN / W209R / S211D / T213R / Q215V / P219G / S221_A222delinsQE and optionally comprises the amino acid sequence of SEQ ID NO:13. Section 69 64. The DNase enzyme of Clause 63, wherein the enzyme comprises the building block substitution A226_P228delinsVKKS and optionally comprises the amino acid sequence of SEQ ID NO:14. Section 70 64. The DNase enzyme of clause 63, comprising the building block substitutions Q79_T84delinsRNSRRGIT, H86N / V88_V89delinsVI / E91_P92delinsSR, A136_I137delinsFV, R199_Q202delinsPKKA / S204_S205delinsKN / W209R / S211D / T213R / Q215V / P219G / S221_A222delinsQE, A226_P228delinsVKKS, and optionally comprising the amino acid sequence of SEQ ID NO: 15. Section 71 71. The DNase enzyme of any one of clauses 41 to 70, comprising the building block substitutions Y275F / V279_M280delinsFK / K282delinsQSSRAFTNSKKSVTLRKKTKSKRS. Section 72 72. The DNase enzyme according to any one of claims 41 to 71, wherein the enzyme exhibits one or more properties selected from: a similar or higher affinity for protein-free DNA compared to the enzyme of SEQ ID NO: 1, a higher chromatin degradation activity compared to the enzyme of SEQ ID NO: 1, an enzymatic activity that is resistant to inhibition by actin compared to the enzyme of SEQ ID NO: 1, and combinations thereof. Section 73 A DNase enzyme comprising an amino acid sequence at least 95% identical to SEQ ID NO:15. Section 74 74. An isolated polynucleotide encoding the DNase enzyme according to any one of items 41 to 73. Section 75 75. A vector comprising the polynucleotide according to item 74. Section 76 A host cell comprising the vector of paragraph 75. Section 77 A pharmaceutical composition comprising the enzyme according to any one of items 41 to 73, the isolated polynucleotide according to item 74, or the vector according to item 75, and a pharma- ceutically acceptable carrier. Section 78 78. A pharmaceutical composition according to paragraph 77, comprising a DNase enzyme formulated for parenteral or pulmonary administration. Section 79 78. The pharmaceutical composition of claim 77, formulated for intradermal, intramuscular, intraperitoneal, intraarticular, intravenous, subcutaneous, intraarterial, oral, sublingual, pulmonary, topical, or transdermal administration. Section 80 78. The pharmaceutical composition of claim 77, wherein the enzyme is produced in Chinese hamster ovary cells. Section 81 78. The pharmaceutical composition of claim 77, wherein the enzyme is non-glycosylated and the enzyme is produced in a non-mammalian expression system. Section 82 82. The pharmaceutical composition of claim 81, wherein the non-mammalian expression system is Pichia pastoris. Section 83 83. The pharmaceutical composition of claim 82, wherein the Pichia pastoris encodes an enzyme with a signal peptide of SEQ ID NO:1. Section 84 84. The pharmaceutical composition according to any one of items 77 to 83, further comprising DNase1-like 3 protein (D1L3) or a variant thereof. Section 85 A method for treating a subject in need of extracellular DNA degradation, extracellular chromatin degradation, extracellular trap (ET) degradation and / or neutrophil extracellular trap (NET) degradation, the method comprising administering a therapeutically effective amount of the D1L3 variant described in any one of items 1 to 16, or the DNase enzyme described in any one of items 17 to 20, or the composition described in any one of items 24 to 32, or the D1 variant described in any one of items 33 to 40, or the DNase enzyme described in any one of items 41 to 73, or the composition described in any one of items 77 to 84. Section 86 86. The method of claim 85, wherein upon treatment, the subject exhibits extracellular DNA degradation, extracellular chromatin degradation, extracellular trap (ET) degradation and / or neutrophil extracellular trap (NET) degradation. Section 87 87. The method of claim 85 or 86, wherein the subject has a chronic or acute inflammatory disorder. Section 88 87. The method of paragraph 85 or 86, wherein the subject has an acute or chronic infection. Section 89 89. The method of any one of paragraphs 85 to 88, wherein the subject has or is at risk of having a vascular obstruction including a NET. Section 90 The subject may be suffering from chronic neutrophilia (e.g., elevated neutrophil count), neutrophil aggregation and leukostasis, thrombosis and vascular occlusion (e.g., sickle cell disease), ischemia-reperfusion injury (e.g., intestinal volvulus, testicular torsion, limb ischemia-reperfusion, vital organ ischemia-reperfusion, organ transplant), surgical and traumatic tissue injury, acute or chronic inflammatory responses or diseases, autoimmune diseases (e.g., systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis, vasculitis, systemic sclerosis), cardiovascular disease (e.g., myocardial infarction, stroke, atherosclerosis, venous thromboembolism including thrombolytic therapy), metabolic disease (e.g., diabetes), systemic inflammation (e.g., systemic inflammatory responses, 85. The method according to claim 85, wherein the patient has an inflammatory disease of the airway (e.g., cystic fibrosis, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), smoking-related lung injury, transfusion-associated acute lung injury (TRALI), acute respiratory distress syndrome (ARDS), and asthma, atelectasis, bronchitis, empyema), renal inflammatory disease (acute and chronic kidney disease including acute kidney injury (AKI) and chronic kidney disease (CKD), inflammatory disease associated with transplanted tissue (e.g., graft-versus-host disease), and cancer (e.g., leukemia, tumor metastasis, and solid tumor). Section 91 91. The method according to any one of items 85 to 90, wherein the protein or composition is administered intravenously, intra-arterially, intra-articularly, intramuscularly, subcutaneously, topically, or by pulmonary administration. Section 92 86. The method of claim 85, wherein the subject has or is at risk of having a ductal obstruction in the ductal system. Section 93 93. The method of claim 92, wherein the ductal system is selected from the group consisting of bile duct, lacrimal duct, mammary duct, cystic duct, hepatic duct, ejaculatory duct, parotid duct, submandibular duct, greater sublingual duct, Bartholin's duct, cerebral aqueduct, pancreas, mammary gland, vas deferens, ureter, urinary bladder, gallbladder, and liver. Section 94 94. The method of claim 93, wherein the subject has pancreatitis, cholangitis, conjunctivitis, mastitis, dry eye disease, obstruction of the vas deferens, or renal disease. Section 95 95. The method according to any one of items 90 to 94, wherein the DNase enzyme is administered intravenously, intraarterially, or intraperitoneally. Section 96 96. The method of claim 95, wherein the subject has primary sclerosing cholangitis. Section 97 The method of claim 85, wherein the subject has or is at risk of having a NET that accumulates in an endothelial surface (e.g., post-surgical adhesions), skin (e.g., wounds / scars, ulcers), or synovial joints (e.g., gout, arthritis). Section 98 98. The method of claim 97, wherein the subject has undergone or is undergoing an invasive medical procedure and is at risk for post-operative adhesions. Section 99 99. The method of claim 98, wherein said DNase therapy is administered during surgery to prevent or inhibit the formation of post-operative adhesions. Item 100 98. The method of claim 97, wherein the DNase therapy is administered topically to the skin to prevent or treat wounds and / or scarring. Section 101 98. The method of claim 97, wherein said DNase therapy is administered to a synovial joint to prevent or treat gout and arthritis. Section 102 The subject is selected from the group consisting of thrombosis, stroke, sepsis, lung injury, atherosclerosis, viral infection, sickle cell disease, myocardial infarction, ear infection, wound healing, liver injury, endocarditis, liver infection, pancreatitis, primary graft dysfunction, limb ischemia reperfusion injury, kidney injury, blood clotting, alum-induced inflammation, hepatorenal injury, pleural effusion, hemothorax, intrabiliary blood clot, post-pneumonia anemia, ulcers, ear, nose and throat conditions, oral infections, minor injuries, sinusitis, 86. The method according to clause 85, wherein the patient has postoperative rhinoplasty, infertility, bladder catheter, wound irrigation, skin reaction test, pneumococcal meningitis, gout, leg ulcer, cystic fibrosis, Kartegener's syndrome, asthma, lobar atelectasis, chronic bronchitis, bronchiectasis, lupus, primary ciliary dyskinesia, bronchiolitis, empyema, pleural infection, cancer, dry eye disease, lower respiratory tract infection, chronic hematoma, Alzheimer's disease, and obstructive pulmonary disease. Section 103 Item 103. The method according to any one of items 85 to 102, wherein the subject further exhibits coronary artery disease. Section 104 103. The method of claim 102, wherein the subject has cystic fibrosis. Section 105 Item 105. The method according to any one of items 85 to 104, comprising monitoring NET-degrading activity in blood, plasma, or serum from the subject. Section 106 1. A method of treating a subject exhibiting or at risk of exhibiting intravascular obstruction involving a NET, said method comprising administering a therapeutically effective amount of D1L3 or a variant thereof, and / or a therapeutically effective amount of D1 or a variant thereof. Section 107 107. The method of claim 106, wherein the subject is administered an enzyme comprising an amino acid sequence having 80% or more sequence identity to the enzyme defined by SEQ ID NO:2. Section 108 108. The method of claim 107, wherein the enzyme comprises the amino acid sequence of the enzyme defined by SEQ ID NO:2. Section 109 A method of treating a subject having or at risk of having a ductal obstruction in the ductal system comprising administering a therapeutically effective amount of D1L3 or a variant thereof, and / or a therapeutically effective amount of D1 or a variant thereof. Section 110 110. The method of claim 109, wherein the subject is administered an enzyme comprising an amino acid sequence having 80% or more sequence identity to the enzyme defined by SEQ ID NO:2 and / or an enzyme comprising an amino acid sequence having 80% or more sequence identity to the enzyme defined by SEQ ID NO:1. Section 111 111. The method of claim 110, wherein the enzyme comprises the amino acid sequence of the enzyme defined by SEQ ID NO:2 and / or comprises the amino acid sequence of the enzyme defined by SEQ ID NO:1. Section 112 Item 112. The method according to any one of Items 109 to 111, wherein the ductal system is a bile duct, a lacrimal duct, a mammary duct, a cystic duct, a hepatic duct, an ejaculatory duct, a parotid duct, a submandibular duct, a greater sublingual duct, a Bartholin's duct, aqueduct of the cerebral aqueduct, a pancreas, a mammary gland, a vas deferens, a ureter, a urinary bladder, a gallbladder, and a liver. Section 113 Item 113. The method according to any one of Items 109 to 112, wherein the subject has pancreatitis, cholangitis, conjunctivitis, mastitis, dry eye disease, obstruction of the vas deferens, or renal disease. Section 114 114. The method of any one of paragraphs 109 to 113, wherein the DNase enzyme is administered by intravenous, intraarterial, or intraperitoneal administration. Section 115 115. The method of claim 114, wherein the subject has primary sclerosing cholangitis. Section 116 A method for treating a subject in need of extracellular DNA degradation, extracellular chromatin degradation, extracellular trap (ET) degradation and / or neutrophil extracellular trap (NET) degradation, said method comprising administering therapeutically effective amounts of D1L3 or a variant thereof and D1 or a variant thereof. Section 117 117. The method of claim 116, wherein the D1L3 or variant thereof and the D1 or variant thereof are administered in a single pharmaceutical composition or in separate pharmaceutical compositions, and the ratio of D1L3 or variant thereof to D1 or variant thereof is optionally in the range of 100:1 to 1:100 by mass, 10:1 to 1:10 by mass, and optionally about 1:1. Section 118 118. The method of claim 117, wherein upon treatment, the subject exhibits extracellular DNA degradation, extracellular chromatin degradation, extracellular trap (ET) degradation, and / or neutrophil extracellular trap (NET) degradation. Section 119 Item 119. The method according to any one of items 116 to 118, wherein the subject has a chronic or acute inflammatory disorder. Section 120 Item 119. The method of any one of items 116 to 118, wherein the subject has an acute or chronic infection. Section 121 121. The method according to any one of items 116 to 120, wherein the subject has or is at risk of having a vascular obstruction, including a NET. Section 122 The subject may be diagnosed with chronic neutrophilia (e.g., elevated neutrophil counts), chronic neutrophilia (e.g., elevated neutrophil counts), neutrophil aggregation and leukostasis, thrombosis and vascular occlusion (e.g., sickle cell disease), ischemia-reperfusion injury (e.g., intestinal volvulus, testicular torsion, limb ischemia-reperfusion, vital organ ischemia-reperfusion, organ transplant), surgical and traumatic tissue injury, acute or chronic inflammatory responses or diseases, autoimmune diseases (e.g., systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis, vasculitis, systemic sclerosis), cardiovascular disease (e.g., myocardial infarction, stroke, atherosclerosis, venous thromboembolism including thrombolytic therapy), metabolic disease (e.g., diabetes), systemic inflammation (e.g., For example, systemic inflammatory response syndrome (SIRS), sepsis, septic shock, disseminated intravascular coagulation (DIC), and thrombotic microangiopathy (TMA)), inflammatory diseases of the airways (e.g., cystic fibrosis, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), smoking-related lung injury, transfusion-related acute lung injury (TRALI), acute respiratory distress syndrome (ARDS), and asthma, atelectasis, bronchitis, and empyema), renal inflammatory diseases (acute and chronic kidney diseases including acute kidney injury (AKI) and chronic kidney disease (CKD), inflammatory diseases associated with transplanted tissues (e.g., graft-versus-host disease), and cancer (e.g., leukemia, tumor metastasis, and solid tumors). The method according to any one of claims 116 to 117. Section 123 Item 123. The method according to any one of Items 116 to 122, wherein each of the D1L3 or variant thereof and the D1 or variant thereof is administered by a route independently selected from intravenous, intraarterial, intraarticular, intramuscular, subcutaneous, topical, and pulmonary administration. Section 124 The method of claim 123, wherein the subject has or is at risk of having a ductal obstruction in the ductal system. Section 125 Item 125. The method of item 124, wherein the ductal system is selected from the group consisting of bile duct, lacrimal duct, mammary duct, cystic duct, hepatic duct, ejaculatory duct, parotid duct, submandibular duct, greater sublingual duct, Bartholin's duct, cerebral aqueduct, pancreas, mammary gland, vas deferens, ureter, urinary bladder, gallbladder, and liver. Section 126 126. The method of claim 125, wherein the subject has pancreatitis, cholangitis, conjunctivitis, mastitis, dry eye disease, obstruction of the vas deferens, or renal disease. Section 127 127. The method of any one of paragraphs 124 to 126, wherein the DNase enzyme is administered as a single composition administered by intravenous, intraarterial, or intraperitoneal administration. Section 128 128. The method of claim 127, wherein the subject has primary sclerosing cholangitis. Section 129 119. The method of any one of paragraphs 116 to 118, wherein the subject has or is at risk of having NETs accumulated in an endothelial surface, skin, or synovial joint. Section 130 130. The method of claim 129, wherein the subject has undergone or is undergoing an invasive medical procedure and is at risk for post-operative adhesions. Section 131 131. The method of claim 130, wherein said DNase therapy is administered during surgery to prevent or inhibit the formation of post-operative adhesions. Section 132 130. The method of claim 129, wherein the DNase therapy is administered topically to the skin to prevent or treat wounds and / or scars. Section 133 130. The method of claim 129, wherein said DNase therapy is administered to a synovial joint to prevent or treat gout and arthritis. Section 134 The subject is selected from the group consisting of thrombosis, stroke, sepsis, lung injury, atherosclerosis, viral infection, sickle cell disease, myocardial infarction, ear infection, wound healing, liver injury, endocarditis, liver infection, pancreatitis, primary graft dysfunction, limb ischemia reperfusion injury, kidney injury, blood clotting, alum-induced inflammation, hepatorenal injury, pleural effusion, hemothorax, intrabiliary clot, post-pneumonia anemia, ulcers, ear, nose and throat conditions, oral infections, minor injuries, sinusitis, post-operative rhinoplasty Item 119. The method according to any one of Items 116 to 118, wherein the patient has an illness such as infertility, bladder catheter, wound irrigation, skin reaction test, pneumococcal meningitis, gout, leg ulcer, cystic fibrosis, Kartegener's syndrome, asthma, lobar atelectasis, chronic bronchitis, bronchiectasis, lupus, primary ciliary dyskinesia, bronchiolitis, empyema, pleural infection, cancer, dry eye disease, lower respiratory tract infection, chronic hematoma, Alzheimer's disease, or obstructive pulmonary disease. Section 135 Item 135. The method according to any one of items 116 to 134, wherein the subject further exhibits coronary artery disease. Section 136 135. The method of claim 134, wherein the subject has cystic fibrosis. Section 137 137. The method of any one of claims 116 to 136, comprising monitoring NET-degrading activity in blood, plasma, or serum from the subject. Section 138 1. A method of treating a subject exhibiting or at risk for intravascular obstruction involving a NET, said method comprising administering a therapeutically effective amount of D1L3 or a variant thereof, and / or a therapeutically effective amount of D1 or a variant thereof. Section 139 139. The method of claim 138, wherein the subject is administered an enzyme comprising an amino acid sequence having 80% or more sequence identity to the enzyme defined by SEQ ID NO:2. Section 140 140. The method of claim 139, wherein the enzyme comprises the amino acid sequence of the enzyme defined by SEQ ID NO:2. Section 141 A method of treating a subject having or at risk of having a ductal obstruction in the ductal system comprising administering a therapeutically effective amount of D1L3 or a variant thereof, and / or a therapeutically effective amount of D1 or a variant thereof. Section 142 142. The method of claim 141, wherein the subject is administered an enzyme comprising an amino acid sequence having 80% or more sequence identity to the enzyme defined by SEQ ID NO:2 and / or an enzyme comprising an amino acid sequence having 80% or more sequence identity to the enzyme defined by SEQ ID NO:1. Section 143 143. The method of claim 142, wherein the enzyme comprises the amino acid sequence of the enzyme defined by SEQ ID NO:2 and / or the amino acid sequence of the enzyme defined by SEQ ID NO:1. Section 144 Item 144. The method according to any one of Items 141 to 143, wherein the ductal system is a bile duct, a lacrimal duct, a mammary duct, a cystic duct, a hepatic duct, an ejaculatory duct, a parotid duct, a submandibular duct, a greater sublingual duct, a Bartholin's duct, aqueduct of the cerebral aqueduct, a pancreas, a mammary gland, a vas deferens, a ureter, a urinary bladder, a gallbladder, and a liver. Section 145 Item 144. The method according to any one of items 141 to 143, wherein the subject has pancreatitis, cholangitis, conjunctivitis, mastitis, dry eye disease, obstruction of the vas deferens, or renal disease. Section 146 146. The method of any one of paragraphs 141 to 145, wherein the DNase enzyme is administered intravenously, intraarterially, or intraperitoneally. Section 147 147. The method of claim 146, wherein the subject has primary sclerosing cholangitis. Section 148 A method for producing a pharmaceutical composition for reducing accumulation of neutrophil extracellular traps (NETs), comprising: providing a genetically modified mouse deficient in DNase1 and DNase1-like 3 activity, expressing a heterologous GCSF polynucleotide or repeatedly stimulating with a microbial compound to allow NETs to accumulate in the genetically modified mouse; administering a candidate NET inhibitor or candidate DNase enzyme; selecting a NET inhibitor or DNase enzyme that reduces NET accumulation; and formulating the NET inhibitor or DNase enzyme for administration to a human patient. Section 149 149. The method of claim 148, wherein the composition is formulated for parenteral or pulmonary administration. Section 150 149. The method of paragraph 148, wherein the compound is formulated for intravenous, intraarterial, intraarticular, intramuscular, subcutaneous, topical, or pulmonary administration. Section 151 149. The method of claim 148, wherein the genetically modified mouse expresses a heterologous G-CSF polynucleotide in hepatocytes. Section 152 1. A method for recombinantly producing a DNase enzyme selected from human D1, human D1L3, or a variant thereof, comprising: culturing a Pichia pastoris host cell encoding the DNase enzyme with a native signal peptide; and recovering the DNase from the culture medium. Section 153 153. The method of claim 152, wherein the DNase enzyme is human D1L3 or a variant thereof having at least 80% sequence identity to the enzyme of SEQ ID NO:2. Section 154 154. The method of claim 153, wherein the DNase enzyme is human D1L3. Section 155 1. A method for DNase enzyme modification comprising: Providing a protein-protein alignment of the donor and recipient DNase enzymes; The method comprises identifying a variable amino acid sequence for transfer, where the variable amino acid is adjacent to one or more conserved amino acids in the donor and recipient DNase enzymes; substituting the variable amino acid of the recipient DNase with the variable amino acid of the donor DNase to create a chimeric DNase; and recombinantly producing the chimeric DNase. Section 156 156. The method of claim 155, wherein the DNase enzyme is selected from human D1, human DNase 1-like 1 (D1L1) defined by SEQ ID NO: 38, human DNase 1-like 2 (D1L2) defined by SEQ ID NO: 39, and human D1L3. Section 157 157. The method of claim 155 or 156, wherein the building block substitution has at least two amino acids, or at least three amino acids, or at least four amino acids, or at least five amino acids. [Brief description of the drawings]

[0025] [Figure 1]We show that circulating DNase1 and DNase1l3 degrade NETs in vitro and characterize the DNA degradation activity of serum from WT, DNase1- / - (D1- / -), DNase1l3- / - (D1L3- / -), and DNase1 / DNase1l3- / - (D1 / D1L3- / -) mice. Figure 1A provides detection of DNase1 (D1), DNase1l3 (D1L3), and total DNase activity by zymography assays DPZ and SRED. Figure 1B shows images and Figure 1C shows quantification of DNA staining of NETs generated in vitro after incubation in the presence of serum from the indicated genotypes (N=6). Scale bar: 50 μm. Figure 1D shows DPZ and SRED analysis of serum from D1 / D1L3- / - mice stably expressing plasmids containing DNase1 (D1), DNase1l3 (D1L3), or a control plasmid (Ctrl). Figure 1E shows images and Figure 1F shows quantification of DNA staining of NETs generated in vitro after incubation in the presence of buffer or serum from D1 / D1L3- / - mice expressing D1, D1L3, or Ctrl (N=5). Scale bar: 50 μm. Images are representative of two or more independent experiments. Statistics: (Figure 1C and Figure 1F) One-way ANOVA followed by Bonferroni's multiple comparison post-hoc test. §P<0.001 vs. all other groups. [Diagram 2]We show that DNase1 or DNase1l3 is required to resist chronic neutrophilia. Chronic neutrophilia was induced by injection of a G-CSF expression plasmid (CSF3). Controls received an empty plasmid (Ctrl). Figure 2A shows the blood neutrophil counts of WT mice and controls after 2 weeks (N=3–6). Figure 2B shows NET-like structures (arrows) in DNA staining of blood smears of WT mice after 1 week (N=3). Scale bar: 20 μm. Figure 2C shows the survival rates of WT (N=7), DNase1− / − (D1− / −, N=6), DNase1l3− / − (D1L3− / −, N=6), DNase1 / DNase1l3− / − mice (D1 / D1L3− / −, N=6) and controls (Ctrl, N=4). Figure 2D shows the survival rate of D1 / D1L3- / - mice co-expressing CSF3 and DNase1 (CSF3 / D1, N=5), DNase1l3 (CSF3 / D1L3, N=6), and control (CSF3 / Ctrl, N=4). Figures 2E-2I characterize the mortality rate during chronic neutrophilia (N=4). Figure 2E shows the change in peripheral body temperature. Figure 2F shows the photographs of plasma and urine. Figure 2G shows the concentration of hemoglobin in the blood. Figure 2H shows the image of the blood smear. The arrows point to pulsated red blood cells. Scale bar: 20 μm. Figure 2I shows the LDH concentration in plasma. UT: untreated mice (N=5-6). Images are representative of 3 or more mice. Statistics: (Fig. 2A, 2H, 2I) one-way ANOVA and (Fig. 2E) two-way ANOVA followed by Bonferroni's multiple comparison post-hoc test, (Fig. 2B) Student's t-test, (Fig. 2C, 2D) log-rank test; #P<0.01, §P<0.001 vs. all other groups or baseline (BL). [Diagram 3]Figure 3 shows that DNase1 and DNase1l3 prevent vascular occlusion by NET clots during chronic neutrophilia. Histological analysis of DNase1 / DNase1l3- / - mice (D1 / D1L3- / -) co-expressing CSF3 with DNase1 (CSF3 / D1, N=4), DNase1l3 (CSF3 / D1L3, N=4), or control plasmid (CSF3 / Ctrl, N=4). Figure 3A shows hematoxylin and eosin staining (H&E) of the lungs. Scale bar: 500 μm (schematic), 25 μm (detail). Figure 3B shows quantification of pulmonary vessels occluded by hematoxylin-positive clots per field of view (FOV). Untreated WT mice (UTWT, N=4), untreated D1 / D1L3- / - mice (UT; N=4). Figure 3C shows immunostaining of occluded vessels for the neutrophil marker myeloperoxidase (MPO) and chromatin. Figures 3D and 3E show immunostaining for von Willebrand factor (vWF), fibrin, and DNA. Three types of NET clots were detected (α, vWF+ / fibrin-; β, vWF+ / fibrin+; γ, vWF- / fibrin-). Figure 3F shows quantification of vWF and fibrin in NET clots. Data are shown as mean ± SD, n = 108. Figure 3G shows survival rates of CSF3-expressing D1 / D1L3- / - mice treated with IgG (N = 4), antiplatelet IgG (N = 5), and dabigatran (N = 5). Scale bar: 50 μm. Images are representative of ≥3 mice. (Figures 3C, 3D, 3E) Dotted lines indicate vessel walls. Statistics: (Fig. 3B) One-way ANOVA followed by Bonferroni's multiple comparison post hoc test; P<0.001 vs. all other groups, (Fig. 3G) Log-rank test; P>0.05 for antiplatelet IgG or dabigatran vs. IgG. [Figure 4]4 shows that DNase1 and DNase1l3 protect against host injury in sepsis. WT mice (N=5) and DNase1 and DNase1l3 (D1 / D1L3- / -) combined deficient mice expressing DNase1 (D1, N=7), DNase1l3 (D1L3, N=8), or control plasmid (Ctrl, N=11) were treated with lipopolysaccharide and heat-killed E. coli to induce sepsis. Figure 4A shows the survival time of septic mice. Figure 4B shows the hemoglobin concentration in blood. Figure 4C shows the photographs of plasma and urine. Figure 4D shows the LDH concentration in plasma. Figure 4E shows the quantification of ruptured red blood cells in blood per field of view (FOV). Figure 4F shows the quantification of occluded blood vessels in lungs per FOV. Figure 4G shows hematoxylin and eosin staining (H&E) of lungs. Arrows point to occluded blood vessels. Scale bar: 500 μm. Figures 4H and 4I show H&E staining of partially and completely occluded blood vessels. Arrows point to NETs covering the intercellular spaces. Inset is a schematic diagram. Scale bar: 50 μm. Statistics: (Figure 4A) Log-rank test; #P<0.01 vs. all other groups, (Figures 4B-4F) One-way ANOVA followed by Bonferroni's multiple comparison post-hoc test; §P<0.001, #P<0.01. [Diagram 5]Mouse model of chronic neutrophilia. Four-week-old WT mice were injected with a CSF3-expressing plasmid (CSF3) or an empty control plasmid (Ctrl). Figure 5A shows G-CSF levels in plasma (N=3-6). BL: baseline, before injection; Ctrl: mice expressing the control plasmid without CSF3 for 2 weeks (N=4-5). Figure 5B shows immunostaining of neutrophil elastase in lung, kidney, and liver. Scale bar: 200 μm. Figure 5C shows photographs and weights of the spleen (N=5-6). Scale bar: 1 cm. Figure 5D shows the weights of mice at the indicated times (N=3-5). Figure 5E shows neutrophil counts in whole blood and plasma levels of ALT, AST, BUN, and creatinine 2 weeks after injection. Images are representative of 3 or more mice. Statistics: (Fig. 5A, 5C) one-way ANOVA followed by (Fig. 5D) Bonferroni's multiple comparison post-hoc test, and (Fig. 5E) Student's t-test; #P<0.01, §P<0.001 versus (Fig. 5A) BL, or (Fig. 5C) UT. [Figure 6] Figure 6 shows that DNase1 and DNase1l3 prevent NET clot formation and liver and kidney organ damage during chronic neutrophilia. Analysis of DNase1 / DNase1l3- / - mice (D1 / D1L3- / -) co-expressing CSF3 from a control plasmid (CSF3 / Ctrl, N=4) with DNase1 (CSF3 / D1, N=4) or DNase1l3 (CSF3 / D1L3, N=4). Controls include untreated WT mice (UTWT, N=4) and untreated D1 / D1L3- / - mice (UT; N=4). Figure 6A shows plasma levels of alanine and aspartate aminotransferase (ALT, AST). Figure 6B shows plasma levels of blood urea nitrogen (BUN) and creatinine. Figure 6C shows quantification of intravascular hematoxylin-rich clots in liver per section and kidney per field of view (FOV). Figure 6D shows H&E staining of liver and kidney. Scale bars: 500 μm (schematic), 50 μm (detailed). Images are representative of ≥3 mice. Statistics: (Figures 6A, 6B, 6C) One-way ANOVA followed by Bonferroni's multiple comparison post-hoc test; #P<0.01, §P<0.001 vs. all other groups. [Figure 7] Hematoxylin-positive clots are shown to consist of NETs. Analysis of lungs from DNase1 / DNase1l3- / - mice (D1 / D1L3- / -) with chronic neutrophilia (D1 / D1L3- / -+CSF3 / Ctrl) shown in Figures 3A-3G. Figure 7A shows hematoxylin and eosin (H&E) staining for DNA and chromatin of serial lung sections. Scale bar: 200 μm. Figure 7B shows immunostaining of occluded blood vessels for chromatin, CRAMP (cathelin-related antimicrobial peptide), and DNA. Scale bar: 50 μm. Figure 7C shows immunostaining of occluded blood vessels for chromatin, citrullinated histone 3 (citH3), and DNA. Scale bar: 50 μm. Images are representative of 3 or more mice. [Figure 8] Human NETs form clots in vitro. Figure 8A shows a photograph of a NET clot (arrow) generated by PMA-activated human neutrophils in vitro. Untreated neutrophils (UT) or neutrophils activated in the presence of recombinant human DNase1 (PMA+D1) served as controls. Scale bar: 5 mm. Figure 8B shows hematoxylin and eosin staining (H&E) and immunostaining for chromatin and the neutrophil marker myeloperoxidase (MPO) of the in vitro generated NET clot. Scale bar: 200 μm. Images are representative of three or more independent experiments. [Figure 9] We show that NET degradation correlates with disease activity in STEC-HUS. Figure 9A shows images and Figure 9B shows quantification of DNA staining of NETs generated in vitro after incubation in the presence of buffer, plasma from normal healthy donors (N=7), or plasma from 11 STEC-HUS patients collected in acute disease pathology (Acute) and remission (Rem.). Scale bar: 50 μm. Statistics: One-way ANOVA followed by Bonferroni's multiple comparison post-hoc test; § P<0.001 vs. all other groups. [Figure 10]A table showing the classification of human tissues from different patients tested, including number of patients, cause of death as indicated in the autopsy report (ARDS, acute respiratory distress syndrome); sex and age of the patients; and type of tissue analyzed. Tissues were analyzed in a three-step procedure: first, identification of hematoxylin-rich clots / aggregates in hematoxylin and eosin staining; second, identification of NETs in hematoxylin-rich clots by immunostaining for chromatin and myeloperoxidase (MPO); and third, identification of the localization of NET clots within the lung structures. [Figure 11] Figure 11 shows that human NETs form clots in situ. Lung tissues taken at autopsy from two patients with sepsis (patients #6 and #7 in Figure 10). Figure 11A shows H&E staining of two hematoxylin-rich intravascular clots in lung tissue from patient #6. Figure 11B shows immunostaining of serial sections for chromatin and myeloperoxidase (MPO) of the left vessel shown in panel A. Figure 11C shows H&E stained vessels of lung tissue from patient #7, showing hematoxylin-rich intravascular clots. Figure 11D shows immunostaining of serial sections for chromatin and MPO. Arrows point to NET clots. Scale bar: 50 μm. [Figure 12] NET clots in septic mice occlude blood vessels. Immunostaining for DNA, chromatin, and myeloperoxidase (MPO) of a completely occluded blood vessel from a septic DNase1 / DNase1l3- / - mouse. DNA and chromatin staining of NETs (arrows) appears darker than nuclear staining (asterisk) and covers the intercellular spaces. Scale bar: 10 μm. [Figure 13]We show that DNase1 and DNase1l3 degrade NETs by distinct mechanisms. Figure 13A shows DNA staining of PFA-fixed NETs generated in vitro after incubation in the presence of serum from WT, DNase1- / - (D1- / -), DNase1l3- / - (D1L3- / -), and DNase1 / DNase1l3- / - mice (D1 / D1L3- / -). Data are representative of three or more independent experiments. Scale bar: 50 μm. Figure 13B shows the concentration of cell-free DNA fragments released from PFA-fixed NETs after incubation in the presence of serum from WT, D1- / -, D1L3- / -, and D1 / D1L3- / - mice. Figure 13C shows DNA staining of non-fixed NETs generated in vitro after incubation in the presence of vehicle, recombinant mouse DNase1 (rmD1), or recombinant mouse DNase1l3 (rmD1L3). Figure 13D shows the concentration of cell-free DNA fragments released from non-fixed NETs generated in vitro after incubation in the presence of vehicle, rmD1, or rmD1L3. Figure 13E shows DNA staining of PFA-fixed NETs generated in vitro after incubation in the presence of vehicle, rmD1, or rmD1L3. Figure 13F shows the concentration of cell-free DNA fragments released from PFA-fixed NETs generated in vitro after incubation in the presence of vehicle, rmD1, or rmD1L3. Statistics by one-way ANOVA followed by Bonferroni's multiple comparison post-hoc test; §P<0.0001. [Figure 14]14A-14E show DNase activity in human and mouse plasma quantified by SRED. FIG. 14A shows that the addition of a polyclonal antibody against human DNase 1 (α-hDNase 1) to plasma from normal healthy donors (NHD) blocks DNA degradation activity in a concentration-dependent manner, but not with IgG (vs. IgG, *: p<0.05). FIG. 14B shows that plasma spiked with 200 μg / ml of α-hDNase 1 and heparin, an inhibitor of DNase 1l3, blocks residual DNase activity in plasma spiked with 200 μg / ml of α-hDNase 1 (vs. NHD, *: p<0.05). FIG. 14C-14E ​​show a comparison of DNase activity in serial dilutions of plasma from mice and NHD. FIG. 14C shows that total DNase activity in WT mice is approximately 10-fold higher than in NHD. FIG. 14D shows that DNase1 activity in plasma from DNase1l3− / − mice is approximately 10-fold higher than in human plasma spiked with 500 μg / ml heparin. (E) DNase1l3 activity in plasma from DNase1- / - mice is approximately 10-fold higher than in human plasma supplemented with 200 μg / ml α-hDNase1. (F, G) In vitro NET degradation is shown in Figures 14F and 14G. Figure 14F shows activated neutrophils incubated in the presence of NHD-derived plasma alone or plasma supplemented with 200 μg / ml α-hDNase1, plasma from a TMA patient, and plasma from WT, DNase1- / -, and DKO mice (scale bar: 200 μm). Figure 14G shows cell-free DNA in the supernatant of activated neutrophils incubated in the presence of plasma from the indicated sources (vs. NHD, §: p<0.001). In vitro NET degradation by human plasma is dependent on DNase1, as DNase1l3 in human plasma is not sufficient to degrade NETs. [Figure 15]Figure 15 shows the fatal course of chronic neutrophilia in a surrogate strain of DNase1 / DNasel3- / - mice. A surrogate strain of DNase1- / - mice (see methods in Example 1) was crossed with DNase1l3- / - mice to generate mice with combined deficiency. Figure 15A shows survival curves of neutrophilia in WT (N=9), DNase1- / - (D1- / -, N=5), and DNase1 / DNase1l3- / - mice (D1 / D1L3- / -, N=5). Chronic neutrophilia was induced by injection of a CSF3 expression plasmid (CSF3). Figure 15B shows hematoxylin and eosin staining (H&E) of lung sections. Arrows indicate hematoxylin-positive clots in D1 / D1L3- / - mice. Scale bar: 500 μm. Figure 15C shows the survival rate of D1 / D1L3- / - mice co-expressing CSF3 with a control plasmid (CSF3 / Ctrl, N=6), DNase1 (CSF3 / D1, N=5), or DNase1l3 (CSF3 / D1L3, N=6). Statistics: log-rank test; § P<0.001. [Figure 16]Screening approach to identify hyperactive variants of DNase1 and DNase1L3 in vitro. Figure 16A shows a library of DNases including wild-type DNase1L3 (I, D1L3), wild-type DNase1 (II, D1), and their variants. D1 and D1L3 variants were designed by transferring amino acids from D1L3 to D1 (III, D1V) and from D1 to D1L3 (IV, D1L3V). DNase activity was tested using high molecular weight (HMW) DNA, dsDNA, and chromatin degradation as substrates. In Figure 16B, dsDNA degradation activity is shown as black circles by zymography. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., D1, 0.0005 ng). D1 degrades dsDNA approximately 100 times more efficiently than D1L3. Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin shows a shift from high molecular weight DNA to smaller, i.e., low molecular weight DNA, which correlates with chromatin degrading activity. D1L3 degrades chromatin approximately 100 times more efficiently than D1. At a ratio of 10:1 or 1:1 (m / m), D1 and D1L3 show synergistic effects in degrading chromatin. [Figure 17] 1 shows an amino acid sequence alignment of human DNase 1 (SEQ ID NO: 1) and human DNase 1L3 (SEQ ID NO: 2). The signal peptide, conserved amino acids, additional arginine and lysine residues in the variable region of D1L3, and the C-terminal tail of D1L3 are highlighted. The sequence rulers indicate the amino acid positions. [Figure 18] A list of arginine and lysine residues present only in DNase1L3 is shown. The corresponding amino acids in DNase1 and the amino acid substitutions in DNase1 are shown. The numbers in brackets are the amino acid positions in the mature protein without the signal peptide. The arginine and lysine residues located in the C-terminal tail of D1L3 are shown in lanes 29-37. In this application, 22 of the 37 possible DNase1 variants were tested. [Figure 19]Characterization of DNase 1 variants with single arginine and lysine amino acid substitutions as described in Figure 18. Zymography shows dsDNA degradation activity as black circles. dsDNA degradation activity correlates with diameter. Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin shows a shift from high molecular weight DNA to smaller, i.e. low molecular weight DNA, which correlates with chromatin degradation activity. Amino acid substitutions that cause an increase in chromatin degradation activity are highlighted in blue. Samples without such effect are shown in light blue. [Figure 20] Shown is an amino acid sequence alignment of human DNase1 (SEQ ID NO:1), mouse DNase1 (SEQ ID NO:3), rat DNase1 (SEQ ID NO:4), and human DNase1L3 (SEQ ID NO:2). The sequence rulers indicate the position of the amino acids. The signal peptide is highlighted in grey. Cationic amino acid residues (arginine: R, lysine: K) that are present in mouse / rat DNase1 and human DNase1L3 but not in human DNase1 are highlighted. Four such R / K residues are shown in mouse DNase1 (Q31R, Q49K, Q79R, W209R). Rat DNase1 contains two additional R / K residues (Q177K, G262K). [Figure 21]Comparison of mouse and human DNase1. (Figure 21A) Zymography shows dsDNA degradation activity as black circles. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., Ctrl). Mouse DNase1 (mD1) and human DNase1 (D1) show similar levels of dsDNA degradation activity. Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin shows a shift from high molecular weight DNA to smaller, i.e., low molecular weight DNA, which correlates with chromatin degradation activity. Mouse DNase1 (mD1) shows higher chromatin degradation activity compared to human DNase1 (D1). (Figure 21B) Gene therapy with human DNase1 provides only partial protection from lethal vascular occlusion due to NETs. Chronic neutrophilia, which is complicated by intravascular NET formation, was induced by hepatic expression of Csf3, which encodes G-CSF. Data show survival curves of Csf3-expressing Dnase1- / -Dnase1l3- / - mice. Animals were injected with Csf3 and empty control vector (Ctrl, N=6), a mixture of Csf3 and human DNase1 (hDnase1, N=12), and Csf3 and mouse DNase1 (mDnase1, N=5). P values ​​were calculated using the log-rank test. [Figure 22]Characterization of rodent-like human DNase1 variants in vivo and in vitro. (Fig. 20A) Gene therapy with rodent-like DNase1 variants provides complete protection from lethal vascular occlusion due to NETs. Chronic neutrophilia concomitant with intravascular NET formation was induced by hepatic expression of Csf3, encoding G-CSF. Data show survival curves of Csf3-expressing Dnase1- / -Dnase1l3- / - mice. As shown in Fig. 21, animals were injected with Csf3 and empty control vector (Ctrl, N=6), a mixture of Csf3 and human DNase1 (hDnase1, N=12). The third group of Dnase1- / -Dnase1l3- / - mice were injected with Csf3 and a gene encoding a mouse-like DNase1 variant containing four amino acid mutations Q31R / Q49K / Q79R / W209R (Q31R / Q49K / Q79R / W209R, N=6). The fourth group of Dnase1- / -Dnase1l3- / - mice were injected with Csf3 and a gene encoding a rat-like DNase1 variant containing six amino acid mutations Q31R, Q49K, Q79R, Q177K, W209R, and G262K (Q31R / Q49K / Q79R / Q177K / W209R / G262K, N=6). P values ​​were calculated using the log-rank test. (Figure 22B) Zymography was used to show dsDNA degradation activity as black circles. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., Ctrl). Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin shows a shift from high molecular weight DNA to smaller, i.e., low molecular weight DNA, which correlates with chromatin degradation activity. Mouse-like variants of human DNase1 (Q31R / Q49K / Q79R / W209R) and rat-like variants of human DNase1 (Q31R / Q49K / Q79R / Q177K / W209R / G262K) show similar dsDNA degradation activity, but higher chromatin degradation activity than wild-type human DNase1. [Diagram 23]Amino acid sequence alignment of human DNase1 (D1, SEQ ID NO:1) and human DNase1L3 (D1L3, SEQ ID NO:2). Sequence rulers indicate amino acid positions. Amino acids in D1 with published mutations are highlighted. Human D1L3 contains three mutations (Q31R / T227K / A136F) associated with gain-of-function in human DNase1 and four mutations not associated with increased activity. [Figure 24]Characterization of DNase1 variants (D1V) with mutations Q31R, T227K, and / or A136F. (Figure 24A) Culture supernatants of transfected HEK293 cells were analyzed. HEK cells transfected with wild-type DNase1 (D1) and DNase1L3 (D1L3) served as controls. Zymography showed dsDNA degradation activity as black circles. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., Ctrl). Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin showed a shift from high molecular weight DNA to smaller, i.e., low molecular weight DNA, which correlates with chromatin degradation activity. D1V featuring the three amino acid mutations Q31R / T227K / A136F has similar dsDNA degradation activity as D1 and D1V featuring Q31R, T227K, A136F, or Q31R / T227K, but has enhanced chromatin degradation capacity. (Figure 24B) Gene therapy with hyperactive D1V provides complete partial protection from lethal vascular occlusion due to NETs. Chronic neutrophilia concomitant with intravascular NET formation was induced by hepatic expression of Csf3, encoding G-CSF. Data show survival curves of Csf3-expressing Dnase1- / -Dnase1l3- / - mice. As shown in Figure 21, animals were injected with Csf3 and empty control vector (Ctrl, N=6), a mixture of Csf3 and human DNase1 (hDnase1, N=12). In addition, a group of Dnase1- / -Dnase1l3- / - mice was injected with Csf3 and the gene encoding the human Dnase1 variant containing the triple amino acid mutation Q31R / T227K / A136F (Q31R / T227K / A136F, N = 6). P values ​​were calculated using the log-rank test. [Diagram 25]Comparison of wild-type DNase1 (D1) and a DNase1 variant (D1V) featuring the mutations Q31R / T227K / A136F is shown. Purified proteins were analyzed at the indicated amounts. dsDNA degradation activity is shown by zymography as black circles. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., 0 ng). Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin shows a shift from high molecular weight DNA to smaller, i.e., lower molecular weight DNA, which correlates with chromatin degradation activity. The DNase1 variant featuring the mutations Q31R / T227K / A136F degrades chromatin approximately 10-20 times more efficiently than wild-type DNase1. [Figure 26] Comparison of DNase1 variants with amino acid mutations A164K, A136F, and A164K / A136F (D1V) with wild-type DNase1 (D1) and wild-type (D1L3) is shown. Culture supernatants of transfected HEK cells were analyzed. Zymography shows dsDNA degradation activity as black circles. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., Ctrl). Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin shows a shift from high molecular weight DNA to smaller, i.e., low molecular weight DNA, which correlates with chromatin degradation activity. DNase1 variants characterized by A136F / A164K degrade chromatin most efficiently. [Figure 27]Development of DNase1 variant with mutation A226_T227insK. (Figure 27A) Amino acid sequence alignment of human DNase1 (SEQ ID NO: 1) and human DNase1L3 (SEQ ID NO: 2). Sequence rulers indicate the position of amino acids. The key arginine residue of DNase1L3 is highlighted. Shared amino acids between DNase1 and DNase1L3 are highlighted, which act as anchors to replace the amino acid sequence ATP of DNase1 with VKKS of DNase1L3. (Figure 27B) dsDNA degradation activity is shown by zymography as black circles. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., Ctrl). Gels were loaded with wild-type DNase1 (D1), DNase1 variant (D1V) characterized by mutations A226_T227insK, T227K, and A226_P228delinsVKKS. A226_T227insK, but not A226_P228delinsVKKS, correlates with reduced dsDNA degradation activity. [Figure 28] The structure of human DNase1[4AWN] is shown, highlighting the N- and C-terminal β-sheets as well as the motifs S272 / D273 / H274 that are conserved among members of the D1 protein family. [Figure 29] This illustrates the concept of building block engineering of homologous proteins, in which a single or multiple variable amino acids adjacent to a conserved single or multiple variable amino acids are transferred between donor and recipient proteins. [Diagram 30] Amino acid sequence alignment of mouse (SEQ ID NOs: 3 and 34), rat (SEQ ID NOs: 4 and 35), chimpanzee (SEQ ID NOs: 36 and 37), and human (SEQ ID NOs: 1 and 2) DNase1 and DNase1L3 is shown. The N-terminal signal peptide and conserved amino acids are highlighted. Variable amino acids are not highlighted and serve as building blocks that can be transferred from DNase1 to DNase1L3 and vice versa. Abbreviations: AA, amino acid. [Figure 31A]Figure 1 shows a list of building blocks for human DNase 1 (D1) and human DNase 1L3 (D1L3). Conserved amino acids in D1 and D1L3 are shown, which serve as N-anchors and C-anchors, respectively. Building blocks are variable amino acids in D1 and D1L3. Mutations that transfer building blocks from D1L3 to D1 are shown. [Figure 31B] The building blocks of human DNase1 (D1) and human DNase1L3 (D1L3) are listed. The N-anchor and C-anchor of D1L3 are shown. The mutations that transfer the building blocks from D1 to D1L3 are listed. AA: amino acid. [Diagram 32] The application of building block engineering of homologous proteins is shown. The application uses the transfer of clusters of building blocks between homologous donor and recipient proteins as an initial screening step. An additional optional step is the transfer of individual building blocks followed by the transfer of individual amino acids. In a final step (not shown), multiple amino acids, building blocks and building block clusters may be combined to create chimeric enzymes. [Diagram 33] Characterization of a DNase1 variant (D1V) featuring building blocks derived from DNase1L3 (D1L3) is shown. Zymography shows dsDNA degradation activity as black circles. dsDNA degradation activity correlates with diameter. Samples without activity showed loading wells as small black spots (e.g., Ctrl). Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin shows a shift from high molecular weight DNA to more compact, i.e. low molecular weight DNA, which correlates with chromatin degradation activity. Substitutions of building blocks that cause an increase in chromatin degradation activity are highlighted in dark shading. Samples without such an effect are shown in light shading. DNase1 variants featuring combinations of building blocks 11, 12-14, 26, 41-48, and 49 show chromatin degradation activity similar to wild-type DNase1L3. [Diagram 34]Development of DNase1L3 variants that do not contain the C-terminal tail of wild-type DNase1L3. Figure 34A shows an amino acid sequence alignment of human DNase1 (SEQ ID NO:1) and human DNase1L3 (SEQ ID NO:2). The sequence ruler indicates the position of the amino acids. The C-terminus of DNase1L3 is highlighted and its nuclear localization signal is enclosed in a rectangle. The shared amino acids between DNase1 and DNase1L3 are shown. Amino acids located after the conserved SDH motif were exchanged in building block cluster 60-62 between DNase1 and DNase1L3. Figure 34B shows a zymogram showing dsDNA degradation activity as black circles. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., Ctrl). Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin showed a shift from high molecular weight DNA to smaller, i.e., lower molecular weight DNA, which correlates with chromatin degradation activity. Wild-type DNase1 (D1), a DNase1 variant featuring BB cluster 60-62 derived from D1 (D1V), and a DNase1L3 variant featuring BB cluster 60-62 derived from D1 (D1L3V) were loaded onto the gel, and D1L3V with two mutations (K301A, K303A) was also created to inactivate NLS2. D1L3V, which contains BB cluster 60-62 derived from D1, showed higher chromatin degradation activity than wild-type D1L3. [Diagram 35]Development of a glycosylated DNase1L3 variant (D1L3V). Figure 35A shows an amino acid sequence alignment of human DNase1 (SEQ ID NO:1) and human DNase1L3 (SEQ ID NO:2). The sequence rulers indicate the amino acid positions. The glycosylation motifs N40-X-T42 and N128-X-T130 of DNase1 are highlighted. This site is part of building block (BB) 4 and building block cluster (BB) 23-25. The relevant shared amino acids between DNase1 and DNase1L3 are highlighted. (Figure 35B) Zymography shows dsDNA degradation activity as black circles. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., Ctrl). Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin showed a shift from high molecular weight DNA to lower, i.e., low molecular weight DNA, which correlates with chromatin degrading activity. Wild-type DNase1L3 (D1L3), a DNase1L3 variant characterized by BB 4 of D1 (D1L3V), and a DNase1L3 variant characterized by BB clusters 23-25 ​​of D1 (D1L3V) were loaded onto the gel. Western blot (WB) with an antibody against D1L3 detected that D1L3V showed a greater increase in the amount of protein. Both glycosylated DNase1L3 variants (D1L3V) retained the ability to degrade chromatin. [Diagram 36]The therapeutic effect of DNase1L3 (SEQ ID NO: 2) and its variants (SEQ ID NO: 17) on NETs in vivo is shown. Figure 36A shows H&E staining of mouse heart and dense clots of intraventricular NETs with hematoxylin enrichment. Figure 36B shows the timeline starting from induction of NETs and leading to vascular occlusion and death due to NETs. Hematuria and hypothermia are external signs of NET clots in vivo. (Figure 36C) Outline of experimental design: Csf3 was expressed in Dnase1- / -Dnase1l3- / - to induce vascular clots of NETs. Mice that showed hematuria and hypothermia were randomized by injection of vehicle (N=3), dornase alpha (D1, N=3), purified DNase1L3 (D1L3, N=3), or purified DNase1L3 variants (SEQ ID NO: 17, D1L3V, N=3). After 30 minutes, lungs and serum were collected. Treatment with D1L3 or D1L3V significantly reduced pulmonary NET-induced vascular obstruction (FIG. 36D) and increased serum DNA levels (FIG. 36E), whereas saline or D1 did not. FIG. 36F shows oligonucleosomes in serum from mice receiving D1L3 therapy. Mice administered D1L3V showed smaller mono- and dinucleosomes. DNA isolation from serum from mice receiving D1 therapy showed faint DNA smears of various sizes, whereas no DNA could be isolated from serum from vehicle-injected mice. [Figure 37]The therapeutic effect of DNase1L3 variant (SEQ ID NO: 17) in a rat model of ischemia-reperfusion (IR) injury is shown. (Figure 37A) Overview of experimental design: One testis of male wild-type rats was subjected to testicular torsion. The procedure causes ischemic tissue damage. Mice were randomized. After testis detorsion, they were injected with vehicle (N=6), dornase alpha (D1, N=6), or purified DNase1L3 variant (SEQ ID NO: 17, D1L3V, N=6). Untreated and ischemic testes were harvested 7 days later. Figure 37B shows that treatment with D1L3V, but not saline or D1, significantly reduced atrophy of the ischemic testes. Figure 37C quantifies macroscopic tissue damage. All untreated testes were brownish and well vascularized, indicating healthy tissue (Ctrl, score: 0). Testicular torsion and subsequent reperfusion injury resulted in tissue that appeared whitish (IR, score: 4). Treatment with D1L3V substantially reduced tissue damage, with 4 / 6 testes showing no signs of injury, but not with saline or D1. Scale bar: 1 cm. [Figure 38] Expression levels of DNase1, DNase1L3, and its variants are shown. (Figure 38A) Stable pools of CHO cells producing wild-type DNase1 (D1), its variant (D1V, SEQ ID NO: 7), wild-type D1L3, and its variant (D1L3V, SEQ ID NO: 17) were cultivated in bioreactors. Samples were taken periodically and analyzed by Western blot. Expression of D1 and D1V was detected, while the levels of D1L3 and D1L3V were low. (Figure 38B) Robust expression of D1L3 and D1L3V was achieved in Pichia pastoris. (Figure 38C) dsDNA degradation activity was shown as black circles by zymography. dsDNA degradation activity correlates with diameter. Samples without activity show loading wells as small black spots (e.g., D1L3, 0.0005 ng). Agarose gel electrophoresis (AGE) of DNA isolated from digested chromatin shows a shift from high molecular weight DNA to smaller, i.e., low molecular weight DNA, which correlates with chromatin degrading activity. D1L3V degrades chromatin approximately 10-fold more efficiently than D1L3. [Figure 39] Specific DNase variants according to the present disclosure are shown. The amino acid mutations of DNase1 and DNase1L3 including the signal peptide, as well as the mature protein without the signal peptide are shown. Mutations generated using building block modifications are marked with a "+" and the building blocks are shown in brackets. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] The present invention provides modified DNase proteins, members of the DNase 1 protein family (including DNase 1-like 3 and DNase 1), useful in the treatment of conditions characterized by the accumulation and / or release of neutrophil extracellular traps (NETs). In some aspects, the present invention provides compositions and methods for preventing or treating NET-related vascular occlusion. As shown herein, NETs are involved in a non-canonical mechanism of vascular occlusion and are fibrin and platelet independent.

[0027] As used herein, the term "neutrophil extracellular trap" or "NET" refers to any extracellular trap ("ET") containing extracellular DNA formed by cells, including, but not limited to, neutrophils, monocytes, macrophages, basophils, eosinophils, mast cells, cancer cells, damaged cells (e.g., damaged endothelial cells), etc. Unless the context indicates otherwise, the terms NET and ET are used interchangeably herein.

[0028] There are two extracellular DNase enzymes found in the circulation of humans and mice, DNase1 (D1) and DNase1-like 3 (D1L3). These enzymes may lack the ability and mechanisms to degrade NETs in vitro and in vivo and are found at relatively low concentrations in humans and mice. The native enzymes do not have the physical, enzymatic, and / or pharmacodynamic properties that are ideal for recombinant therapy, especially systemic therapy.

[0029] D1 and D1L3, along with DNase1-like 1 (D1L1) and DNase1-like 2 (D1L2), belong to the DNase1 protein family. D1 and D1L3 are expressed in various species, including humans, primates, and rodents. In humans and mice, D1 and D1L3 show 49–52% protein similarity. However, despite their homology, D1 and D1L3 differ in their cellular origin, sensitivity to inhibitors, and substrate affinity. D1 preferentially cleaves protein-free DNA (e.g., bacterial DNA, plasmid DNA), whereas D1L3 targets chromatin, a complex of DNA and histones commonly found in the nuclei of eukaryotic cells. D1 activity is inhibited upon binding to monomeric actin and is highly sensitive to physiological salt concentrations. Furthermore, D1 is glycosylated at N40 (corresponding to N18 in the mature enzyme without the signal peptide) and N128 (N106), which renders the enzyme resistant to inactivation by serum proteases. In contrast, D1L3 lacks the glycosylation and actin-binding sites, which renders it sensitive to several proteases and resistant to actin, respectively.

[0030] In some aspects, the invention provides D1L3 variants that have been modified to have physical, pharmacodynamic, and / or enzymatic properties that are more suitable for treatment, for example, to reduce or prevent NET accumulation in a subject. In various embodiments, the invention provides recombinant D1L3 protein variants that include one or more glycosylations, one or more amino acid changes resulting in increased substrate affinity, inactivation of a nuclear localization signal, deletion of all or part of the C-terminal tail, pegylation, and fusion to a carrier protein or moiety. In various embodiments, the D1L3 variants have increased protein stability, increased protease resistance, increased bioavailability, increased half-life in circulation, and / or substantially equivalent or better DNA and / or chromatin and / or NET degrading activity, higher production levels in an in vitro expression system (e.g., Chinese hamster ovary cells and / or Pichia pastoris) compared to the wild-type D1L3 protein of SEQ ID NO:2.

[0031] In various embodiments, the D1L3 variant has an amino acid sequence that has at least 80% sequence identity to the enzyme defined by the amino acid sequence of SEQ ID NO:2 and has one or more amino acid modifications relative to SEQ ID NO:2 as described herein. In some embodiments, the D1L3 variant has an amino acid sequence that has at least 90%, or at least 95%, or at least 97%, or at least 98% sequence identity to the DNase enzyme defined by SEQ ID NO:2.

[0032] As used herein, when referring to sequence identity with wild-type DNase enzyme, and unless otherwise specified, the sequence refers to the mature enzyme lacking the signal peptide. Furthermore, unless otherwise specified, the amino acid positions are numbered with respect to the complete translated DNase sequence, including the signal peptide, for clarity. Thus, for example, reference to sequence identity with the enzyme of SEQ ID NO:2 refers to the percentage of identity with the mature enzyme having M21 at the N-terminus. Similarly, reference to sequence identity with the enzyme of SEQ ID NO:1 (human D1) refers to the percentage of identity with the mature enzyme having L23 at the N-terminus.

[0033] The similarity of nucleotide and amino acid sequences, i.e., the percentage of sequence identity, can be determined through sequence alignment, as known in the art. Such alignment can be performed using several algorithms known in the art, such as the mathematical algorithm of Karlin and Altschul (Karlin & Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877), hmmalign (HMMER package, http: / / hmmer.wustl.edu / ) or the CLUSTAL algorithm (Thompson, JD, Higgins, DG & Gibson, TJ (1994) Nucleic Acids Res. 22, 4673-80). An exemplary algorithm is incorporated in the BLASTN and BLASTP programs of Altschul et al (1990) J. Mol. Biol. 215:403-410. When using BLAST programs, the default parameters of the respective programs are used.

[0034] In some embodiments, the recombinant D1L3 protein variant comprises one or more glycosylation consensus sequences, such as NX(T / S). The human wild-type enzyme (SEQ ID NO:2) does not comprise a consensus glycosylation sequence. However, the incorporation of a glycosylation consensus sequence into D1L3 can confer glycosylation (and protease resistance) without substantially affecting the enzyme activity. In some embodiments, the glycosylation consensus sequence comprises a D38N substitution and an N40T or N40S substitution, and / or an A127N substitution and a V129T or V129S substitution from the wild-type sequence (e.g., SEQ ID NO:2). In some embodiments, the recombinant D1L3 enzyme has one, two, three, or four glycosylation sites. The consensus sequence can be introduced into the protein at a position that does not affect its enzymatic activity, and in some embodiments is located near a portion of the enzyme that is important for maintaining the structure of the enzyme (e.g., amino acids 25-289, and in some embodiments, amino acids 24-150).

[0035] In some embodiments, the invention provides a DNase enzyme having an amino acid sequence that is at least 80% identical to the amino acid sequence of the enzyme defined by SEQ ID NO:2, where the enzyme has an asparagine substitution at a position corresponding to positions 38 and / or 127 of SEQ ID NO:2, and N38 and / or N127 are glycosylated. In some embodiments, the substitution at positions 38 and / or 127 is made by a building block substitution from SEQ ID NO:1 as described herein.

[0036] In various embodiments, D1L3 variants having one or more glycosylations exhibit increased resistance to serum protease degradation and / or increased serum half-life compared to the wild-type D1L3 protein (SEQ ID NO:2).

[0037] In some embodiments, the D1L3 protein variant comprises an inactivation of the nuclear localization signal (NLS). D1L3 has two nuclear localization sites (NLS1, NLS2), both of which direct the enzyme to the nucleus during apoptosis. Indeed, D1L3 is required for nuclear DNA fragmentation in apoptotic and necrotic cells in vivo. NLS1 is located near the N-terminus (approximately amino acids 80-96, relative to SEQ ID NO:2). NLS2 (amino acids 291-304, relative to SEQ ID NO:2) is embedded within the C-terminal tail (amino acids 283-305, relative to SEQ ID NO:2) and is unique to D1L3 and absent from D1. The C-terminal tail is believed to be necessary for D1L3 to degrade different extracellular DNA substrates, namely lipid-encapsulated DNA and chromatin within apoptotic bodies. Lipids encapsulate DNA during transfection. Briefly, cDNA, protein-free DNA, and cationic lipids form a complex that penetrates the plasma membrane of the target cell. D1L3 interferes with transfection, and the C-terminus is critical for this function. The physiological substrate of D1L3 is apoptotic bodies, extracellular lipid vesicles filled with chromatin from apoptotic cells. The C-terminal tail allows D1L3 to penetrate the lipid membrane of apoptotic bodies and disassemble the chromatin packing. The C-terminal tail is also thought to be required for D1L3-mediated disassembly of lipid-free extracellular chromatin. Thus, the C-terminal tail, a unique molecular feature of D1L3, appears to be responsible for the distinct substrate affinities of D1 and D1L3.

[0038] Inactivation of one or more NLSs increases the availability and / or activity of the enzyme in circulation. In some embodiments, NLS inactivation is achieved by deletion of all or part of NLS1 and / or NLS2. In some embodiments, the NLS is inactivated by substitution and / or deletion of amino acids within NLS1 and / or NLS2. In some embodiments, NLS2 is fully or partially deleted. In some embodiments, the D1L3 protein variant comprises deletion of all or part of the C-terminal tail and / or substitution of one or more amino acids in the C-terminal tail.

[0039] In certain embodiments, the D1L3 variant comprises one or more, for example, 1, 2, 3, 4, 5 or more amino acid substitutions, additions (e.g., insertions) or deletions in the NLS1 domain. The NLS2 domain or a portion thereof may be deleted. In certain embodiments, the D1L3 protein variant comprises one or more, for example, 1, 2, 3, 4, 5 or more amino acid substitutions, additions or deletions in the C-terminal tail domain. The C-terminal tail domain or a portion thereof may be deleted. In various embodiments, the D1L3 protein variant comprises one or more, for example, 1, 2, 3, 4, 5 or more amino acid substitutions, additions or deletions in the NLS2 domain located in the C-terminal tail domain. The NLS2 domain or a portion thereof may be deleted in the D1L3 protein variant.

[0040] In various aspects, the present invention provides protein modification techniques based on the transfer of single or multiple adjacent amino acids, called "building blocks", between two members of a protein family, such as DNase 1 protein family members, to generate enzymatically active variants of DNase 1 protein family members, including variants of D1 and D1L3. The "building blocks" are defined by amino acids that are variable between two or more members of the DNase 1 protein family. These variable amino acids are flanked by amino acids that are conserved between two or more members of the DNase 1 protein family ("anchors"). The transfer of the variable single or multiple consecutive amino acids ("building blocks") between the conserved single or multiple consecutive amino acids ("anchors") allows them to be exchanged between members of the DNase 1 protein family.

[0041] This approach is referred to herein as "building block protein modification". When three or more amino acids are transferred, up to 1 / 3 of the amino acids may be further replaced. For example, when three or six amino acids are transferred as building blocks, one or up to two residues may be further replaced, respectively. In some embodiments, four or more amino acids are transferred as building block replacements, and up to 25% of the transferred amino acids are further replaced, for example, with conservative or non-conservative amino acid modifications. For example, when 4, 8, or 12 amino acids are transferred, one, two, or three amino acids (respectively) may be further replaced with building block replacements.

[0042] In various aspects (including those related to the above embodiments), the D1L3 variant comprises at least one building block substitution from D1. Figure 31 shows 62 building block substitutions between D1 and D1L3.

[0043] Exemplary building block substitutions from D1 include one or more of the following: Substitution of 1-20 (MSRELAPLLLLLLSIHSALA) in SEQ ID NO:2 with 1-22 (MRGMKLLGALLALAALLQGAVS) derived from SEQ ID NO:1; substitution of 21-25 (MRICS) in SEQ ID NO:2 with 23-27 (LKIAA) derived from SEQ ID NO:1; substitution of 28-30 (VRS) in SEQ ID NO:2 with 30-32 (IQT) derived from SEQ ID NO:1; substitution of 33-34 (ES) in SEQ ID NO:2 with 35-36 (ET) derived from SEQ ID NO:1; substitution of 36-45 (QEDKNAMDVI) in SEQ ID NO:2 with 38-47 (MSNATLVSYI) derived from SEQ ID NO:1; 47-51 (KVIK) of SEQ ID NO:2 are replaced with 49-53 (QILS) derived from SEQ ID NO:1; 52 (C) of SEQ ID NO:2 are replaced with 54 (Y) derived from SEQ ID NO:1; 54-58 (IILVM) of SEQ ID NO:2 are replaced with 56-60 (IALVQ) derived from SEQ ID NO:1; 60-61 (IK) of SEQ ID NO:2 are replaced with 62-63 (VR) derived from SEQ ID NO:1; 63-70 (SNNRICPI) of SEQ ID NO:2 are replaced with 65-72 (SHLTAVGK) derived from SEQ ID NO:1; 72-74 (MEK) of SEQ ID NO:2 are replaced with 74-76 (LDN) derived from SEQ ID NO:1; 77-84 (RNS) of SEQ ID NO:2 are replaced with 86(N) of SEQ ID NO:2 is replaced with 86(H) of SEQ ID NO:1; 88-89(VI) of SEQ ID NO:2 is replaced with 88-89(VV) of SEQ ID NO:1; 91-92(SR) of SEQ ID NO:2 is replaced with 91-92(EP) of SEQ ID NO:1; 96-97(NT) of SEQ ID NO:2 is replaced with 96-97(NS) of SEQ ID NO:1; 101(Q) of SEQ ID NO:2 is replaced with 101(R) of SEQ ID NO:1; 103(A) of SEQ ID NO:2 is replaced with 103(L) of SEQ ID NO:1; 105(L) of SEQ ID NO:2 is replaced with 105(V) from SEQ ID NO:1; 107-110(KEKL) from SEQ ID NO:2 from 107-110(RPDQ) from SEQ ID NO:1; 113-116(VKRS) from SEQ ID NO:2 from 113-116(AVDS) from SEQ ID NO:1; 118(H) from SEQ ID NO:2 from 118(Y) from SEQ ID NO:1; 120(H) from SEQ ID NO:2 from 120(D) from SEQ ID NO:1; 122-127(YQDGDA) from SEQ ID NO:2 from 122-128(GCEPCGN) from SEQ ID NO:1; 129(V) from SEQ ID NO:2 from 130(T) from SEQ ID NO:1;131 (S) of SEQ ID NO:2 is replaced with 132 (N) derived from SEQ ID NO:1; 135-136 (FV) of SEQ ID NO:2 is replaced with 136-137 (AIV) derived from SEQ ID NO:1; 138 (W) of SEQ ID NO:2 is replaced with 139 (R) derived from SEQ ID NO:1; 140-143 (QSPH) of SEQ ID NO:2 is replaced with 141-144 (FSRF) derived from SEQ ID NO:1; 145-148 (AVKD) of SEQ ID NO:2 is replaced with 146-149 (EVRE) derived from SEQ ID NO:1; 150 (V) of SEQ ID NO:2 is replaced with 151 (A) derived from SEQ ID NO:1; 152 (I) of SEQ ID NO:2 is replaced with Substitute 153(V) from SEQ ID NO:1; substitute 156-157(TT) from SEQ ID NO:2 with 157-158(AA) from SEQ ID NO:1; substitute 159-161(ETS) from SEQ ID NO:2 with 160-162(GDA) from SEQ ID NO:1; substitute 163(K) from SEQ ID NO:2 with 164(A) from SEQ ID NO:1; substitute 167(E) from SEQ ID NO:2 with 168(A) from SEQ ID NO:1; substitute 169-170(VE) from SEQ ID NO:2 with 170-171(YD) from SEQ ID NO:1; substitute 173(T) from SEQ ID NO:2 with 174(L) from SEQ ID NO:2 176-178 (KHR) is replaced with 177-179 (QEK) derived from SEQ ID NO:1; 180-181 (KA) of SEQ ID NO:2 is replaced with 181-182 (GL) derived from SEQ ID NO:1; 183-186 (NFIF) of SEQ ID NO:2 is replaced with 184-187 (DVML) derived from SEQ ID NO:1; 198-201 (PKKA) of SEQ ID NO:2 is replaced with 199-202 (RPSQ) derived from SEQ ID NO:1; 203-204 (KN) of SEQ ID NO:2 is replaced with 204-205 (SS) derived from SEQ ID NO:1; 208 (R) of SEQ ID NO:2 is replaced with 209 (W) derived from SEQ ID NO:1; 210(D) of SEQ ID NO:2 is replaced with 211(S) derived from SEQ ID NO:1; 212(R) of SEQ ID NO:2 is replaced with 213(T) derived from SEQ ID NO:1; 214(V) of SEQ ID NO:2 is replaced with 215(Q) derived from SEQ ID NO:1; 218(G) of SEQ ID NO:2 is replaced with 219(P) derived from SEQ ID NO:1; 220-221(QE) of SEQ ID NO:2 is replaced with 221-222(SA) derived from SEQ ID NO:1; 225-228(VKKS) of SEQ ID NO:2 is replaced with 226-228(ATP) derived from SEQ ID NO:1; 230(N) of SEQ ID NO:2 is replaced with 230(H) derived from SEQ ID NO:1;238-240 (LRG) of SEQ ID NO:2 is replaced with 238-240 (VAG) derived from SEQ ID NO:1; 241-246 (QEIVSS) of SEQ ID NO:2 is replaced with 241-246 (MLLRGA) derived from SEQ ID NO:1; 250 (K) of SEQ ID NO:2 is replaced with 250 (D) derived from SEQ ID NO:1; 252-254 (NSV) of SEQ ID NO:2 is replaced with 252-254 (ALP) derived from SEQ ID NO:1; 256 (D) of SEQ ID NO:2 is replaced with 256 (N) derived from SEQ ID NO:1; 259-260 (KA) of SEQ ID NO:2 is replaced with 259-260 (AA ... 62(K) is replaced with 262(G) derived from SEQ ID NO:1; 264-267(TEEE) of SEQ ID NO:2 is replaced with 264-267(SDQL) derived from SEQ ID NO:1; 269-271(LDV) of SEQ ID NO:2 is replaced with 269-271(QAI) derived from SEQ ID NO:1; 275(F) of SEQ ID NO:2 is replaced with 275(Y) derived from SEQ ID NO:1; 279-280(FK) of SEQ ID NO:2 is replaced with 279-280(VM) derived from SEQ ID NO:1; and 282-305(QSSRAFTNSKKSVTLRKKTKSKRS) of SEQ ID NO:2 is replaced with 282(K) derived from SEQ ID NO:1.

[0044] These building block substitutions from D1 result in variants of D1L3 characterized by one or more of the following mutations: M1_A20delinsMRGMKLLGALLALAALLQGAVS, M21_S25delinsLKIAA, V28_S30delinsIQT, E33_S34delinsET, Q36_I45delinsMSNATLVSYI, K47_K50delinsQILS, C52Y, I54_M58delinsIALVQ, I60_K61delinsVR, S63_I7 ... linsSHLTAVGK, M72_K74delinsLDN, R77_T84delinsQDAPDT, N86H, V88_I89delinsVV, S91_R92delinsEP, N96_T97delinsNS, Q101R, A103L, L 105V, K107_L110delinsRPDQ, V113_S116delinsAVDS, H118Y, H120D, Y122_A127delinsGCEPCGN, V129T, S131N, 135F_136VdelinsAI, W138R, Q 140_H143delinsFSRF, A145_D148delinsAVKD, V150A, I152A, T156_T157delinsAA, E159_S161delinsGDA, K163A, E167A, V169_E170delinsY D, T173L, K176_R178delinsQEK, K180_A181delinsGL, N183_F186delinsDVML, P198_A201delinsRPSQ, K203_N204delinsSS, R208W, D210S, R2 12T, V214Q, G218P, Q220_E221delinsSA, V225_S228delinsATP, N230H, L238_R239delinsVA, Q241_S246delinsMLLRGA, K250D, N252_V254del insALP, D256N, K259_A260delinsAA, K262G, T264_E267delinsSDQL, L269_V271delinsQAI, F275Y, F279_K280delinsVM, Q282_S305delinsK.

[0045] The term "delins" refers to a deletion between two amino acids as described, with an amino acid or sequence of amino acids inserted at the deletion site. For example, the designation E91_P92delinsSR means deleting amino acids E91 through P92 and inserting amino acids SR at the deletion site (e.g., the resulting amino acid sequence would be S91 and R92).

[0046] The term "ins" refers to the insertion of an amino acid between the two amino acids described. For example, the notation E91_P92insSR means inserting the amino acid SR between E91 and P92, resulting in the sequence E91, S92, R93, and P94.

[0047] Multiple mutations in one enzyme are separated by " / ", e.g., T227K / A136F or R199_Q202delinsPKKA / S204_S205delinsKN / W209R / S211D / T213R / Q215V / P219G / S221_A222delinsQE.

[0048] In some embodiments, the D1L3 variant comprises one or more adjacent building block substitutions. For example, the D1L3 variant may comprise the mutations F275Y / F279_K280delinsVM / Q282_S305delinsK (SEQ ID NO: 17) with respect to SEQ ID NO: 2. In some embodiments, the D1L3 variant may comprise the mutations Q36_I45delinsMSNATLVSYI (SEQ ID NO: 19) with respect to SEQ ID NO: 2. In some embodiments, the D1L3 variant may comprise the mutations Y122_A127delinsGCEPCGN / V129T / S131N (SEQ ID NO: 20) with respect to SEQ ID NO: 2.

[0049] In an exemplary embodiment, the D1L3 variant comprises two or three substitutions selected from the following mutations relative to SEQ ID NO:2: Q36_I45delinsMSNATLVSYI, Y122_A127delinsGCEPCGN / V129T / S131N, F275Y / F279_K280delinsVM / Q282_S305delinsK.

[0050] Thus, in some embodiments, the invention provides a DNase enzyme having an amino acid sequence that is at least 80% identical to the amino acid sequence of the enzyme defined by SEQ ID NO:2, and including at least one building block substitution from the amino acid sequence of SEQ ID NO:1. The building block substitutions between SEQ ID NOs:1 and 2 are illustrated and numbered in Figure 31. For example, in some embodiments, the enzyme includes the mutations F275Y / F279_K280delinsVM / Q282_S305delinsK, and optionally has the amino acid sequence of SEQ ID NO:17. In some embodiments, the enzyme includes the mutations Q36_I45delinsMSNATLVSYI, Y122_A127delinsGCEPCGN, V129T, or S131N, and optionally has the amino acid sequence of SEQ ID NO:19 or SEQ ID NO:20.

[0051] Exemplary D1L3 variants include those having the amino acid sequences of SEQ ID NOs: 17-20. In some embodiments, the invention includes derivatives having 1-10 (e.g., 1-5) amino acid insertions, deletions, or substitutions compared to any of SEQ ID NOs: 17-20. In some embodiments, the D1L3 variants include one or more additional block amino acid substitutions from a homologous DNase (e.g., from D1). Such block substitutions may replace at least 2, at least 3, at least 4, or at least 5 amino acids. In some embodiments, block substitutions replace 2-20 amino acids, e.g., 3-15 amino acids, or 3-10 amino acids, with the equivalent building blocks from a homologous DNase.

[0052] Modified variants of the D1L3 protein may include one or more additional amino acid substitutions, additions (insertions), deletions, or truncations in the amino acid sequence of human D1L3 (SEQ ID NO: 2). The amino acid substitutions may include conservative and / or non-conservative substitutions.

[0053] For example, "conservative substitutions" may be made based on, for example, similarity in polarity, charge, size, solubility, hydrophobicity, hydrophilicity, and / or amphipathicity of the amino acid residues involved. The 20 natural amino acids can be classified into the following six standard amino acid groups: (1) hydrophobic: Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr; Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that affect chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. A "conservative substitution" is defined as the replacement of an amino acid with another amino acid listed within the same group of the six standard amino acid groups above. For example, the replacement of Asp with Glu retains one negative charge in the so modified polypeptide. Additionally, glycine and proline may be substituted for each other based on their ability to disrupt α-helices. As used herein, a "non-conservative substitution" is defined as the exchange of one amino acid with another amino acid listed in a different group of the six standard amino acid groups (1) to (6) above.

[0054] In some embodiments, the DIL3 protein variant comprises an N- or C-terminal fusion to a half-life extending moiety such as albumin, transferrin, Fc, or elastin-like protein. See US9,458,218, which is incorporated herein by reference in its entirety. In some embodiments, D1L3 is dimerized by an immunoglobulin hinge region. For example, the modified enzymes described herein may also comprise an Fc fusion domain (e.g., an immunoglobulin hinge and a CH2 domain and a CH3 domain). In other cases, the modified D1L3 protein is fused to albumin, e.g., human albumin or a fragment thereof. See WO2015 / 066550; US9,221,896, which are incorporated herein by reference in their entirety. Albumin may be attached at the N- or C-terminus of the modified D1 protein, and may optionally comprise an amino acid linker. In some embodiments, D1L3 and D1 are linked and dimerized by the Fc hinge region to create a dimeric molecule with synergistic functional properties for degrading NETs.

[0055] In some embodiments, the recombinant D1L3 protein variant comprises one or more polyethylene glycol (PEG) moieties that may be conjugated at one or more positions or at the C-terminus. In some embodiments, the native amino acid at that position is replaced with an amino acid having a side chain suitable for crosslinking with a hydrophilic moiety to facilitate attachment of the hydrophilic moiety to the peptide. In other embodiments, an amino acid modified to contain a hydrophilic group is added to the C-terminus of the peptide. The PEG chain(s) may have a molecular weight ranging from about 500 to about 40,000 daltons. In some embodiments, the PEG chain(s) have a molecular weight ranging from about 500 to about 5,000 daltons. In some embodiments, the PEG chain has a molecular weight of about 10,000 to about 20,000 daltons.

[0056] In various embodiments, the D1L3 protein variants have increased protein stability, increased serum availability, and substantially equivalent or better NET degradation activity (measured in vitro or in vivo) compared to wild-type D1L3 protein. In various embodiments, the D1L3 variants include one or more of the following properties compared to wild-type D1L3: higher protein-free DNA (naked DNA) degradation activity, equivalent or substantially equivalent (e.g., at least 50%) chromosomal DNA degradation activity, protease resistance, increased half-life, and higher production levels in in vitro expression systems (e.g., Chinese hamster ovary cells and / or Pichia pastoris).

[0057] DNA fragmentation can be measured using methods known to those skilled in the art, such as gel electrophoresis and DNase activity assay. Methods for quantifying NETs, ​​NET degradation, and DNA fragmentation activity are described, for example, in Hakkim et al., Proc.Natl.Acad.Sci USA, 2010, 107(21):9813-9818; Napirei et al. Biochem J, 2005, 389:355-364. Fuchs et al., J Cell Biol, 2007, 176(2):231-241, Sisirak et al. Cell, 2016, 166:88-101, and Jimenez-Alcazar et al. J Thromb Haemost, 2015, 13, 732-742.

[0058] In some aspects, the invention provides DNase1 (D1) variants that are modified to have physical, pharmacodynamic, and / or enzymatic properties that are more suitable for treatment, for example, to reduce or prevent NET accumulation in a subject. In some embodiments, the variants are suitable for recombinant expression, thereby providing significant manufacturing advantages. In various embodiments, the modified D1 variants have an amino acid sequence that is at least 80% identical to the mature enzyme defined by the amino acid sequence of SEQ ID NO: 1 and has one or more mutated DNA binding sites, an added chromatin binding site, a mutated actin binding site, a mutated glycosylation site, an added nuclear localization signal (e.g., having similarity or identity to NLS1 or NLS2 of D1L3), and / or one or more amino acid substitutions, additions, or deletions that result in a C-terminal domain similar to the C-terminal tail of D1L3. D1 variants have an amino acid sequence that is at least 80% identical to the amino acid sequence of the enzyme defined by SEQ ID NO: 1 and has one or more amino acid modifications with respect to SEQ ID NO: 1, as described herein. In some embodiments, the D1L3 variant has an amino acid sequence that has at least 90%, or at least 95%, or at least 97%, or at least 98% identity to the enzyme of SEQ ID NO:1.

[0059] In various embodiments, the D1 variant comprises one or more amino acid substitutions, additions, deletions, or truncations in the amino acid sequence of human D1 (SEQ ID NO:1). In some embodiments, the amino acid substitutions can include conservative and / or non-conservative substitutions as described. For example, the D1 variant can comprise 1-20 (or 1-10, or 1-5) amino acid substitutions, deletions, or insertions relative to the enzyme of SEQ ID NO:1.

[0060] In some embodiments, the D1 variant comprises one or more additional block amino acid substitutions from a homologous DNase (e.g., from D1L3). Such block substitutions may substitute 1 to 24 amino acids, e.g., 3 to 15 amino acids, or 3 to 10 amino acids, respectively, from the homologous DNase. In some embodiments, the D1 variant comprises 2 to 5 block substitutions from a homologous DNase (e.g., D1L3). In some embodiments, two or three consecutive building block substitutions are transferred.

[0061] In various embodiments, the D1 variant is modified to include one or more of the following characteristics compared to the wild-type enzyme: substantially the same or higher protein-free DNA (naked DNA) degradation activity (e.g., at least 50% or higher), higher chromosomal DNA degradation activity, similar or improved protease resistance, actin resistance, increased serum half-life, improved penetration from blood into urine or bile, or a combination of such properties.

[0062] In some embodiments, the modified D1 enzyme has an amino acid sequence that has at least 50% (or at least 70%, 80%, 90%) sequence identity to the C-terminal domain of the wild-type D1L3 protein (e.g., amino acids 283-305 of SEQ ID NO:2).

[0063] In some embodiments, the D1 enzyme has an amino acid sequence that has at least 50% or at least 75% sequence identity to NLS1 (amino acids 35-51 of SEQ ID NO:2) of wild-type D1L3, and an NLS2 that has substantial sequence identity to nuclear localization signal 2 (NLS2) (amino acids 296-304 of SEQ ID NO:2) of the wild-type D1L3 protein.

[0064] In various embodiments, the recombinant D1 variant comprises one or more building block substitutions selected from the following: 1-22 (MRGMKLLGALLALAALLQGAVS) from SEQ ID NO:1 replaced with 1-20 (MSRELAPLLL LLLSIHSALA) from SEQ ID NO:2; 23-27 (LKIAA) from SEQ ID NO:1 replaced with 21-25 (MRICS) from SEQ ID NO:2; 30-32 (IQT) from SEQ ID NO:1 replaced with 28-30 (VRS) from SEQ ID NO:2; 35-36 (ET) from SEQ ID NO:1 replaced with 33-34 (ES) from SEQ ID NO:2; 38-47 (MSNATLVSYI) from SEQ ID NO:1 replaced with 36-45 (QEDKNAMDVI) from SEQ ID NO:2; 49-52 from SEQ ID NO:1 (QILS) is replaced with 47-50 (KVIK) from SEQ ID NO:2; 54 (Y) from SEQ ID NO:1 is replaced with 52 (C) from SEQ ID NO:2; 56-60 (IALVQ) from SEQ ID NO:1 is replaced with 54-58 (IILVM) from SEQ ID NO:2; 62-63 (VR) from SEQ ID NO:1 is replaced with 60-61 (IK) from SEQ ID NO:2; 65-72 (SHLTAVGK) from SEQ ID NO:1 is replaced with 63-70 (SNNRICPI) from SEQ ID NO:2; 74-76 from SEQ ID NO:1 (LDN) is replaced with 72-74 (MEK) from SEQ ID NO:2; 79-84 (QDAPDT) from SEQ ID NO:1 is replaced with 77-84 (RNSRRGIT) from SEQ ID NO:2; 86 (H) from SEQ ID NO:1 is replaced with 86 (N) from SEQ ID NO:2; 88-89 (VV) from SEQ ID NO:1 is replaced with 88-89 (VI) from SEQ ID NO:2; 91-92 (EP) from SEQ ID NO:1 is replaced with 91-92 (SR) from SEQ ID NO:2; 96-97 (NS) from SEQ ID NO:1 is replaced with SEQ ID NO:2 96-97 (NT) from SEQ ID NO:1 replaced with 101 (Q) from SEQ ID NO:2; 101 (R) from SEQ ID NO:1 replaced with 101 (Q) from SEQ ID NO:2; 103 (L) from SEQ ID NO:1 replaced with 103 (A) from SEQ ID NO:2; 105 (V) from SEQ ID NO:1 replaced with 105 (L) from SEQ ID NO:2; 107-110 (RPDQ) from SEQ ID NO:1 replaced with 107-110 (KEKL) from SEQ ID NO:2; 113-116 (AVDS) from SEQ ID NO:1 replaced with 113-116 (VKRS) from SEQ ID NO:2;118(Y) from SEQ ID NO:1 is replaced with 118(H) from SEQ ID NO:2, 120(D) from SEQ ID NO:1 is replaced with 120(H) from SEQ ID NO:2; 122-128(GCEPCGN) from SEQ ID NO:1 is replaced with 122-127(YQDGDA) from SEQ ID NO:2, 130(TF) from SEQ ID NO:1 is replaced with 129(V) from SEQ ID NO:2; 132(N) from SEQ ID NO:1 is replaced with 131(S) from SEQ ID NO:2; 136-137(AI) from SEQ ID NO:1 is replaced with 135-136(FV) from SEQ ID NO:2; 139(R) from SEQ ID NO:1 138 (W) from SEQ ID NO:2; 141-144 (FSRF) from SEQ ID NO:1 are replaced with 140-143 (QSPH) from SEQ ID NO:2; 146-149 (EVRE) from SEQ ID NO:1 are replaced with 145-148 (AVKD) from SEQ ID NO:2; 151 (A) from SEQ ID NO:1 is replaced with 150 (V) from SEQ ID NO:2; 153 (V) from SEQ ID NO:1 is replaced with 152 (I) from SEQ ID NO:2; 157-158 (AA) from SEQ ID NO:1 are replaced with 156-157 (TT) from SEQ ID NO:2; 160-162 (GDA) from SEQ ID NO:1 are replaced with 159-161 (ETS) from SEQ ID NO:2; 164 (A) from SEQ ID NO:1 is replaced with 163 (K) from SEQ ID NO:2; 168 (A) from SEQ ID NO:1 is replaced with 167 (E) from SEQ ID NO:2; 170-171 (YD) from SEQ ID NO:1 is replaced with 169-171 (VE) from SEQ ID NO:2; 174 (L) from SEQ ID NO:1 is replaced with 173 (T) from SEQ ID NO:2; 177-179 (QEK) from SEQ ID NO:1 is replaced with 176-178 (KHR) from SEQ ID NO:2; 181-182 (GL) from SEQ ID NO:1 is replaced with 180-181 from SEQ ID NO:2 (KA); 184-187 (DVML) from SEQ ID NO:1 is replaced with 183-187 (NFIF) from SEQ ID NO:2; 199-202 (RPSQ) from SEQ ID NO:1 is replaced with 198-201 (PKKA) from SEQ ID NO:2; 204-205 (SS) from SEQ ID NO:1 is replaced with 203-204 (KN) from SEQ ID NO:2; 209 (W) from SEQ ID NO:1 is replaced with 208 (R) from SEQ ID NO:2; 211 (S) from SEQ ID NO:1 is replaced with 210 (D) from SEQ ID NO:2; 213 (T) from SEQ ID NO:1 is replaced with 212 (R) from SEQ ID NO:2;215(Q) from SEQ ID NO:1 is replaced with 214(V) from SEQ ID NO:2; 219(P) from SEQ ID NO:1 is replaced with 218(G) from SEQ ID NO:2; 221-222(SA) from SEQ ID NO:1 is replaced with 220-221(QE) from SEQ ID NO:2; 226-228(ATP) from SEQ ID NO:1 is replaced with 225-228(VKKS) from SEQ ID NO:2; 230(H) from SEQ ID NO:1 is replaced with 230(N) from SEQ ID NO:2; 238-239(VA) from SEQ ID NO:1 is replaced with 238-239(LR) from SEQ ID NO:2; 241-246(MLLRGA) from SEQ ID NO:1 is replaced with 241-246(QEIVSS) from SEQ ID NO:2; 250-251(D) from SEQ ID NO:1 is replaced with 250-251(K) from SEQ ID NO:2; 252-254(ALP) from SEQ ID NO:1 is replaced with 2 269-271 (QAI) from SEQ ID NO:1 is replaced by 269-271 (LDV) from SEQ ID NO:2; 275 (Y) from SEQ ID NO:1 is replaced by 275 (F) from SEQ ID NO:2; 279-280 (VM) from SEQ ID NO:1 is replaced by 279-280 (FK) from SEQ ID NO:2; and 282 (K) from SEQ ID NO:1 is replaced by 282-305 (QSSRAFTNSKKSVTLRKKTKSKRS) from SEQ ID NO:2. ;

[0065] Building block substitutions from D1L3 result in variants of D1 characterized by one or more of the following mutations: 1M_S22delinsMSRELAPLLLLLLSIHSALA, L23_A27delinsMRICS, I30_T32delinsVRS, E35_T36delinsES, M38_I47delinsQEDKNAMDVI, Q49_S52delinsKVIK, Y54C, I56_Q60delinsIILVM, V62_R63delinsIK, S65_K72delinsSNNRI CPI, L74_N76delinsMEK, Q79_T84delinsRNSRRGIT, H86N, V88_V89delinsVI, E91_P92delinsSR, N96_S97delinsNT, R101Q, L103A, V105L, R107 _Q110delinsKEKL, A113_S116delinsVKRS, Y118H, D120H, G122_N128delinsYQDGDA, T130S, N132S, A136_I137delinsFV, R139W, F141_F144deli nsQSPH, E146_E149delinsAVKD, A151V, V153I, A157_A158delinsTT, G160_A162delinsETS, A164K, A168E, Y170_D171delinsVE, L174T, Q177_K 179delinsKHR, G181_L182delinsKA, D184_L187delinsNFIF, R199_Q202delinsPKKA, S204_S205delinsKN, W209R, S211D, T213R, Q215V, P219G, S221_A222delinsQE, A226_P228delinsVKKS, H230N, V238_A239delinsLR, M241_A246delinsQEIVSS, D250K, A252_P254delinsNSV, N256D, A25 9_A260delinsKA, G262K, S264_L267delinsTEEE, Q269_I271delinsLDV, Y275F, V279_M280delinsFK, K282delinsQSSRAFTNSKKSVTLRKKTKSKRS.

[0066] In some embodiments, the recombinant D1 variant comprises the following modifications with respect to SEQ ID NO: 1: Y275F, V279_M280delinsFK, and K282delinsQSSRAFTNSKKSVTLRKKTKSKRS (SEQ ID NO: 16). Such variants contain a C-terminal tail and exhibit higher affinity for DNA-lipid complexes.

[0067] In some embodiments, the recombinant D1 variant comprises the following amino acid modifications with respect to SEQ ID NO: 1: Q79_T84delinsRNSRRGIT (e.g., SEQ ID NO: 10); H86N, and / or V88_V89delinsVI, and / or E91_P92delinsSR (e.g., SEQ ID NO: 11 including all three); A136_I137delinsFV (e.g., SEQ ID NO: 12); R199_Q202delinsPKKA, and / or S204_S205delinsKN, and / or W209R, and / or S211D, and / or T213R, and / or Q215V, and / or P219G, and / or S221_A222delinsQE (e.g., SEQ ID NO: 13 including all eight); and A226_P228delinsVKKS (e.g., SEQ ID NO: 14).

[0068] In some embodiments in which the D1 variant comprises the substitution H86N, the variant comprises at least one further modification, e.g., a building block substitution or other point mutation described herein (e.g., the addition or substitution of a cationic amino acid that confers resistance to actin).

[0069] In some embodiments, the D1 variant comprises at least two adjacent consecutive building block substitutions resulting in the following mutations relative to SEQ ID NO:1: H86N / V88_V89delinsVI (e.g., SEQ ID NO:11); R199_Q202delinsPKKA / S204_S205delinsKN / W209R / S211D / T213R / Q215V / P219G / S221_A222delinsQE (e.g., SEQ ID NO:13); Y275F / V279_M280delinsFK / K282delinsQSSRAFTNSKKSVTLRKKTKSKRS (SEQ ID NO:16).

[0070] In some embodiments, the invention provides a DNase enzyme having an amino acid sequence that is at least 80% identical to the amino acid sequence of the enzyme defined by SEQ ID NO: 1 and comprising at least one building block substitution from the amino acid sequence of SEQ ID NO: 2, wherein the DNase enzyme has increased chromatin degradation activity compared to the DNase enzyme of SEQ ID NO: 1. In some embodiments, the enzyme comprises at least two adjacent building block substitutions from SEQ ID NO: 2. The building block substitutions between D1 (SEQ ID NO: 1) and D1L3 (SEQ ID NO: 2) are shown in FIG.

[0071] In some embodiments, the enzyme includes the following modifications with respect to SEQ ID NO:1: Q79_T84delinsRNSRRGIT, and optionally has the amino acid sequence of SEQ ID NO:10.

[0072] In some embodiments, the enzyme comprises the following modifications with respect to SEQ ID NO:1: H86N / V88_V89delinsVI / E91_P92delinsSR, and optionally has the amino acid sequence of SEQ ID NO:11.

[0073] In some embodiments, the enzyme comprises the following modifications with respect to SEQ ID NO:1: A136_I137delinsFV, and optionally has the amino acid sequence of SEQ ID NO:12.

[0074] In some embodiments, the enzyme comprises two or more of the following modifications relative to SEQ ID NO:1: R199_Q202delinsPKKA, and / or S204_S205delinsKN, and / or W209R, and / or S211D, and / or T213R, and / or Q215V, and / or P219G, and / or S221_A222delinsQE, and optionally has the amino acid sequence of SEQ ID NO:13 (including all eight).

[0075] In some embodiments, the enzyme includes the following modifications with respect to SEQ ID NO:1: A226_P228delinsVKKS, and optionally has the amino acid sequence of SEQ ID NO:14.

[0076] In some embodiments, the enzyme comprises two or more of the following modifications with respect to SEQ ID NO:1: Q79_T84delinsRNSRRGIT, and / or H86N, and / or V88_V89delinsVI, and / or E91_P92delinsSR, and / or A136_I137delinsFV, and / or R199_Q202delinsPKKA, and / or S204_S205delinsKN, and / or W209R, and / or S211D, and / or T213R, and / or Q215V, and / or P219G, and / or S221_A222delinsQE, and / or A226_P228delinsVKKS, and optionally has the amino acid sequence of SEQ ID NO:15.

[0077] In some embodiments, the enzyme includes two or more of the following modifications relative to SEQ ID NO:1: Y275F, and / or V279_M280delinsFK, and / or K282delinsQSSRAFTNSKKSVTLRKKTKSKRS, and optionally has the amino acid sequence of SEQ ID NO:16.

[0078] Exemplary D1 variants include those having the amino acid sequences of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16. In some embodiments, the invention includes derivatives having 1-10 (e.g., 1-5) amino acid insertions, deletions, or substitutions relative to any one of SEQ ID NOs:5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16. In some embodiments, the D1 variant includes one or more additional block amino acid substitutions from a homologous DNase (e.g., D1L3). Such block substitutions replace 2-20 amino acids, e.g., 3-15 amino acids, or 3-10 amino acids of the D1 variant with building block amino acids from a homologous DNase (e.g., D1L3, SEQ ID NO:2). Building block substitutions between D1 and D1L3 are shown in FIG. 31. In some embodiments, the DNase enzyme has an amino acid sequence that is at least 95% or at least 97% identical to SEQ ID NO:15.

[0079] In various embodiments, the enzyme exhibits one or more properties selected from: affinity for protein-free DNA similar to or greater than that of the enzyme of SEQ ID NO:1, greater chromatin degrading activity than that of the enzyme of SEQ ID NO:1, enzymatic activity that is resistant to inhibition by actin compared to that of the enzyme of SEQ ID NO:1, and combinations thereof.

[0080] In some embodiments, the D1 variant comprises an N- or C-terminal fusion to a half-life extending moiety such as albumin, transferrin, Fc, or elastin-like protein, as described for D1L3. In some embodiments, the D1 enzyme is dimerized by an immunoglobulin hinge region.

[0081] In various embodiments, the D1 variant exhibits one or more properties selected from: similar or higher protein-free DNA (naked DNA) degrading activity, higher chromosomal DNA (chromatin) degrading activity, similar or improved protease resistance, actin resistance, similar or improved penetration from blood to urine and / or bile, and higher production levels in in vitro expression systems (e.g., Chinese hamster ovary cells and / or Pichia pastoris), and combinations thereof.

[0082] In various embodiments, the DNase enzyme has an amino acid sequence that is at least 80% identical to the amino acid sequence of the enzyme defined by SEQ ID NO:1 and includes one or more arginine and / or lysine residue substitutions, insertions, or additions, whereby the DNase enzyme has increased chromatin degradation activity compared to the enzyme of SEQ ID NO: 1. In some embodiments, the one or more arginine and / or lysine residues are amino acid substitutions selected from substitutions at positions corresponding to 31, 41, 49, 52, 68, 76, 79, 81, 92, 109, 114, 115, 164, 177, 181, 200, 201, 204, 209, 213, 227, 239, 250, 259, 262, and 280 of SEQ ID NO:1. Exemplary modifications at these positions include Q31R, A41K, Q49R, S52K, T68R, N76K, Q79R, D80_A81insR, A81R, P92R, D109K, V114K, D115R, A164K, Q177K, G181K, P200K, S201K, S204R, W209R, T213R, A226_T227insK, T227K, A239R, D250K, A259K, G262K, and K280M. In various embodiments, the enzyme comprises substitutions and / or insertions of at least two, or at least three, or at least four, or at least five, or at least six arginine and / or lysine residues. In some embodiments, the DNase enzyme comprises an arginine or lysine at one or more positions corresponding to positions 31, 49, 76, 79, 92, 109, 164, 177, 200, 201, 204, 209, 213, and 262 of SEQ ID NO: 1, optionally selected from Q31R, Q49R, N76K, Q79R, P92R, D109K, A164K, Q177K, P200K, S201K, S204R, W209R, T213R, W209R, and G262K. These positions / substitutions can independently provide better activity, such as chromatin degradation activity.

[0083] In various embodiments, where the enzyme comprises a Q31R or T227K substitution, the enzyme comprises at least two amino acid modifications selected from Q31R, A41K, Q49R, S52K, T68R, N76K, Q79R, D80_A81insR, A81R, P92R, D109K, V114K, D115R, A164K, Q177K, G181K, P200K, S201K, S204R, W209R, T213R, A226_T227insK, T227K, A239R, D250K, A259K, G262K, and K280M. In some embodiments, the amino acid substitutions include Q31R and T227K with respect to SEQ ID NO:1.

[0084] In some embodiments, the DNase enzyme has an arginine or lysine at positions corresponding to 31, 49, 79, and 209 of SEQ ID NO:1, and can optionally include the following amino acid substitutions: Q31R, Q49K, Q79R, and W209R, which retain arginine or lysine in mouse D1 but not in wild-type human D1, allowing the transfer of chromatin degrading activity to human D1.

[0085] In some embodiments, the DNase enzyme has an arginine or lysine at positions corresponding to 31, 49, 79, 177, 209, and 262 of SEQ ID NO: 1, and may optionally contain the amino acid substitutions Q31R, Q49K, Q79R, A136F, Q177K, W209R, G262K. Four of these positions contain arginine or lysine in rat D1 but not in wild-type human D1, and together can transfer chromatin degrading activity to human D1.

[0086] In some embodiments, the DNase enzyme has a lysine or arginine residue at positions corresponding to positions 31 and 227 of SEQ ID NO:1.

[0087] In some embodiments, the DNase enzyme has a lysine or arginine at the position corresponding to position 164 of SEQ ID NO:1, which is optionally lysine (A164K).

[0088] In various embodiments, the modified D1 protein comprises one or more amino acid modifications (e.g., substitutions, additions, and deletions) in the actin binding site (e.g., substitution of A136, e.g., A136F), thereby disrupting or preventing actin binding. As such, the modified D1 protein can be actin-resistant or substantially actin-resistant. See Ulmer et al., PNAS USA Vol. 93, pp 8225-8229 (1996). Thus, in various embodiments, the DNase enzyme comprises an amino acid substitution at position 136 with respect to SEQ ID NO: 1, which is optionally A136F. Mutations to D1 that provide actin resistance, for example, a mutation at position 136 (e.g., A136F, or substitution of another bulky, hydrophobic, cyclic, or aromatic amino acid at this position), may be combined with other mutations described herein, including addition of a cationic residue or substitution of a building block.

[0089] In some embodiments, the D1 variant is resistant to actin inhibition and can degrade chromatin. For example, the D1 variant can include the following amino acid substitutions with respect to SEQ ID NO: 1: Q31R, T227K, and A136F. In some embodiments, the DNase enzyme includes the following amino acid substitutions: A164K and A136F.

[0090] In some embodiments, the DNase enzyme comprises a glycosylation consensus sequence that includes an N40S substitution and / or an N128S substitution with respect to SEQ ID NO: 1. For example, in some embodiments, the enzyme includes the following amino acid substitutions with respect to SEQ ID NO: 1: Q31R, N40S, A136F, N128S, and T227K.

[0091] In various embodiments, the D1 variants contain one or more amino acid modifications (e.g., substitutions, additions, insertions, and deletions) at the glycosylation site, thereby increasing the affinity for lipid-encapsulated DNA. Thus, the modified D1 protein can degrade lipid-encapsulated DNA in the transfection reaction. See Wilber et al., Mol Ther 6, 35-42 (2002).

[0092] In various embodiments, the D1 variants can be glycosylated or non-glycosylated, particularly where a long circulating half-life is not required. The amino acid changes described herein can be made with either glycosylated or non-glycosylated variants.

[0093] In some embodiments, the D1 variant is resistant to actin inhibition and can degrade chromatin in lipid vesicles. Exemplary D1 variants include one or more amino acid modifications selected from: Q31R, T227K, A136F, N40D or N40A, and N128D or N128S, with amino acids numbered according to SEQ ID NO: 1. Such variants may lack glycosylation sites, which is advantageous from a manufacturing standpoint.

[0094] In some embodiments, the D1 variant is resistant to actin inhibition, can degrade chromatin within lipid vesicles, and contains the amino acid modifications Q31R, T227K, A136F, N40D, and N128D with respect to SEQ ID NO:1.

[0095] Other modifications to D1 may be as described in J Biol Chem, 1998, 273, 11701-11708 and US2014 / 0199329, the disclosures of which are incorporated by reference in their entireties.

[0096] The modified D1 variants can increase or extend serum half-life compared to the wild-type D1 protein (SEQ ID NO:1). In some embodiments, the modified D1 comprises an Fc fusion domain (e.g., an immunoglobulin hinge region, and / or a CH2 domain and a CH3 domain). In some embodiments, the modified D1 is fused to albumin, e.g., human albumin or a fragment thereof. Albumin can be attached to the N-terminus or C-terminus of the modified D1 enzyme, optionally via an amino acid linker.

[0097] In some aspects, the present invention provides pharmaceutical compositions comprising recombinant D1L3 and / or D1 variants, or a polynucleotide or vector encoding the same, and a pharma- ceutically acceptable carrier. In various embodiments, the recombinant D1L3 protein variants are formulated for parenteral or pulmonary administration. In some embodiments, the compositions are formulated for intravenous, intraarterial, intraperitoneal, intraarticular, intramuscular, topical, or subcutaneous administration, or other routes described herein. In some embodiments, the compositions include both D1L3 and D1, each of which is optionally a modified variant as described herein. In some embodiments, the recombinant D1L3 variants and recombinant D1 variants are formulated for parenteral or pulmonary administration.

[0098] The term "pharmaceutically acceptable carrier" includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the component and is not toxic to the patient to which it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline, water, emulsions such as oil / water emulsions, various types of wetting agents, sterile solutions, and the like. Such carriers can be formulated in conventional manner and administered to the subject in appropriate doses. Preferably, the compositions are sterile. These compositions may also include adjuvants such as preservatives, emulsifiers, and dispersing agents. Various antibacterial and antifungal agents may be included to ensure prevention of the action of microorganisms.

[0099] Routes of administration include, for example: intradermal, intramuscular, intraperitoneal, intraarticular, intravenous, subcutaneous, intraarterial, oral, sublingual, pulmonary, or transdermal. In some embodiments, administration is oral or by parenteral injection or infusion. In some embodiments, the route of administration is topical, such as as an eye drop or mouthwash.

[0100] In yet another aspect, the invention provides a method for producing a pharmaceutical composition for reducing or preventing neutrophil extracellular trap (NET) accumulation. In these embodiments, the invention uses genetically modified mice lacking D1 and D1L3 activity and heterologous expression of G-CSF polynucleotides (e.g., in hepatocytes) or induction of sustained endogenous G-CSF expression (e.g., by repeated administration of a microbial compound). This mouse model accumulates NETs and rapidly develops NET-associated vascular occlusion. In these embodiments, the invention includes administering a candidate NET inhibitor or candidate DNase enzyme (including a D1L3 or D1 variant according to the present disclosure) to the genetically modified mice and selecting a NET inhibitor or DNase enzyme that reduces NET accumulation. The selected inhibitor or enzyme is formulated (as described) for administration to a human patient.

[0101] Those skilled in the art will appreciate that double knockout Dnase 1 - / - Dnase1l3 - / - Standard methods for generating mice are recognized, and detailed descriptions can be found, for example, in European Application No. EP17152528.0.

[0102] In some aspects, the present invention provides a method for treating a subject in need of neutrophil extracellular trap (NET) degradation. The method comprises administering a therapeutically effective amount of D1L3 and / or D1 (which may comprise a variant described herein, including for combination therapy of D1L3 and D1, or in some embodiments, one or more wild-type enzymes) according to the present disclosure. D1L3 or D1 may be administered as a pharmaceutical composition comprising a recombinant protein or, in some embodiments, a DNA or RNA encoding it or a vector comprising it.

[0103] In some embodiments, the method comprises administering a therapeutically effective amount of D1L3 or a variant thereof and D1 or a variant thereof. The D1L3 or a variant thereof and the D1 or a variant thereof may be administered in a single pharmaceutical composition or in separate pharmaceutical compositions. In some embodiments, the ratio of D1L3 or a variant thereof to D1 or a variant thereof ranges from 100:1 to 1:100 by mass, or from 10:1 to 1:10 by mass, and optionally is about 1:1.

[0104] In some embodiments, the subject exhibits impaired NET degradation and / or abnormal NET accumulation. In some embodiments, the subject has a chronic or acute inflammatory disorder. In some embodiments, the subject has an acute or chronic infection.

[0105] In various embodiments, the invention relates to the treatment of diseases or conditions characterized by the presence or accumulation of NETs, ​​such as chronic neutrophilia (e.g., elevated neutrophil counts), neutrophil aggregation and leukostasis, thrombosis and vascular occlusion (e.g., sickle cell disease), ischemia-reperfusion injury (e.g., intestinal volvulus, testicular torsion, limb ischemia-reperfusion, vital organ ischemia-reperfusion, organ transplant), surgical and traumatic tissue injury, acute or chronic inflammatory responses or conditions, autoimmune diseases (e.g., systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis, vasculitis, systemic sclerosis), cardiovascular diseases (e.g., myocardial infarction, stroke, atherosclerosis, venous thromboembolism including thrombolytic therapy), metabolic diseases (e.g., diabetes), systemic inflammation (e.g., systemic inflammatory responses, These include, but are not limited to, inflammatory diseases of the airways (e.g., cystic fibrosis, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), smoking-related lung injury, transfusion-associated acute lung injury (TRALI), acute respiratory distress syndrome (ARDS), and asthma, atelectasis, bronchitis, empyema), renal inflammatory diseases (acute and chronic kidney disease, including acute kidney injury (AKI) and chronic kidney disease (CKD), inflammatory diseases associated with transplanted tissues (e.g., graft-versus-host disease), and diseases associated with cancer (e.g., leukemia, tumor metastasis, and solid tumors).

[0106] In some embodiments, the subject has or is at risk for having a NET that blocks the ductal system. The present invention can be administered to a subject to treat pancreatitis, cholangitis, conjunctivitis, mastitis, dry eye disease, blockage of the vas deferens, or kidney disease. In such embodiments, the method includes administering a therapeutically effective amount of D1L3 or a variant thereof, and / or a therapeutically effective amount of D1 or a variant thereof. For example, the subject may be administered an enzyme having an amino acid sequence with 80% or more sequence identity to the enzyme defined by SEQ ID NO:2 and an enzyme having an amino acid sequence with 80% or more sequence identity to the enzyme defined by SEQ ID NO:1. In some embodiments, the enzyme has the amino acid sequence of the enzyme defined by SEQ ID NO:2 and the amino acid sequence of the enzyme defined by SEQ ID NO:1.

[0107] In some embodiments, the ductal system is the bile duct, lacrimal duct, lactiferous duct, cystic duct, hepatic duct, ejaculatory duct, parotid duct, submandibular duct, sublingual duct, Bartholin's duct, aqueduct, pancreas, mammary gland, vas deferens, ureter, bladder, gallbladder, and liver. For example, the subject may have pancreatitis, cholangitis (e.g., primary sclerosing cholangitis), conjunctivitis, mastitis, dry eye disease, obstruction of the ductus deferens, or renal disease. In some embodiments, the DNase enzyme is administered intravenously, intraarterially, or intraperitoneally. In various embodiments, the DNase is present in an enzymatically active form in various ductal systems, for example in bile fluid, when administered, for example, intravenously.

[0108] In some embodiments, the subject has or is at risk for NETs accumulating on endothelial surfaces (e.g., post-surgical adhesions), skin (e.g., wounds / scars), or synovial joints (e.g., gout and arthritis). The present invention can be administered to a subject to treat conditions characterized by accumulation of NETs on endothelial surfaces, such as, but not limited to, post-surgical adhesions. In various embodiments, the present invention can be administered to a subject to treat conditions characterized by accumulation of NETs on skin, such as, but not limited to, wounds and scars. In certain embodiments, the present invention can be administered to a subject to treat conditions characterized by accumulation of NETs in synovial joints, such as, but not limited to, gout and arthritis.

[0109] In some embodiments, the subject has or is at risk for a vascular occlusion involving a NET. In such embodiments, the method comprises administering a therapeutically effective amount of D1L3 or a variant thereof, and / or a therapeutically effective amount of D1 or a variant thereof. For example, the subject may be administered an enzyme having an amino acid sequence having 80% or more sequence identity to the enzyme defined by SEQ ID NO:2. In some embodiments, the enzyme has the amino acid sequence of the enzyme defined by SEQ ID NO:2. In some embodiments, the subject is further administered an enzyme having an amino acid sequence having 80% or more sequence identity to the enzyme defined by SEQ ID NO:1, e.g., the enzyme defined by SEQ ID NO:1.

[0110] In some embodiments, the subject has a condition associated with a NET, such as those described in WO2016 / 118476 and US9,642,822, which are incorporated by reference in their entireties.

[0111] In various embodiments, the subject has a disease that is being treated or has been treated with wild-type DNase, including D1 and streptodornase, such as thrombosis, stroke, sepsis, lung injury, atherosclerosis, viral infection, sickle cell disease, myocardial infarction, ear infection, wound healing, liver injury, endocarditis, liver infection, pancreatitis, primary graft dysfunction, limb ischemia reperfusion injury, kidney injury, blood clotting, alum-induced inflammation, hepatorenal injury, pleural effusion, hemothorax, intrabiliary clots, post-pneumonic anemia, ulcers, ear, nose and throat conditions, and oral infections. , minor injuries, sinusitis, post-operative rhinoplasty, infertility, bladder catheters, wound irrigation, skin reaction tests, pneumococcal meningitis, gout, leg ulcers, cystic fibrosis, Kartegener's syndrome, asthma, lobar atelectasis, chronic bronchitis, bronchiectasis, lupus, primary ciliary dyskinesia, bronchiolitis, empyema, pleural infections, cancer, dry eye disease, lower respiratory tract infections, chronic hematomas, Alzheimer's disease, and obstructive pulmonary disease.

[0112] In certain embodiments, the present invention relates to the treatment of diseases or conditions characterized by deficiencies of D1, deficiencies of D1L3, and deficiencies of D1 and D1L3. In some cases, the subject has a mutation in the Dnase1 and / or Dnase1l3 gene. Such subjects may also have an autoimmune disease (e.g., SLE, systemic sclerosis) or an inflammatory disease. In some cases, the subject has an acquired D1 inhibitor (e.g., anti-DNase1 antibody and actin) and / or D1L3 (e.g., anti-DNase1l3 antibody). Such subjects may also have an autoimmune disease (e.g., SLE, systemic sclerosis) or an inflammatory disease (e.g., sepsis and ischemia-reperfusion injury).

[0113] In some embodiments, the subject has cystic fibrosis and the DNase composition is administered by pulmonary delivery.

[0114] In various embodiments, for example, if a subject is at risk for or exhibits symptoms of NET-associated vaso-occlusion, the protein or composition (e.g., comprising D1L3, D1, or a variant of D1L3 or D1, including a variant described herein) may be administered intravenously, intramuscularly, subcutaneously, or intra-arterially.

[0115] In various embodiments, the subject is monitored for NET degrading activity in blood, plasma, or serum. For example, the subject is monitored for about 1 week to about 4 weeks to reduce the risk of vascular or ductal obstruction by NETs, ​​or organ damage associated with NETs. In some embodiments, the subject may be administered 1-4 times over 1 week to 1 month (or 1-2 weeks) as needed to prevent or reduce intravascular NET accumulation (including NET-associated intravascular obstruction) during acute infection or inflammatory events. In other embodiments, the subject may be infused continuously for 1 hour to 1 month (or 1-2 weeks). In some cases, in the case of severe disease such as sepsis, stroke, or myocardial infarction, the subject may be given at least one infusion daily, for example (but not limited to), 1, 2, 3, 4 or more infusions.

[0116] The treatment of NET-related disease or condition can include administration of D1 variant, D1L3 variant, or combination comprising D1 variant and D1L3 variant.In some embodiments, administer two or more variants of D1 protein as described herein.In some embodiments, administer two or more variants of D1L3 protein as described herein.

[0117] The D1 and D1L3 protein variants of the invention can be administered as a prophylactic therapy, eg, prior to the onset of one or more symptoms of a disease or condition.

[0118] As used herein, "treatment" or "treating" or "treat" refers to a therapeutic procedure aimed at delaying (alleviating) an undesirable physiological condition, disorder or disease, or obtaining beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; attenuation of the extent of a condition, disorder or disease; stabilization of the condition, disorder or disease state (i.e., no progression); delay in onset or delay in progression of a condition, disorder or disease; amelioration of a condition, disorder or disease state; and remission (partial or total), or enhancement or amelioration of a condition, disorder or disease, whether detectable or undetectable. Treatment includes eliciting a clinically significant response without excessive levels of side effects. In other embodiments, "treatment" or "treating" or "treat" refers to a preventative measure, e.g., aimed at delaying the onset or reducing the severity of an undesirable physiological condition, disorder or disease in an individual predisposed to the disease (e.g., an individual carrying genetic markers for a disease such as lupus).

[0119] In the method of the present invention, the treatment is used to provide a positive therapeutic response with respect to a disease or condition. A "positive therapeutic response" refers to an improvement in a disease or condition and / or an improvement in symptoms associated with the disease or condition. For example, a positive therapeutic response refers to one or more of the following improvements in a disease: (1) a reduction in neutrophil extracellular traps; (2) a reduction in intravascular clots; (3) a reduction in vascular clots; (4) a reduction in the accumulation of NETs in synovial joints; (5) an increase in the degradation of neutrophil extracellular traps; (6) an increase in the degradation of extracellular protein-free DNA; (7) an increase in the degradation of extracellular chromosomal DNA or protein-bound DNA; (8) an increase in the degradation of neutrophil extracellular traps in the presence of autoantibodies; (9) a reduction in tissue / organ inflammation; (10) a reduction in tissue / organ damage; (11) a reduction in tissue / organ atrophy; (12) an increase in patient survival; and (13) a reduction in one or more symptoms associated with a disease or condition.

[0120] The positive therapeutic response in a given disease or condition can be determined by the standardized response criteria specific to that disease or condition.The clinical response can be evaluated for the change of vascular obstruction and the presence of NET using screening techniques such as magnetic resonance imaging (MRI), ultrasound, histology, and counting NET in circulation.In addition to these positive therapeutic responses, the subject undergoing treatment may experience the beneficial effect of improving the symptoms associated with the disease.

[0121] Dosage regimen is adjusted to provide the optimum desired response (e.g., therapeutic response). For example, a single bolus may be administered, or several divided doses may be administered over time, or the dose may be proportionally increased or decreased, as indicated by the exigencies of the therapeutic situation. Parenteral compositions may be formulated in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form, as used herein, refers to physically discrete units suitable as unitary doses for subjects to be treated; each unit contains a predetermined amount of active compound calculated to produce the desired therapeutic effect, together with the required pharmaceutical carrier.

[0122] In various embodiments, the present invention provides expression vectors comprising nucleic acids encoding wild-type or D1L3 or D1 variants as described herein, which may find use in gene therapy. Gene therapy may be useful for chronic diseases, such as genetic deficiencies (e.g., deleterious mutations) in D1L3 and / or D1. In various embodiments, the expression vector comprises DNA or RNA. In various embodiments, the expression vector is a mammalian expression vector.

[0123] In some embodiments, the expression vector comprises a nucleic acid encoding a protein variant operably linked to an expression control region, or a complementary region thereof, that functions in a host cell (e.g., a prokaryotic, eukaryotic, or mammalian cell). The expression control region is capable of driving expression of the nucleic acid encoding the blocking agent and / or stimulating agent, resulting in production of the blocking agent and / or stimulating agent in a human cell transformed with the expression vector.

[0124] Expression control regions are regulatory polynucleotides (sometimes referred to herein as elements), such as promoters and enhancers, that affect the expression of operably linked nucleic acids. The expression control regions of the expression vectors of the present invention are capable of expressing operably linked encoding nucleic acids in human cells. In one embodiment, the expression control region confers regulatable expression to the operably linked nucleic acid. A signal (sometimes referred to as a stimulus) can increase or decrease the expression of a nucleic acid operably linked to such an expression control region. Such expression control regions that increase expression in response to a signal are often referred to as inducible. Such expression control regions that decrease expression in response to a signal are often referred to as inhibitory. Usually, the amount of increase or decrease provided by such elements is proportional to the amount of signal present; the greater the amount of signal, the greater the increase or decrease in expression.

[0125] Expression systems that function in human cells are well known in the art and include viral systems. In general, a promoter that functions in human cells is any DNA sequence that can bind mammalian RNA polymerase and initiate transcription of a downstream (3') coding sequence into mRNA. A promoter has a transcription initiation region, usually located proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs upstream from the transcription initiation site. The TATA box is believed to direct RNA polymerase II to begin RNA synthesis at the correct location. A promoter also typically contains an upstream promoter element (enhancer element), usually located within 100-200 base pairs upstream of the TATA box. The upstream promoter element determines the rate at which transcription is initiated and can act in either direction. Particularly useful as promoters are promoters from mammalian viral genes, since viral genes are often highly expressed and have a wide host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter.

[0126] Where appropriate, gene delivery agents such as integration sequences can also be used. Numerous integration sequences are known in the art (see, for example, Nunes-Duby et al., Nucleic Acids Res. 26:391-406, 1998; Sadwoski, J. Bacteriol., 165:341-357, 1986; Bestor, Cell, 122(3):322-325, 2005; Plasterk et al., TIG 15:326-332, 1999; Kootstra et al., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). These include recombinases and transposases. Examples include Cre (Sternberg and Hamilton, J. Mol. Biol., 150:467-486, 1981), lambda (Nash, Nature, 247, 543-545, 1974), FIp (Broach, et al., Cell, 29:227-234, 1982), R (Matsuzaki, et al., J. Bacteriology, 172:610-618, 1990), cpC31 (Groth et al., J. Mol. Biol. 335:667-678, 2004), sleeping beauty, transposases of the mariner family (Plasterk et al., supra), and antiviral (Kootstra et al., supra), which have components for integrating viruses such as AAV, retroviruses, and components providing viral integration such as retroviral or lentiviral LTR sequences and AAV ITR sequences. (e.g., Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). In addition, direct and targeted gene integration strategies, including CRISPR / CAS9, zinc finger, TALEN, and meganuclease gene editing technologies, may be used to insert nucleic acid sequences encoding chimeric fusion proteins.

[0127] All references cited are expressly incorporated herein by reference in their entirety. EXAMPLES

[0128] Example 1: Host DNase prevents vascular occlusion by neutrophil extracellular traps Platelet and fibrin clots occlude blood vessels in hemostasis and thrombosis. Herein, we report a non-canonical mechanism of vascular occlusion based on neutrophil extracellular traps (NETs), antimicrobial DNA fibers released by activated neutrophils. We show that two DNases, DNase1 and DNase1-like 3, degrade NETs in the circulation during episodes of inflammation in mice. In the absence of both DNases, intravascular NETs form clots that occlude blood vessels and cause organ damage. Vascular occlusion in patients with severe bacterial infections is associated with defective ex vivo NET degradation and the formation of intravascular NET clots. DNase1 and DNase1-like 3 are expressed independently, thus providing a dual host protection against the deleterious effects of NETs in inflammation.

[0129] Inflammation is an essential host response to control invading microorganisms and heal damaged tissues (1). Uncontrolled and persistent inflammation leads to tissue damage with excessive inflammatory disorders. Neutrophils are the primary leukocytes in acute inflammation. During infection, neutrophils generate extracellular traps (NETs), lattices of DNA filaments decorated with toxic histones and enzymes that immobilize and neutralize bacteria (2). The relevance of NETs in host protection is explained by the fact that extracellular DNases function as virulence factors in several pathogenic bacteria (3, 4). However, inappropriately released NETs can harm host cells due to their cytotoxic, proinflammatory, and prothrombotic activities (5-7). Indeed, NETs are frequently associated with inflammatory or ischemic organ damage, and therapeutic infusion of DNases limits host damage in various animal models (8, 9).

[0130] How the host degrades NETs in vivo to limit tissue damage during inflammatory episodes is poorly understood. Previous studies have shown that DNase1 in serum digests the DNA backbone of NETs in vitro (10). We analyzed serum from wild-type mice by zymography and detected two enzymatically active DNases, DNase1 and DNase1-like 3 [(DNase1l3) (Figure 1A)]. Both enzymes are members of the DNase1 protein family but differ in their origin and substrate affinity. DNase1 is expressed in nonhematopoietic tissues and preferentially cleaves protein-free DNA (11,12). DNase1l3, also known as DNaseγ, is secreted by immune cells and targets DNA-protein complexes such as nucleosomes (11,13). We generated mice lacking serum DNA degradation activity by combined deficiency of DNase1 and DNase1l3 (Figure 1A). In vitro generated NETs remained intact after exposure to DNase1 / DNase1l3- / - serum, whereas serum from wild-type, DNase1- / -, and DNase1l3- / - mice degraded NETs (Figure 1B and 1C). Using hepatocyte-specific expression plasmids in combination with hydrodynamic gene delivery, we stably expressed DNase1 or DNase1l3 cDNA in the liver of DNase1 / DNase1l3- / - mice. Given that both enzymes contain secretory protein signal sequences (11), this approach restored the activity of DNase1 or DNase1l3 in the circulation (Figure 1D) and restored the ability of serum from DNase1 / DNase1l3- / - mice to degrade NETs (Figure 1E and 1F). Taken together, these data indicate that two independently expressed host enzymes, DNase1 and DNase1l3, degrade NETs in vitro.

[0131] To test the requirement of DNase1 and DNase1l3 for NET degradation in vivo, we aimed to chronically stimulate wild-type, DNase1- / -, DNase1l3- / - and DNase1 / DNase1l3- / - mice with granulocyte colony-stimulating factor (G-CSF). G-CSF induces neutrophilia, a hallmark of acute inflammation, and stimulates a subpopulation of neutrophils to spontaneously release NETs ex vivo (14). The cDNA of CSF3, which encodes G-CSF, was cloned into a hepatocyte-specific expression plasmid. Hydrodynamic injection of CSF3-plasmid into wild-type mice resulted in chronically elevated G-CSF levels in plasma (Figure 5A). As a result, neutrophil blood counts were steadily increased and spontaneously formed NETs were detected in blood smears (Figures 2A and 2B). Furthermore, an increase in the number of resident neutrophils in vital organs and splenomegaly was observed (Figures 5B and 5C). Importantly, wild-type mice injected with CSF3 grew normally, did not develop organ damage, and did not show gross signs of distress or abnormal behavior (Figure 5D and Figure 5E). Collectively, these data suggest that chronic neutrophilia, which is accompanied by NET formation, is well tolerated in wild-type mice.

[0132] Next, we stably expressed CSF3 in the livers of DNase1- / -, DNase1l3- / -, and DNase1 / DNase1l3- / - mice. Mice with a single deficiency of DNase1 or DNase1l3 showed no signs of distress (not shown), but all mice with combined deficiencies died within 6 days after CSF3 injection (Figure 2C). DNase1 / DNase1l3- / - mice administered a control plasmid lacking CSF3 survived without showing any abnormalities (Figure 2C, not shown). DNase1 or DNase1l3 was co-expressed with CSF3 in DNase1 / DNase1l3- / - mice to induce neutrophils and NETs while simultaneously restoring DNase1 or DNase1l3 in the circulation. Expression of either DNase was sufficient for DNase1 / DNase1l3- / - mice to survive without showing any signs of distress (Figure 2D). DNase1 / DNase1l3- / - mice co-expressing CSF3 with a control plasmid lacking DNase1 and DNase1l3 died within 5 days after gene delivery (Figure 2D). The lethality of these mice was preceded by rapidly progressive hypothermia, which was manifested as a strong drop in peripheral body temperature within 8 hours prior to outcome (Figure 2E). Hypothermia was accompanied by hemolytic anemia and reduced blood hemoglobin, indicated by reddish plasma and urine (Figure 2F and Figure 2G). Abundant schistocytes in the blood smear indicated that the hemolytic anemia was caused by red blood cell fragmentation (Figure 2H). Furthermore, elevated plasma levels of lactate dehydrogenase (LDH), liver transaminases, and renal injury markers blood urea nitrogen and creatinine were detected, indicating multiple organ damage (Figure 2I, Figure 6A, and Figure 6B). Co-expression of DNase1 or DNase1l3 with CSF3 maintained body temperature and red blood cell and organ integrity (Figures 2E-I; Figures 6A and 6B). In conclusion, these data indicate that either DNase1 or DNase1l3 is required to prevent host damage during chronic neutrophilia.

[0133] Histological analysis of chronic neutrophilia DNase1 / DNase1l3- / - mice showed intravascular hematoxylin-positive clots with encapsulated red blood cells (Figures 3A and B; Figures 6C and 6D), which completely or partially occluded blood vessels in the lungs, liver, and kidneys. Expression of DNase1 or DNase1l3 in the circulation prevented these vascular occlusions. Hematoxylin-positive clots showed an abundant light purple staining pattern sporadically interspersed with dark purple staining of individual leukocyte nuclei, suggesting that decondensed DNA was the major clot component (Figure 3A). Because nuclear disintegration and unfolding of tightly packed chromatin are hallmarks of NET formation (15), we stained hematoxylin-positive clots for NET markers. Robust staining with a fluorescent double-stranded DNA intercalator dye and antibodies against chromatin was observed (Figure 7A). Colocalization of decondensed chromatin with the neutrophil granule-derived enzyme myeloperoxidase, antimicrobial cathelicidin peptides, and citrullinated histones, a surrogate NET marker, confirmed that the clots were composed of NETs (Figures 3C, 7B, and 7C). To identify components of a canonical clot, we stained NET clots for fibrin and von Willebrand factor (vWF), a protein stored in secretory vesicles of platelets and in the vascular endothelium. NET clots were highly heterogeneous in vWF and fibrin content (Figures 3D and 3E). On average, 46% of NET clot cross sections were covered with vWF, whereas 9% of NET clots did not stain for vWF (Figures 3E and 3F). Fibrin was almost absent and was only detected in less than 23% of occluded vessels (Figure 3E). These data are consistent with findings that NETs function as a fibrin-independent scaffold to immobilize platelets and red blood cells in vitro (6). The absence of vWF and fibrin in some clots suggests that NETs may be sufficient for vascular occlusion. To support this idea, we aimed to generate NET clots in vitro from pure neutrophils. We isolated neutrophils from blood and induced NET formation while exposing the cells to shear forces to mimic blood flow.In this setup, we observed macroscopically visible DNase-sensitive clots (Figure 8A), which resembled the appearance of NET clots in mouse blood vessels (Figure 8B). In DNase1 / DNase1l3- / - mice expressing CSF3, platelets were depleted from the circulation and thrombin was pharmacologically inhibited to block fibrin formation. Unlike DNase1- or DNase1l3-expression, neither antithrombotic treatment was able to prevent the death of these animals (Figure 3H). Taken together, the data suggest that upon chronic neutrophilia in DNase1 / DNase1l3- / - mice, NET clots are sufficient to occlude blood vessels.

[0134] Formation of NET clots in DNase1 / DNase1l3- / - mice is associated with features of infection-induced thrombotic microangiopathy (TMA) and disseminated intravascular coagulation in patients, including vascular occlusion leading to schistocytes, hemolytic anemia, and organ failure. Plasma from patients with TMA and hemolytic uremic syndrome due to infection with Shiga toxin-producing Escherichia coli [STEC-HUS, (16)] was analyzed. Frequent complications in these patients were sepsis and septic shock (17). In vitro generated NETs remained intact after exposure to plasma from patients in acute disease states, whereas plasma from patients in remission degraded the NETs (Figures 9A and 9B). This data extends previous reports, as it shows a transient, acquired defect in NET degradation (18,19). Of note, patients with STEC-HUS were effectively treated with a regimen that included infusion of plasma from healthy donors, a source of DNase that potentially restored NET degradation ( 17 ).

[0135] Large aggregates of NETs have been reported to form in the synovial fluid and pancreatic ducts of patients (21, 22), but have not yet been described in other tissues. Therefore, we aimed to identify intravascular aggregates of NETs in patients with severe inflammatory diseases. We screened lung tissues obtained at autopsy from patients with acute respiratory distress syndrome and / or sepsis (Figure 10). We detected hematoxylin-positive clots in the blood vessels of two septic patients (Figures 11A and 11C). In both cases, the clots consisted of chromatin and MPO (Figures 11B and 11D), indicating that NETs can form intravascular clots in human sepsis.

[0136] Sepsis is a potent and rapid trigger of intravascular NET formation in mice (7). Therefore, we hypothesized that defects in NET degradation could exacerbate the disease. Indeed, we observed that mice with combined DNase1 and DNase1l3 deficiency were hypersensitive to low-dose lipopolysaccharide and heat-killed E. coli, but not wild-type mice (Figure 4A). Similar to neutrophil DNase1 / DNase1l3- / - mice, blood analysis of septic DNase1 / DNase1l3- / - mice showed increased levels of plasma LDH and schistocytes in blood smears (Figure 4D-E), along with hemolytic anemia and hematuria (Figure 4B-C). Furthermore, we detected abundant partially or completely occluded blood vessels in the lungs (Figure 4F-G). Detailed analysis of partially occluded blood vessels revealed NET clots within the vascular lumen (Figure 4H). In completely occluded vessels, NET clots were congested with encapsulated red and white blood cells (Figure 4I; Figures S12A and S12B). Importantly, hepatic expression of DNase1 or DNase1l3 in DNase1 / DNase1l3- / - mice prevented vascular occlusion and restored the wild-type phenotype. Collectively, these data indicate that circulating DNase1 or DNase1l3 prevents NET clot formation and host injury in sepsis.

[0137] Taken together, although platelets and fibrin form hemostatic clots and pathological thrombi (23), our data introduce NET clots as a noncanonical mechanism of vascular occlusion in inflammatory conditions. Similar to fibrin strands, NETs are ultra-large and stable molecules (6). At high concentrations, such as those found in chronic neutrophilia or sepsis, intravascular NETs can form clots that are large enough to occlude blood vessels, thus damaging red blood cells and organs. To maintain blood and tissue integrity during inflammation, the host independently expresses DNase1 and DNase1l3 as a dual protection system against intravascular NETs. However, acquired and genetic defects in these host factors may delay NET degradation and thus promote disease. Acquired defects may include DNase1 inhibition by monomeric actin that is externalized from damaged tissues, and inactivation of DNase1l3 by serum proteases (11). Mutations in DNase1 and DNase1l3 have been identified in patients and are associated with the systemic autoimmune disease systemic lupus erythematosus (SLE) (24, 25). Interestingly, DNase1- and DNase1l3-deficient mice spontaneously develop SLE-like disease with age (13, 26). NETs consist of prominent autoantigens, and neutrophils from SLE patients have an increased capacity to release NETs (27). A reduced clearance capacity could increase the half-life of NETs and thus promote autoimmune disease (10, 27). In conclusion, host DNase deficiency could result in the deleterious effects of NETs in hyperinflammatory diseases.

[0138] As a result, DNase1- and DNase1l3-mediated NET degradation offers an attractive therapeutic opportunity for patients suffering from inflammatory conditions. To test whether DNase1 and DNase1l3 degrade NETs by the same or distinct mechanisms, fixatives were used to crosslink proteins in NETs. Immobilized NETs were efficiently degraded by DNase1l3- / - serum, but were resistant to degradation by DNase1- / - serum (Figures 13A and 13B). In line with these results, exposure of NETs to recombinant DNase1 or DNase1l3 showed that both DNases degraded naive NETs (Figures 13C and 13D), whereas immobilized NETs were resistant to DNase1l3 activity (Figures 13E and 13F). Taken together, these in vitro data suggest that DNase1 and DNase1l3 degrade NETs via distinct mechanisms.

[0139] Finally, the activities of DNase1 and DNase1l3 in the circulation were compared between mice and humans. To distinguish between DNase1 and DNase1l3 activity, an antibody against human DNase1 (α-hDNase1) was generated to block DNase1 activity in plasma from normal healthy donors (NHD) (Figure 14A). Heparin is a known inhibitor of DNase1l3 and was used to block DNA degradation activity by DNase1l3 (Figure 14B). Mouse plasma showed approximately 10-fold higher total DNase activity (Figure 14C), DNase1 activity (Figure 14D), and DNase1l3 activity (Figure 14E) than human plasma. Furthermore, DNase1l3 in mouse plasma efficiently degraded NETs, ​​whereas DNase1l3 in human plasma did not (Figures 14F and 14G). The data suggest that the concentration of DNase1l3 in the human circulation is not sufficient to degrade NETs. Therefore, enabling DNase1l3-mediated NET degradation in patients represents a novel and promising therapeutic strategy for inflammatory diseases.

[0140] Materials and Methods Patient plasma Citrated plasma samples were obtained from patients during the 2011 STEC-HUS outbreak in Germany (16). Criteria for inclusion in the study were positive identification of STEC / enterohemorrhagic E. coli or bloody diarrhea, platelet count ≤150 × 109 / L or a ≥25% decrease over 1 week, evidence of hemolysis (LDH above the normal limit, haptoglobin below the normal limit, or the presence of schistocytes), and acute kidney injury stage ≥1.

[0141] Human tissue Human tissues were fixed in 5% phosphate-buffered formalin overnight at room temperature. All tissues were collected at autopsy, originally submitted to us for diagnostic purposes, and studied in accordance with national ethical principles. The causes of death of the patients are shown in Figure 10.

[0142] mouse All mice were on a C57BL / 6 genetic background. DNase1 / DNase1l3 mice were generated by crossing previously described DNase1- / - and DNase1-like3- / - mice (26,28). This line of DNase1- / - mice was recently reported to contain an off-target mutation in the DNase1 overlapping gene Trap1 / Hsp75, which encodes a mitochondrial chaperone (29). Therefore, we included an alternative DNase1- / - line (30) to generate DNase1 / DNase1l3- / - mice for control experiments (Figure S15A-C).

[0143] Detection of DNase1 by denaturing polyacrylamide gel electrophoresis zymography (DPZ) DPZ was performed as previously described with modifications (19). Briefly, sodium dodecyl sulfate (SDS) polyacrylamide gels were prepared with a 4% (v / v) stacking gel without DNA and a 10% (v / v) separating gel containing 200 μg / ml salmon testis DNA (Sigma-Aldrich, Germany). To detect DNase1, 0.5 μl of mouse serum was mixed with 14.5 μl water and 5 μl SDS gel loading buffer (BioRad, Germany). The mixture was boiled for 5 min and loaded onto the gel. Electrophoresis was performed at 120 V using Tris / glycine electrophoresis buffer (25 mM Tris, 192 mM glycine, 0.1% (w / v) SDS, pH 8.7). After electrophoresis, the proteins were refolded by incubating the gel overnight at 37° C. in refolding buffer containing 5% (w / v) milk powder, 10 mM Tris / HCl pH 7.8, 3 mM CaCl2, 3 mM MgCl2, 100 U / mL penicillin, and 100 μg / mL streptomycin. The gel was transferred to refolding buffer without milk powder and incubated for another 24 h at 37° C. DNA was fluorescently labeled with 1× SYBR Safe (Thermo Scientific, Germany) and fluorescent images of the gel were recorded using a fluorescent scanner (Molecular Imager FX, BioRad, Germany).

[0144] Detection of DNase1l3 by DPZ For detection of DNase1l3, 2 μl of serum was mixed with 12 μl of water, 5 μl of SDS gel loading buffer, and 1 μl of β-mercaptoethanol (BME, Sigma-Aldrich). BME reduces the disulfide bridges of DNase1, causing its inactivation (11). The mixture was boiled for 5 min and loaded onto the gel. Electrophoresis was performed as described for DNase1. SDS was removed by washing the gel twice with 10 mM Tris / HCl pH 7.8 at 50°C for 30 min. The protein was refolded by incubating it at 37°C for 48 h in refolding buffer containing 10 mM Tris / HCl pH 7.8, 1 mM BME, 100 U / mL penicillin, and 100 μg / mL streptomycin. The gel was then incubated for an additional 48 h at 37°C in refolding buffer supplemented with 3 mM CaCl2 and 3 mM MnCl2. To enable efficient degradation of protein-free DNA by DNase1l3, Mn 2+ (11) DNA was labeled and imaged as described for DNase 1.

[0145] Detection of total DNase activity by single radial enzyme diffusion (SRED) assay To measure total DNase activity, Mn 2+ 55 μg / ml DNA from salmon testis was dissolved in a buffer containing 20 mM Tris-HCl pH 7.8, 10 mM MnCl2, 2 mM CaCl2, and 2x SYBR Safe. The DNA solution was heated at 50°C for 10 min and mixed with an equal volume of 2% ultra-pure agarose (Thermo Scientific). The mixture was poured into a plastic tray and stored at room temperature until solidified. 2 μl of mouse serum was loaded into a 1.0 mm diameter well. The gel was incubated at 37°C for 4 h in a humid chamber. The DNA fluorescence of the gel was recorded with a fluorescence scanner.

[0146] In vitro NET degradation assay NET degradation was analyzed as previously described ( 19 ). Purified human neutrophils in serum-free DMEM were plated at 5 × 10 cells per well in sterile 96-well plates (Falcon, BD Technologies, Germany) coated with 0.001% polylysine (Sigma). 4 Cells were seeded at a concentration of 100 nM phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) for 4 h at 37 °C under 5% CO2 and humidification to induce NET formation. Phosphate-buffered saline (PBS) was added and the 96-well plate was stored at 4 °C overnight. NETs were washed with PBS, treated with 0.5% TritonX-100 in PBS for 5 min, and washed again with PBS. NETs were incubated in the presence of 10% mouse serum or 10% citrated human plasma supplemented with 10 μM PPACK (Santa Cruz, Heidelberg, Germany) in HBSS containing divalent cations (HBSS+; Thermo Scientific). NETs were allowed to degrade for 3 h at 37 °C under 5% CO2 and humidification. The supernatant was discarded and NET degradation was stopped by adding 2% PFA in PBS for 1 h at room temperature. PFA was discarded and 2 μM of the fluorescent DNA dye SytoxGreen (Thermo Scientific) was added in PBS to fluorescently label non-degraded NETs. Images of fluorescently stained NETs were acquired with an inverted fluorescence microscope (Axiovert200M, Zeiss, Germany). Non-degraded NETs were quantified by recording the fluorescence intensity with a plate reader (excitation: 485 nm; emission: 535 nm) or by measuring the area occupied by NETs in micrographs using ImageJ software (NIH, USA).

[0147] Preparation of in vivo expression vectors pLIVE plasmids (Mirus Bio, USA) were used to express proteins in mice. This vector allows long-term hepatocyte-specific protein expression. pLIVE plasmids were generated using mouse DNase1, DNase1l3, and CSF3. For mouse DNase1, PCR of cDNA (Genbank accession number NM010061) was performed with the primer pair DNase1-F 5'-GTCGACATGCGGTACACAGG (SEQ ID NO: 27) and DNase1-R 5'-CTCGAGTCAGATTTTTCTGAGTGTCA (SEQ ID NO: 28), which contain SalI and XhoI restriction enzyme sites. For DNase1l3, PCR of the cDNA (Genbank accession number AF047355) was performed with the primer pair DNase1l3-F 5'-GAAGTCCCAGGAATTCAAAGATGT (SEQ ID NO: 29) and DNase1l3-R 5'-GCGTGATACCCGGGAGCGATTG (SEQ ID NO: 30) containing BamHI and SacI restriction enzyme sites. Both cDNAs were pre-digested with the appropriate enzymes and cloned into the multiple cloning site (MCS) of the pLIVE vector using T4 ligase (New England Biolabs, Germany). The pLIVE vector containing DNase1l3 was subjected to site-directed mutagenesis with the primer pair mutDNase1l3-F 5'-AGTCGACTCCCGGCCACCATGTCCCTGCA (SEQ ID NO: 31) and its complementary mutDNase11l3-R 5'-TGCAGGGACATGGTGGCCGGGAGTCGACT (SEQ ID NO: 32) to match the consensus Kozak sequence and optimize protein expression. The generation of the pLIVE vector containing the cDNA of CSF3 was outsourced (Eurofins Genomics, Germany). The cDNA of CSF3 (Genbank accession number BC120761) was inserted into the MCS between the restriction enzyme sites SalI and XhoI. The sequences of all generated vectors were confirmed by double-stranded DNA sequencing. As a control, the parental pLIVE plasmid without additional insert was used.All plasmids were purified using the PureLink HiPure Plasmid Maxiprep Kit, and potential endotoxin contaminants were removed using High Capacity Endotoxin Removal Spin Columns (both Thermo Scientific).

[0148] In vitro expression of mouse DNase1 and DNase1l3 Plasmids containing DNase1 or DNase1l3 cDNA as described elsewhere were transfected into human embryonic kidney (HEK) cells in serum-free conditions in the presence of DMEM medium (Thermo Scientific) supplemented with 10% KnockOut serum replacement (Thermo Scientific) using Lipofectamine3000 (Thermo Scientific). After 72 h, supernatants were collected, centrifuged at 500 × g for 10 min, sterile filtered, and concentrated by ultracentrifugation using 3K columns (Amicon Ultra, Millipore, Darmstadt, Germany).

[0149] In vivo gene expression pLIVE plasmids containing DNase1, DNase1l3, CSF3, or an empty control plasmid were administered to mice via hydrodynamic tail vein injection. Briefly, 50 μg of plasmid was diluted in 0.9% saline in an amount equivalent to 10% of the mouse's body weight. After the mice were anesthetized with isoflurane, the plasmid solution was injected intravenously via the tail vein over 5–8 seconds. In rare cases, mice did not fully recover from the injection within the first 24 hours, and these animals were excluded from the study. For co-expression studies, 50 μg of CSF3 plasmid was mixed with 50 μg of empty control plasmid, or plasmids containing DNase1 and DNase1l3. The solution containing both plasmids was administered via hydrodynamic tail vein injection.

[0150] Chronic neutrophilia Female mice aged 4 weeks or 8–12 weeks were injected with 50 μg of pLIVE plasmid containing CSF3 to induce G-CSF overexpression and neutrophilia. Mice were monitored every 8 h for the first week after injection and daily thereafter. Perianal temperature was measured with a non-contact infrared thermometer (Etekcity, Germany). In survival studies, mice were euthanized and recorded as “non-survival” if they showed signs of distress (no spontaneous movement, closed eyes, occasional panting). In all cases, these signs of distress were accompanied by rapidly progressive severe hypothermia, defined as a decrease in body temperature of ≥4°C compared to body temperature before plasmid injection, and hematuria. Non-hypothermic mice did not show signs of distress and were euthanized at the end of the experiment. Four groups of three D1 / D1L3− / − mice were analyzed for organ, blood, and urine collections. Mice in each group were injected with a mixture of CSF3 and empty plasma, DNase1, or DNase1l3. Each group of mice was euthanized for biosample collection when the first animal in the group showed signs of distress, severe hypothermia, and hematuria. This time point was defined as "outcome" and occurred within 3 to 6 days after injection.

[0151] Platelet depletion Mice were injected intraperitoneally with 2 μg / g of platelet-depleting antibody or isotype control antibody (both from Emfret, Germany). This treatment depletes >95% of platelets from the circulation. Treatment was started 24 h after injection of CSF3 and repeated every 48 h until the experiment was completed.

[0152] Thrombin Inhibition Powdered dabigatran etexilate (Pradaxa, Boehringer Ingelheim, Germany) was mixed with normal powder (Altromin, Germany) at a dose of 40 mg / g. Pellets were prepared by mixing the powder with distilled water and drying at room temperature. Feeding of dabigatran was started 24 h after injection of CSF3. WT mice fed the dabigatran diet for 1 day showed a 6.48 ± 1.19-fold (mean ± SD, N = 4) increase in activated partial thromboplastin time compared to mice fed a normal diet without dabigatran (Student's t test; P < 0.001).

[0153] Preparation of bacteria for sepsis Escherichia coli (XEN14, Perkin Elmer) was grown overnight in LB medium containing 50 μg / ml kanamycin. Bacteria were pelleted by centrifugation at 4000 × g for 10 min, washed in PBS, and resuspended. 1.5 × 10 9 Aliquots of bacteria / ml were incubated for 15 min at 70° C. to heat kill the bacteria. Aliquots were stored at −20° C. until further use.

[0154] sepsis Male mice aged 8–15 weeks were intraperitoneally injected three times daily with 1 μg / g LPS from Salmonella enterica serovar thyphimurium (Sigma-Aldrich) in 0.9% saline. In addition to the third LPS injection, mice received an intravenous injection of 1.5 × 107 heat-killed E. coli / g. Survival times shown indicate the time after E. coli injection. Blood and organs were collected at the time of euthanasia. Insufficient biological samples were obtained from two animals (1 × D1 / D1L3- / -+Ctrl, 1 × D1 / D1L3- / -+D1L3) to perform the full analysis shown in Figure 4A–I. Mice were euthanized and recorded as “non-survival” if the animals showed signs of severe distress (unresponsiveness to touch). All non-survival mice showed hematuria and limb pallor. Twenty-four hours after intravenous injection of heat-killed E. coli, all surviving mice were euthanized and recorded as “surviving.”

[0155] Collection of mouse blood, plasma, and tissues Blood was collected by submandibular puncture or retroorbital sinus. Blood was collected in 200 μl serum tubes (Monovette; Sarstedt, Germany) and 200 μl EDTA tubes (GK150, KABE Labortechnik, Germany). After centrifugation at 3000×g for 15 min, blood supernatant was collected to obtain plasma. Serum was obtained by allowing blood to clot for 1 h at room temperature followed by centrifugation at 3000×g for 15 min. Serum and plasma samples were stored in aliquots at −20° C. until further use. For organ analysis, mice were perfused by intracardiac injection of PBS. Organs were harvested and fixed in 4% PFA at 4° C. for 24 h. Fixed organs were embedded in paraffin.

[0156] Blood and Plasma Analysis LDH, AST, ALT, creatinine, and BUN in plasma were quantified using standardized kits (Biotron Diagnostics, CA, USA) according to the manufacturer's instructions. Mouse G-CSF was quantified with a Quantikine ELISA Kit (R&D, UK). Hemoglobin in EDTA blood was quantified by an automated hemocytometer (Idexx ProCyte Dx Hematology Analyzer, Netherlands). To quantify neutrophils by FACS, whole blood was incubated for 15 min on ice in the presence of 0.2 μg phycoerythrin-labeled anti-mouse CD11b (M1 / 70, Biolegend, Germany) and 0.5 μg Alexa Fluor488 anti-mouse Ly6G (1AB, Biolegend, Germany). Blood was then diluted with 0.5 ml PBS and analyzed on a FACSCalibur (BD Bioscience, USA). Blood smears of EDTA-anticoagulated blood were prepared on polylysine-coated slides (Hecht Assistant, Germany) and, after air drying, incubated for 1 min on dry ice in methanol supplemented with 1 μM SytoxGreen or stained with Giemsa using a commercial kit (In Vitro Diagnostikum, Germany).

[0157] Immunofluorescence staining Paraffin-embedded sections were dewaxed, rehydrated, and subjected to antigen retrieval in citrate buffer (10 mM sodium citrate, 0.1% Tween, pH 6) at 100°C for 25 min. Sections were then blocked with 2.5% normal goat serum (Vector, UK) for 30 min, followed by incubation with a mouse-on-mouse blocking kit (Vector) for 1 h. Sections were then incubated overnight at 4°C in the presence of 2 μg / ml primary antibodies against MPO (A0398, Agilent, Germany), CRAMP (PA-CRLP-100, Innovagen, Sweden), citrullinated histone 3 (ab5103, Abcam, UK) fibrin [clone 59D8], or a complex of histones H2A, H2B, and DNA to detect chromatin (2). Sections were incubated for 1 h in the presence of anti-rabbit and anti-mouse IgG antibodies conjugated with AlexaFluor488 or AlexaFluor555 (all Thermo Scientific). After washing, DNA was labeled with 1 μg / ml DAPI for 2 min. Autofluorescence was quenched by incubation in the presence of Sudan Black (0.1% in 70% ethanol) for 25 min, and sections were mounted with Fluoromount G (Southern Biotech, USA). Images of fluorescently labeled sections were acquired with an inverted fluorescent microscope (Axiovert200M, Zeiss, Germany) or a confocal microscope (TCS SP5, Leica, Germany). Images of NET clots were quantified using software (ImageJ). A vWF or fibrin stained area of ​​the NET clots less than 3% was considered negative.

[0158] immunohistochemistry After antigen retrieval, deparaffinized sections were blocked with 2.5% normal horse serum (Vector) for 30 min. Sections were incubated overnight at 4°C in the presence of 2 μg / ml primary antibody against neutrophil elastase (ab68672, Abcam). After washing, sections were stained using an anti-rabbit IgG-AP kit (ImmPRESS, Vector) according to the manufacturer's instructions. Sections were counterstained with hemalum (Merck, Germany) and mounted with Neo-Mount media (Merck). Images of stained sections were acquired under an inverted microscope (Axiovert200M, Zeiss).

[0159] Generation of NET clots in vitro Purified human neutrophils were cultured at 3 × 10 7 Neutrophils were seeded in tissue culture plates at 1000 cells / ml. Cells were activated with 0.1 μM PMA for 4 h at 37°C, 5% CO2 under humidified and rotating conditions (300 rpm). Unstimulated neutrophils and neutrophils activated with PMA in the presence of 10 U / ml recombinant human DNase1 (Dornase alpha, Roche, Germany) served as controls. NET clots were fixed in 2% PFA overnight at 4°C. Fixed NET clots were embedded in paraffin and sections stained for NETs as described above.

[0160] Statistical evaluation Data are presented as mean ± standard deviation. Statistical analyses were performed using Prism Software (GraphPad, USA) and included Student's t-test, one-way and two-way ANOVA followed by Bonferroni's multiple comparison test, and log-rank test. Results were considered significant at P < 0.05.

[0161] picture Chronic neutrophilia is tolerated in wild-type mice. The resulting images show wild-type mice one week after injection of a CSF3-expressing plasmid (CSF3) or a control plasmid lacking CSF3 (Ctrl). Both animals exhibit normal behavior and no signs of distress.

[0162] Chronic neutrophilia causes distress in mice lacking DNase1 and DNase1l3. This video shows DNase1 / DNase1l3- / - mice co-expressing CSF3 with a control plasmid (CSF3 / Ctrl), DNase1 (CSF3 / D1), or DNase1l3 (CSF3 / D1L3). Mice expressing circulating DNase, DNase1, or DNase1l3 exhibit normal behavior. Mice lacking circulating DNase (CSF3 / Ctrl) show signs of distress (no spontaneous movements, eyes closed, occasional panting). References 1. V. Kumar, AK Abbas, N. Fausto, JC Aster, Acute and chronic inflammation. In Robbins & Cotran Pathologic Basis of Disease. (Elsevier Health Sciences, 2009), chap. 2. 2. V. Brinkmann, U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, DS Weiss, Y. Weinrauch, A. Zychlinsky, Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535 (2004). 3. P. Li, M. Li, MR Lindberg, MJ Kennett, N. Xiong, Y. Wang, PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207, 1853-1862 (2010). 4. V. Thammavongsa, D. M. Missiakas, O. Schneewind, Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death. Science. 342, 863-866 (2013). 5. S. R. Clark, A. C. Ma, S. A. Tavener, B. McDonald, Z. Goodarzi, M. M. Kelly, K. D. Patel, S. Chakrabarti, E. McAvoy, G. D. Sinclair, E. M. Keys, E. Allen-Vercoe, R. Devinney, C. J. Doig, F. H. Green, P. Kubes, Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med. 13, 463-469 (2007). 6. T. A. Fuchs, A. Brill, D. Duerschmied, D. Schatzberg, M. Monestier, D. D. Myers, Jr., S. K. Wrobleski, T. W. Wakefield, J. H. Hartwig, D. D. Wagner, Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. U. S. A. 107, 15880-15885 (2010). 7. A. Warnatsch, M. Ioannou, Q. Wang, V. Papayannopoulos, Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349, 316-320 (2015). 8. B. Engelmann, S. Massberg, Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34-45 (2013). 9. S. K. Jorch, P. Kubes, An emerging role for neutrophil extracellular traps in noninfectious disease. Nat. Med. 23, 279-287 (2017). 10. A. Hakkim, B.G. Furnrohr, K. Amann, B. Laube, U.A. Abed, V. Brinkmann, M. Herrmann, R.E. Voll, A. Zychlinsky. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U. S. A. 107, 9813-9818 (2010). 11. M. Napirei, S. Ludwig, J. Mezrhab, T. Klockl, H. G. Mannherz, Murine serum nucleases--contrasting effects of plasmin and heparin on the activities of DNase1 and DNase1-like 3 (DNase1l3). FEBS J. 276, 1059-1073 (2009). 12. M. Napirei, A. Ricken, D. Eulitz, H. Knoop, H. G. Mannherz, Expression pattern of the deoxyribonuclease 1 gene: lessons from the Dnase1 knockout mouse. Biochem. J. 380, 929-937 (2004). 13. V. Sisirak, B. Sally, V. D’Agati, W. Martinez-Ortiz, Z. B. Ozcakar, J. David, A. Rashidfarrokhi, A. Yeste, C. Panea, A. S. Chida, M. Bogunovic, Ivanov, II, F. J. Quintana, I. Sanz, K. B. Elkon, M. Tekin, F. Yalcinkaya, T. J. Cardozo, R. M. Clancy, J. P. Buyon, B. Reizis, Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell 166, 88-101 (2016). 14. M. Demers, D. S. Krause, D. Schatzberg, K. Martinod, J. R. Voorhees, T. A. Fuchs, D. T. Scadden, D. D. Wagner, Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. U. S. A. 109, 13076-13081 (2012). 15. T. A. Fuchs, U. Abed, C. Goosmann, R. Hurwitz, I. Schulze, V. Wahn, Y. Weinrauch, V. Brinkmann, A. Zychlinsky, Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176, 231-241 (2007). 16. C. Frank, D. Werber, J. P. Cramer, M. Askar, M. Faber, M. an der Heiden, H. Bernard, A. Fruth, R. Prager, A. Spode, M. Wadl, A. Zoufaly, S. Jordan, M. J. Kemper, P. Follin, L. Muller, L. A. King, B. Rosner, U. Buchholz, K. Stark, G. Krause, HUS Investigation Team, Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 365, 1771-1780 (2011). 17. S. A. Braune, D. Wichmann, M. C. von Heinz, A. Nierhaus, H. Becker, T. N. Meyer, G. P. Meyer, M. Muller-Schulz, J. Fricke, A. de Weerth, W. W. Hoepker, J. Fiehler, T. Magnus, C. Gerloff, U. Panzer, R. A. Stahl, K. Wegscheider, S. Kluge. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit. Care. Med. 41, 1702-1710 (2013). 18. M. Jimenez-Alcazar, M. Napirei, R. Panda, E. C. Kohler, J. A. Kremer Hovinga, H. G. Mannherz, S. Peine, T. Renne, B. Lammle, T. A. Fuchs, Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. J. Thromb. Haemost. 13, 732-742 (2015). 19. J. Leffler, Z. Prohaszka, B. Mikes, G. Sinkovits, K. Ciacma, P. Farkas, M. Reti, K. Kelen, G. S. Reusz, A. J. Szabo, M. Martin, A. M. Blom, Decreased neutrophil extracellular trap degradation in shiga toxin-associated haemolytic uraemic syndrome. J. Innate Immun. 9, 12-21 (2017). 20. M. Leppkes, C. Maueroder, S. Hirth, S. Nowecki, C. Gunther, U. Billmeier, S. Paulus, M. Biermann, L. E. Munoz, M. Hoffmann, D. Wildner, A. L. Croxford, A. Waisman, K. Mowen, D. E. Jenne, V. Krenn, J. Mayerle, M. M. Lerch, G. Schett, S. Wirtz, M. F. Neurath, M. Herrmann, C. Becker, Externalized decondensed neutrophil chromatin occludes pancreatic ducts and drives pancreatitis. Nat. Commun. 7, 10973 (2016). 21. C. Schauer, C. Janko, L. E. Munoz, Y. Zhao, D. Kienhofer, B. Frey, M. Lell, B. Manger, J. Rech, E. Naschberger, R. Holmdahl, V. Krenn, T. Harrer, I. Jeremic, R. Bilyy, G. Schett, M. Hoffmann, M. Herrmann, Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20, 511- 517 (2014). 22. V. Kumar, A. K. Abbas, N. Fausto, J. C. Aster, Hemodynamic disorders, thromboembolic disease, and shock. In Robbins & Cotran Pathologic Basis of Disease. (Elsevier Health Sciences, 2009), chap. 4. [ PubMed ] 23. Al-Mayouf M, Sunker A, Abdwani R, Abrawi SA, Almurshedi N, Alhashmi N, Al Sonbul A, Sewairi W, Qari A, Abdallah E, Al-Owain M, Al Motywee S, Al-Rayes H, Hashem M, Khalak L, Al-Jebali, FS Alkuraya. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat. Genet. 43, 1186–1188 (2011). [ PubMed ] 24. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, and Kuroda Y. DNASE1 mutation in humans with systemic lupus erythematosus. Nat. Genet. 28, 313–314 (2001). [ PMC free article ] [ PubMed ] 25. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T, Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 25, 177–181 (2000). [ PubMed ] 26. S. Gupta, MJ Kaplan, The role of neutrophils and NETosis in autoimmune and renal diseases. Nat. Rev. Fr. Nephrol. 12, 402–413 (2016). 27. R. Mizuta, S. Araki, M. Furukawa, Y. Furukawa, S. Ebara, D. Shiokawa, K. Hayashi, S. Tanuma, D. Kitamura, DNase gamma is the effector endonuclease for internucleosomal DNA fragmentation in necrosis. PloS one 8, e80223 (2013). 28. J. Rossaint, J. M. Herter, H. Van Aken, M. Napirei, Y. Doring, C. Weber, O. Soehnlein, A. Zarbock, Synchronized integrin engagement and chemokine activation is crucial in neutrophil extracellular trap-mediated sterile inflammation. Blood 123, 2573-2584 (2014). 29. A. Bradley, K. Anastassiadis, A. Ayadi, JF Battey, C. Bell, MC Birling, J. Bottomley, SD Brown, A. Burger, CJ Bult, W. Bushell, FS Collins, C. Desaintes, B. Doe, A. Economides, JT Eppig, RH Finnell, D. Fralet, D. Fycher. Frendewey, RH Friedel, FG Grosveld, J. Hansen, Y. Herault, G. Hicks, A. Horlein, R. Houghton, M. Hrabe de Angelis, D. Huylebroeck, V. Iyer, PJ de Jong, JA Kadin, C. Kaloff, K. Kennedy, M. Koutsoura, KC, Marschall, J. Lloyd, S. Marcall. C. McKerlie, MP McLeod, H. von Melchner, M. Moore, AO Mujica, A. Nagy, M. Nefedov, LM Nutter, G. Pavlovic, JL Peterson, J. Pollock, R. Ramirez- Solis, DE Rancourt, M. Raspa, JE Remacle, M. Ringwald, B. Rosen, N. Rosenhal, P. Ross, J. Ross. Noppinger, E. Ryder, JZ Schick, F. Schnutgen, P. Schofield, C. Seisenberger, M. Selloum, EM Simpson, WC Skarnes, D. Smedley, WL Stanford, AF Stewart, K. Stone, K. Swan, H. Tadepally, L. Teboul, GP Tocchini, D. Valentini.Valenzuela, AP West, K. Yamamura, Y. Yoshinaga, W. Wurst, The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm. Genome 23, 580-586 (2012).

[0163] Example 2: Development and Use of DNase1L3 and Variants for Therapy Introduction Uncontrolled inflammation leads to excessive pathology (1). Neutrophil extracellular traps (NETs) are DNA filaments decorated with toxic proteins (2). NETs protect against microbial infections, but excessive NET formation causes and exacerbates inflammatory and autoimmune diseases (3). DNase1 (D1), a DNA-degrading enzyme found in blood, has been widely used to render NETs harmless in vitro and in vivo. Indeed, injection of recombinant human D1, an FDA-approved drug for cystic fibrosis (CF) (dornase α), prevents the pathological effects of NETs in various disease models (3), supporting the use of D1 for preventive therapy.

[0164] DNase1-like 3 is a novel drug candidate for NET-related diseases In Example 1, it was revealed that in addition to D1, DNase1-like 3 (D1L3) also degrades NETs. Both enzymes maintain blood and tissue homeostasis during inflammatory responses. Briefly, we showed that NETs are generated in blood vessels under sterile and infected conditions during neutrophilia, a characteristic of inflammatory conditions. D1 and D1L3 cleave NETs and thus prevent the DNA filaments of NETs from aggregating into blood vessel clots. In the absence of D1 and D1L3, NET clots impede blood flow and cause organ damage and death. NET clots are resistant to conventional antithrombotic therapies because they form independently of platelets or fibrin. Thus, we have discovered NET clots as a new mechanism of vascular occlusion and have also discovered D1L3, a novel preventive therapy against NETs (see Example 1).

[0165] D1 and D1L3 belong to the DNase1 protein family along with DNase1-like 1 (D1L1) and DNase1-like 2 (D1L2) (4). D1 and D1L3 are expressed in various species including humans, primates, and rodents. D1 is mainly expressed in the gastrointestinal tract and exocrine glands (5), whereas hematopoietic cells, namely macrophages and dendritic cells, produce D1L3 (6, 7). Both DNases were found at low concentrations in mouse and human serum (Example 1, Figure 14), but the origin of circulating D1 and D1L3 is unclear (7, 8). D1 preferentially cleaves protein-free DNA (e.g., bacterial DNA, plasmid DNA), whereas D1L3 targets chromatin, a complex of DNA and histones commonly found in the nuclei of eukaryotic cells (7, 9, 10). D1 activity is inhibited upon binding to monomeric actin and is highly sensitive to physiological salt concentrations (11-13). Furthermore, D1 is glycosylated at N40 (corresponding to N18 in the mature enzyme without the signal peptide) and N128 (N106), which renders the enzyme resistant to inactivation by serum proteases (9). In contrast, D1L3 lacks the glycosylation and actin-binding sites, resulting in sensitivity to some proteases and resistance to actin, respectively (9).

[0166] D1 was first discovered in gastrointestinal fluids and urine, where it was involved in the digestion of DNA derived from food intake. During the course of this disclosure, it was observed that systemically administered DNase1 (e.g., by intraperitoneal or intravenous injection) has a relatively short half-life in the circulation and is secreted in an enzymatically active form into the urine and, unexpectedly, into the bile. Secretion into the bile opens up the opportunity to target extracellular DNA and / or NETs in the bile duct via systemic DNase1 therapy.

[0167] D1L3 was first described in the context of programmed cell death (14). D1L3 is characterized by two nuclear localization sites (NLS1, NLS2). NLS2 is integrated within the C-terminal tail, is unique to D1L3, and is absent from D1. Both NLSs direct the enzyme to the nucleus during apoptosis (14). Indeed, intracellular D1L3 is required for nuclear DNA fragmentation in apoptotic and necrotic cells in vivo (15). D1L3 requires its C-terminal tail to degrade extracellular DNA, i.e., lipid-encapsulated DNA as found in transfections, and chromatin in apoptotic bodies (7, 10). In transfections, cDNA and cationic lipids form a complex that penetrates the plasma membrane of target cells. D1L3 interferes with transfection, and the C-terminus is important for this function (10). Apoptotic bodies, lipid vesicles filled with chromatin from apoptotic cells, are physiological substrates of D1L3 (7). Here, the C-terminal tail enables D1L3 to penetrate the lipid membrane of apoptotic bodies and disassemble the chromatin packing. Importantly, the C-terminal tail is also required for the disassembly of lipid-free extracellular chromatin by D1L3 (7). The C-terminal tail appears to be important for the function of D1L3 in the extracellular space.

[0168] While hD1 effectively targets NETs in animal models, primarily mice, it has shown limited or no therapeutic efficacy in clinical trials for CF (16) and emphysema (17), respectively. This indicates that wild-type hD1 is not optimal for targeting NETs in patients, as NETs form in CF (18). Hyperactive variants have been generated to circumvent the therapeutic limitations of D1, but their clinical production is difficult (12). Notably, NET-DNA contains histones and is structurally organized like chromatin (2). It was therefore speculated that an optimal treatment for NETs would require efficient disassembly of chromatin.

[0169] Combination therapy of hD1 and tissue plasminogen activator (tPA, alteplase) in patients with emphysema has been described (17). The data are consistent with our hypothesis, since tPA allows D1 to degrade chromatin in vitro (19). US9,642,822, incorporated herein by reference, further discloses combination therapy with tPA and D1 for therapeutic targeting of NETs (20). However, treatment with tPA is generally associated with an increased risk of bleeding due to its fibrinolytic activity (17). D1L3 may offer a safer strategy to target NETs without exposing patients to the risk of bleeding, but therapy with D1L3 protein has not yet been explored.

[0170] Modification of DNase1 and DNase1-like 3 variants by amino acid transposition In this example, we generated modified variants of D1 and D1L3 for therapeutic use against extracellular chromatin (including NETs). To design the variants, we hypothesized that the ability of human D1L3 to degrade chromatin is encoded by individual amino acids and / or amino acid sequences not present in human D1. We further speculated that transferring these individual amino acids and / or amino acid sequences from human D1L3 to D1 would generate hyperactive D1 variants with increased chromatin degrading activity. Similarly, enzymatic properties (e.g., glycosylation) can be transferred from D1 to D1L3. To test our hypothesis, we employed conventional amino acid mutations and developed novel building block (BB) technology to engineer variants of DNases from the DNase1 protein family.

[0171] To produce D1 and D1L3 variants, in vitro expression systems were used [e.g., Chinese Hamster Ovary (CHO) cells, Human Embryonic Kidney (HEK) cells, Pichia pastoris]. Enzyme activity was characterized using the degradation of high molecular weight (HMW)-DNA as a readout (Figure 16). Two types of HMW-DNA were selected: (a) double-stranded DNA (dsDNA) isolated from salmon testes. The degradation of HMW-dsDNA was analyzed by zymography; (b) nuclear chromatin purified from HEK293 cells. To analyze its degradation, HMW-chromatin was first incubated with DNase variants, followed by DNA isolation and visualization by agarose gel electrophoresis (AGE). Chromatin degradation was detected by low molecular weight (LMW)-DNA. In this setting, wild-type human D1 (SEQ ID NO: 1) has approximately 100-fold higher activity in degrading dsDNA compared to wild-type D1L3 (SEQ ID NO: 2), while wild-type D1L3 degrades chromatin approximately 100-fold more efficiently than wild-type D1 (Figure 16). A synergistic effect of D1 and D1L3 was observed in degrading chromatin but not dsDNA. When D1 and D1L3 were mixed in a 10:1 or 1:1 ratio, increased chromatin degradation was observed compared to each D1 or D1L3 alone (Figure 16). Therefore, we screened for D1 and / or D1L3 variants that showed increased chromatin and / or dsDNA degradation activity.

[0172] Selected D1 and D1L3 variants were further tested to degrade intravascular NETs using an in vivo expression system for members of the D1 protein family (see PCT / EP2018 / 051444, which is incorporated by reference in its entirety). This system consists of two components: (a) expression plasmids that allow stable in vivo transfection of hepatocytes in recipient mice with cDNAs for D1, D1L3, and their variants, and (b) a Dnase1 expression vector characterized by a lack of DNase activity in serum. - / - Dnase1l3 - / -Briefly, the cDNA of a candidate DNase is cloned into a hepatic expression vector. The vector is then cotransfected with the cDNA of mouse Csf3, which encodes granulocyte colony-stimulating factor (G-CSF), to express Dnase1. - / - Dnase1l3 - / - Expression of Csf3 induces neutrophilia accompanied by intravascular NET formation, which leads to aggregation of undigested NETs in the blood vessels and the inhibition of Dnase1 expression. - / - Dnase1l3 - / - To identify drug candidates, we screened for D1, D1L3, and their variants that efficiently degrade NETs and prevent morbidity and mortality in this model.

[0173] result Engineering DNase1 variants by conventional amino acid substitutions Our central hypothesis is that the ability of human D1L3 to degrade chromatin is mediated by amino acids not present in D1. Sequence alignment showed that 44% of the amino acids in human D1 and human D1L3 are identical (Figure 17). Only variable amino acids (56% non-shared amino acids) were mutated to generate D1 and DL3 variants.

[0174] D1L3 is a cationic protein with an isoelectric point of 9.35, whereas D1 and other members are more basic proteins. Therefore, we speculate that the cationic nature of D1L3 allows the enzyme to degrade chromatin. Sequence alignment identified 37 arginine or lysine residues in the variable amino acids that are absent in D1 (Figure 17). These amino acid residues are located at amino acid positions 29 (position 9, including the signal peptide), 39 (9), 47 (7), 50 (30), 66 (46), 74 (54), 77 (57), 80 (60), 81 (61), 92 (72), 109 (89), 114 (94), 115 (95), 163 (143), 176 (156), 180 (160), 199 (179), 200 (180) with respect to SEQ ID NO:2. , 203(183), 208(188), 212(192), 226(206), 227(207), 239(219), 250(230), 259(239), 262(242), 280(260), 285(265), 291(271), 292(272), 297(277), 298(278), 299(279), 301(281), 303(283), 304(284).

[0175] The 26 additional arginine or lysine residues in D1L3 correspond to the following amino acid positions in D1 (SEQ ID NO:1): 31 (position 9 including the signal peptide), 41 (19), 49 (40), 52 (30), 68 (46), 76 (54), 79 (57), 81 (59), 92 (70), 109 (87), 114(92), 115(93), 164(142), 177(155), 181(159), 200(178), 201(179), 204(182), 209(187), 213(191), 227(205), 239(217), 250(228), 259(237), 262(240), and 280(260). Additionally, D1L3 features three arginine or lysine residue insertion sites: R80, K226, and a C-terminal tail (after amino acid position 282 of SEQ ID NO:2) that features three arginine and six lysine residues.

[0176] The aim was to transfer arginine and lysine residues that are part of the core body of D1L3 to D1 by introducing the following mutations into wild type D1 (Figure 18): Q31R, A41K, Q49R, S52K, T68R, N76K, Q79R, D80_A81insR, A81R, P92R, D109K, V114K, D115R, A164K, Q177K, G181K, P200K, S201K, S204R, W209R, T213R, A226_T227insK, T227K, A239R, D250K, A259K, G262K, and K280M with respect to SEQ ID NO: 1, thus generating 28 variants of D1.

[0177] In this example, we were able to generate D1 variants containing 23 of the 28 amino acid substitutions. We expressed the cDNAs of these D1 variants in HEK293 cells and analyzed the dsDNA and chromatin decomposition activity in the culture supernatant. We observed that the following amino acid modifications partially increased the chromatin decomposition activity, but no significant difference was observed in dsDNA decomposition (Figure 19): Q31R, Q49K, N76K, Q79R, P92R, D109K, A164K, Q177K, P200K, S201K, S204R, T213R. Interestingly, mouse and rat D1 (SEQ ID NO: 4), which share 79% and 78% of the amino acids of human D1, respectively, feature some of the analyzed amino acid substitutions, including Q31R, Q49K, and Q79K (Figure 20). Analysis of supernatants from HEK293 cells expressing mouse D1 and human D1 demonstrated that mouse D1 had increased chromatin degrading activity compared to human D1 (Figure 21). - / - Dnase1l3 - / -Mice were injected with a mixture of Csf3 and mouse D1 (mDnase1, SEQ ID NO:3), human D1 (hDnase1, SEQ ID NO:1), or an empty control plasmid (Ctrl). Mice receiving the control plasmid died within 7 days, whereas expression of mouse D1 provided complete protection for at least 28 days (Figure 21). Contrary to expectations, expression of human D1 only provided partial protection from death, with more than half of the animals dying within 14 days (Figure 21), indicating that human D1 is less efficient at degrading intravascular NETs than mouse D1. Mutations at Q31R, Q49K, Q79R, and W209R in human D1 were made to generate the mouse-like D1 variant (SEQ ID NO:5). A total of six mutations (Q31R, Q49K, Q79R, Q177K, W209R, G262K) were made to generate the rat-like D1 variant (SEQ ID NO:6). Both rodent-like D1 variants were cloned into hepatocyte expression vectors and co-expressed with Csf3 and Dnase1 - / - Dnase1l3 - / - We delivered D1 to mice. We observed that gene therapy with mouse- and rat-like variants of D1 provided complete protection against NET-mediated vascular occlusion and death (Figure 22). Importantly, in vitro expression of rodent-like human D1 variants showed increased chromatin degradation activity (Figure 22). Collectively, the data indicate that (a) human D1 has limited ability to degrade NETs in vivo; and (b) transfer of multiple cationic amino acids from human D1L3 to human D1 generates a hyperactive variant.

[0178] Several attempts have been made to generate hyperactive variants of D1 (6, 12, 13, 21-29). 184 mutations were found that change 82 of the 282 amino acid residues of wild-type human D1 (Figure 23). Alignment of the amino acid sequences of wild-type human D1 and human D1L3 revealed three gain-of-function mutations of human D1 already present in wild-type human D1L3: Q31R (corresponding to Q9R in D1 without the signal peptide), T227K (T205K), and A136F (A114F) (Figure 23). Mutations Q31R and T227K alter the DNA-binding properties of hD1, causing hyperactivity, whereas A136F confers resistance to inhibition by monomeric actin (21-24, 26, 29).

[0179] A novel D1 variant with the combination of Q31R / T227K / A136F (SEQ ID NO: 7) was designed and its enzymatic activity was compared with that of wild-type D1 (SEQ ID NO: 1) and D1 variants with single mutations at Q31R, T227K, A136F, or compound mutations at Q31R and T227K (SEQ ID NO: 8). The dsDNA and chromatin degradation activities in the culture supernatant of transfected HEK293 cells were characterized. No significant difference in dsDNA degradation activity was observed in D1 variants with single or compound mutations at Q31R and T227K (Figure 24). Interestingly, chromatin was partially and completely degraded in the A136F mutant and the compound mutation at Q31R / T227K / A136F, respectively (Figure 24). Next, the Q31R / T227K / A136F variant of D1 was found to upregulate Dnase1 in neutrophils. - / - Dnase1l3 - / -We tested whether the D1 variant could prevent NET-mediated fatal vascular occlusion in mice. All mice administered the DNase-free control plasmid died, whereas all mice expressing the D1 variant (SEQ ID NO: 7) survived to the end of the experiment without showing any signs of distress (Figure 24). Using purified protein, we observed that the triple amino acid substitution increased chromatin degradation activity by approximately 10-20 fold compared to wild-type D1 without detectable differences in dsDNA degradation activity (Figure 25). Chromatin and NETs derived from the nucleus contain actin (30, 31). The data suggest that chromatin degradation by the D1 variant requires two features present in wild-type D1L3: a cationic amino acid substitution and a mutation that confers actin resistance. To further support this idea, we generated a D1 variant characterized by a combination of the mutations A164K and A136F (SEQ ID NO: 9). Indeed, a strong increase in chromatin degrading activity was observed in the D1 variant carrying both mutations (Figure 26), supporting the hypothesis.

[0180] Development of building block modifications of DNase1 protein family members D1L3 features three sites that contain additional amino acids: Q282 (NH2-SSRAFT NThe C-terminal tail (SEQ ID NO: 33) starting after the SKKSVTLRKKTKSKRS-COOH), as well as two sites within the enzyme at S79 / R80 and K226 (Figure 17). The C-terminal 23 amino acids of D1L3 are linked to the C-terminus of D1 (10, 28). Insertion of an arginine residue at position 226 of DNase1 (A226_T227insK) generated a D1 variant with reduced enzymatic activity to degrade dsDNA, whereas no such effect was observed with the substitution T227K (Figure 27). Thus, inserting K / R residues carries the risk of reducing D1 function. Insertion of charged amino acids may affect the local protein structure. Considering that D1 is a globular enzyme containing one amino acid chain [Figure 28, (27)], it is conceivable that such local changes may render the entire enzyme inactive. Indeed, many non-conservative mutations throughout the D1 amino acid sequence inactivate the enzyme (12, 25, 26). We hypothesized that the risk of inactivation would be reduced by the transfer of local protein structure by transplanting adjacent amino acid sequences, not just single arginine and lysine residues. Conserved amino acids near A226_T227insK that could be used as anchors for insertion were searched for in D1 and D1L3. We identified the D223 / T224 / T225 motif and the conserved T229 of D1 as N- and C-terminal anchors, respectively (Figure 27). Three amino acids in D1(ATP) were replaced in silico with four amino acids, including K226, from D1L3(V[K]KS). Expression of the cDNA of the novel D1 variant (A226_P228delinsVKKS) in HEK239 cells revealed a functionally active enzyme with similar dsDNA degradation activity when compared to wild-type D1 (Figure 27). The data suggest that variable amino acids between the conserved amino acids are exchangeable between D1 and D1L3.

[0181] We have conceptualized a building block technology for transferring enzymatic properties from one member of the D1 protein family to another. The following basic steps are characteristic of this technology (Figure 29): (1) providing a protein-protein alignment of the donor and recipient DNases; (2) identifying variable amino acids or amino acid sequences (building blocks) for transposition; (3) Identify conserved amino acids in donor and recipient DNases that are located upstream and downstream of the building blocks (anchors), respectively; (4) replacing the cDNA encoding the building block between the C-anchor and N-anchor of the recipient DNase with the cDNA between the anchors of the donor DNase; (5) Synthesize cDNA for the chimeric DNase and then transfect a recipient organism (e.g., CHO cells or Dnase1) that preferably lacks both the donor and recipient DNases. - / - Dnase1l3 - / - The gene is expressed in vitro / in vivo in mice.

[0182] Engineering DNase1 variants using building block technology Multi-species alignment of D1 and D1L3 from human, mouse, rat, and chimpanzee (Figure 30) showed that the N- and C-terminal anchors are conserved among these species. These anchor amino acids or amino acid sequences are flanked by 62 building blocks of variable amino acids and amino acid sequences, including the amino acid sequences of D1 (ATP) and D1L3 (VKKS) from the above experiment as building block #49 (Figure 31).

[0183] Transfer of these building blocks from D1L3 to D1 generates D1 variants with the following mutations (Figure 31): 1M_S22delinsMSRELAPLLLLLLSIHSALA, L23_A27delinsMRICS, I30_T32delinsVRS, E35_T36delinsES, M38_I47delinsQEDKNAMDVI, Q49_S52delinsKVIK, Y54C, I56_Q60delinsIILVM, V62_R63delinsIK, S65_K72delins SNNRICPI, L74_N76delinsMEK, Q79_T84delinsRNSRRGIT, H86N, V88_V89delinsVI, E91_P92delinsSR, N96_S97delinsNT, R101Q, L103A, V105L, R107_Q110delinsKEKL, A113_S116delinsVKRS, Y118H, D120H, G122_N128delinsYQDGDA, T130S, N132S, A136_I137delinsFV, R139W, F141_F144d elinsQSPH, E146_E149delinsAVKD, A151V, V153I, A157_A158delinsTT, G160_A162delinsETS, A164K, A168E, Y170_D171delinsVE, L174T, Q177 _K179delinsKHR, G181_L182delinsKA, D184_L187delinsNFIF, R199_Q202delinsPKKA, S204_S205delinsKN, W209R, S211D, T213R, Q215V, P219G , S221_A222delinsQE, A226_P228delinsVKKS, H230N, V238_A239delinsLR, M241_A246delinsQEIVSS, D250K, A252_P254delinsNSV, N256D, A259_A260delinsKA, G262K, S264_L267delinsTEEE, Q269_I271delinsLDV, Y275F, V279_M280delinsFK, and K282delinsQSSRAFTNSKKSVTLRKKTKSKRS.

[0184] When transferring building blocks from D1 to D1L3, the following D1L3 variants are generated (Figure 31): M1_A20delinsMRGMKLLGALLALAALLQGAVS, M21_S25delinsLKIAA, V28_S30delinsIQT, E33_S34delinsET, Q36_I45delinsMSNATLVSYI, K47_K50delinsQILS, C52Y, I54_M58delinsIALVQ, I60_K61delinsVR, S63_I70delins sSHLTAVGK, M72_K74delinsLDN, R77_T84delinsQDAPDT, N86H, V88_I89delinsVV, S91_R92delinsEP, N96_T97delinsNS, Q101R, A103L, L105 V, K107_L110delinsRPDQ, V113_S116delinsAVDS, H118Y, H120D, Y122_A127delinsGCEPCGN, V129T, S131N, 135F_136VdelinsAI, W138R, Q140 _H143delinsFSRF, A145_D148delinsAVKD, V150A, I152A, T156_T157delinsAA, E159_S161delinsGDA, K163A, E167A, V169_E170delinsYD, T 173L, K176_R178delinsQEK, K180_A181delinsGL, N183_F186delinsDVML, P198_A201delinsRPSQ, K203_N204delinsSS, R208W, D210S, R212T , V214Q, G218P, Q220_E221delinsSA, V225_S228delinsATP, N230H, L238_R239delinsVA, Q241_S246delinsMLLRGA, K250D, N252_V254delinsALP, D256N, K259_A260delinsAA, K262G, T264_E267delinsSDQL, L269_V271delinsQAI, F275Y, F279_K280delinsVM, and Q282_S305delinsK.

[0185] We then conceptualized a sequential approach to engineer D1 variants with D1L3 activity, starting with the transfer of multiple adjacent building blocks (clusters), followed by the transfer of individual building blocks, and ending with the transfer of individual amino acids, or combinations of multiple building blocks, into novel chimeric enzymes (Figure 32). This approach reduces the number of D1-D1L3 chimeras in the initial screen.

[0186] To test this method, a total of 19 D1 variants were designed that contained either individual building blocks or clusters of building block clusters derived from D1L3 (Figure 31).These D1 variants are characterized by the following amino acid mutations: 1M_S22delinsMSRELAPLLLLLLSIHSALA, L23_A27delinsMRICS / I30_T32delinsVRS / E35_T36delinsES, M38_I47delinsQEDKNAMDVI, Q49_S52delinsKVIK / Y54C / I56_Q60delinsIILVM, V62_R63delinsIK / S65_K72delinsSNNRICPI / L74_N76delins MEK, Q79_T84delinsRNSRRGIT, H86N / V88_V89delinsVI / E91_P92delinsSR, N96_S97delinsNT / R101Q / L103A / V105L, R107_Q110delinsKEKL / A113_S116delinsVKRS / Y118H / D120H, G122_N128delinsYQDGDA / T130S / N132S, A136_I137delinsFV, R139W / F141_F144delinsQSPH / E146_ E149delinsAVKD / A151V / V153I / A157_A158delinsTT / G160_A162delinsETS / A164K, A168E / Y170_D171delinsVE / L174T, Q177_K179delinsK HR / G181_L182delinsKA / D184_L187delinsNFIF, R199_Q202delinsPKKA / S204_S205delinsKN / W209R / S211D / T213R / Q215V / P219G / S221_A2 22delinsQE, A226_P228delinsVKKS, H230N / V238_A239delinsLR / M241_A246delinsQEIVSS / D250K / A252_P254delinsNSV, N256D / A259_A260delinsKA / G262K / S264_L267delinsTEEE / Q269_I271delinsLDV, and Y275F / V279_M280delinsFK / K282delinsQSSRAFTNSKKSVTLRKKTKSKRS.

[0187] The cDNA was then cloned into an expression vector, and the expression vector was transfected into HEK293 cells. Analysis of cell supernatants showed dsDNA degradation by all samples (Figure 33). Furthermore, transfer of building blocks (BB) 11 (see SEQ ID NO: 10), BB12-14 (see SEQ ID NO: 11), BB26 (see SEQ ID NO: 12), BB41-48 (see SEQ ID NO: 13), and BB49 (see SEQ ID NO: 14) from D1L3 to D1 resulted in enzymes with increased chromatin degradation activity. All these chimeric enzymes showed the same or greater activity in degrading dsDNA substrates compared to wild-type D1. Building blocks 11 (RNSRRGI in SEQ ID NO: 2) and 49 (VKKS in SEQ ID NO: 2) from D1L3 contain R80 / R81 and K227, respectively, which are absent in D1. D1L3-BB cluster 41-48 (PKKAWKNIRLRTDPRFVWLIGDQE in SEQ ID NO: 2) features five additional arginine and lysine residues compared to its D1 counterpart (RPSQWSSIRLWTSPTFQWLIPDSA in SEQ ID NO: 1). These additional cationic amino acids may be responsible for the hyperactivity. D1 building blocks 12-14 and 26 contain amino acid sequences H86-R95 and A136-V138 in SEQ ID NO: 1, which contain the amino acid residues required for binding actin, a D1 inhibitor. Thus, replacement of these amino acid sequences with the respective building blocks from D1L3 that do not interact with actin may generate actin-resistant variants of D1. BBs 11, 14, 26, and 41-19 were combined into one novel D1 variant (SEQ ID NO: 15). It was observed that the combination of these gain-of-function BBs increased chromatin degradation of the D1 variant to the level of wild-type D1L3 (Figure 33). Thus, the BB technique provides a robust method for generating hyperactive D1 variants.

[0188] Engineering DNase1-like 3 variants by building block technology The BB cluster 60-62 of D1L3 contains amino acids from its C-terminal tail (Figure 33). The tail begins after L281 (Figure 34) and contains the amino acid sequence QSSRAFT N It has the sequence SKKSVTLRKKTKSKRS (SEQ ID NO: 33). D1L3 requires a C-terminal tail to degrade DNA in lipid vesicles, including transfection reagents and apoptotic bodies (7, 10, 28). In addition, the C-terminus is required for degradation of lipid-free and cell-free chromatin by D1L3 (7). Both findings are based on D1L3 variants that are missing the amino acids after Q282, and are therefore inactive in degrading these substrates. Wilbert et al. attached the C-terminal extension of D1L3 to the C-terminus of D1, transferring the DNA degradation power in lipid vesicles to D1 (10, 28). Herein, we used the BB technique to transfer the C-terminus from D1L3 to D1 and vice versa. We used the conserved S272 / D273 / H274 motif (Figure 28), located in front of the terminal β-sheet of D1, as the N-anchor, and exchanged the terminal three building blocks between D1 and D1L3 (Figure 34). This approach resulted in the generation of a D1 variant characterized by a C-terminal extension of D1L3 with the mutations Y275F / V279_M280delinsFK / K282delinsQSSRAFTNSKKSVTLRKKTKSKRS (SEQ ID NO: 16) and a truncated DIL3 variant with the mutations F275Y / F279_K280delinsVM / Q282_S305delinsK (SEQ ID NO: 17). Both variants and wild-type enzymes were expressed in HEK293 cells and DNase activity in the supernatants was characterized. Contrary to expectations, it was observed that the D1 variant with the C-terminus of D1L3 did not degrade chromatin, whereas the D1L3 variant lacking the C-terminus of the wild-type enzyme was still able to cleave chromatin (Figure 34). Indeed, an increased chromatin degradation activity was observed with this D1L3 variant. To support this finding, we tested whether a truncated variant of D1L3 exists in vivo and whether its expression reduces neutrophil Dnase1 - / - Dnase1l3 - / -We observed that C-terminal deletion protects against NET-mediated lethality in mice (Figure 34). In conclusion, C-terminal deletion does not inhibit but rather enhances the function of D1L3 to degrade lipid- and cell-free chromatin.

[0189] Serum proteases, especially plasmin, degrade D1L3 but not D1 (9). The susceptibility of D1L3 to protease activity would limit its use in clinical practice. Glycosylated proteins show increased protection against proteases (32). Using software analysis, we were unable to identify known consensus sequences for glycosylation of human and mouse D1L3. As observed both in silico and in vitro, software analysis of human D1 revealed two glycosylation sites (9). We hypothesized that glycosylated variants of D1L3 may extend their half-life in circulation due to improved resistance to serum proteases. Glycosylation sites should have a minimal consensus sequence of NXT / S. D1 contains two known N-glycosylation sites, N40 (without signal peptide, N18) and N128 [(without signal peptide, N106, (9)]). The amino acids of D1 glycosylation sites N40-X-T42 and N128-X-T130 correspond to D38-X-N40 and A127-X-V129 of D1L3. Therefore, the glycosylated version of D1L3 should feature the amino acid mutations D38N, N40T, A127N, and V129T (see SEQ ID NO: 18). To insert these amino acid substitutions, instead of using traditional point mutations, BB technology was used to transfer D1 glycosylation sites N40-X-T42 located in BB4 (MSNATLVSY in SEQ ID NO: 1) and N128-X-T130 located in BB cluster 23-25 ​​(GCEPCGNDTFN in SEQ ID NO: 1) from D1 to D1L3 (Figure 35). In this way, two novel D1L3 variants were generated, characterized by the mutations Q36_I45delinsMSNATLVSYI (SEQ ID NO: 19) and Y122_A127delinsGCEPCGN / V129T / S131N (SEQ ID NO: 20), respectively. These D1L3 variants and the WT enzyme were expressed in HEK293 cells. The supernatants were then analyzed by Western blot using a polyclonal antibody targeting an epitope in the C-terminal tail of the WT enzyme to detect the WT enzyme and the D1L3 variants.As expected, the D1L3 variants showed higher molecular weight bands, likely due to glycosylation, when compared to the WT enzyme (Figure 35). D1L3 variants glycosylated at N40 or N128 retained chromatin degradation activity (Figure 35). In conclusion, the data suggest that the BB technology can be used to transfer glycosylation sites from D1 to D1L3, which may generate D1L3 variants with increased protease resistance and extended half-life in patients.

[0190] Treatment with DNase1-like 3 and its variants Finally, we tested the therapeutic efficacy of D1L3 in vivo. Histological analysis of vascular clots of NETs showed dense aggregates of chromatin (Figure 36A), indicating that histone-free cleavage sites of D1 are rare in vivo. Therefore, we hypothesized that acute therapy with wild-type D1L3 would be more effective in degrading intravascular NETs compared to wild-type D1. To test our hypothesis, we used Dnase1 - / - Dnase1l3 - / - Csf3 was expressed in Csf3-deficient mice to induce vascular clotting of NETs. Importantly, mice with vascular occlusion due to NETs develop hematuria and hypothermia prior to the outcome, allowing for non-invasive detection. Thus, the animal model allows for the identification, and therefore selection, of mice that have formed NETs to test drug candidates for acute therapy against NETs (Figure 36B). Herein, we report the use of purified wild-type human D1 (dornase alpha; SEQ ID NO: 1), wild-type human D1L3 (SEQ ID NO: 2), and a hyperactive D1L3 variant [D1L3 V (SEQ ID NO: 17)] was tested. - / - Dnase1l3 - / -D1L3-deficient mice were injected with NETs. After 72 hours, the first individual animals started to develop hypothermia and hematuria. A drop in body temperature of 4°C or more and the presence of red urine were used as selection criteria. Mice that developed these phenotypes were randomized into different treatment groups. Animals were intravenously injected with a single dose of 1 mg / kg D1, D1L3, or vehicle via the tail vein. After 30 minutes, animals were euthanized and biological samples (blood and organs) were collected. Quantification of NET clots in the pulmonary vasculature showed that NETs occluded blood vessels in mice receiving vehicle or D1 therapy (Figure 36D). Importantly, D1L3 and D1L3 V Mice injected with D1L3 showed little or no NET clots (Figure 36D). In patients, circulating DNA had the size of mononucleosomal DNA [180 base pairs, (33)], indicating that it is a degradation product of high molecular weight DNA of chromatin. Circulating DNA is commonly used as a surrogate marker for intravascular NET formation, but can also originate from damaged and necrotic tissues (34). DNA was quantified in serum using fluorescent DNA probes. D1L3 and D1L3 V It was observed that injection of D1L3, but not D1 or vehicle, caused a strong increase in circulating DNA levels (Figure 36E). Isolation and visualization of circulating DNA showed multimeric 180 base pair fragments, indicating the presence of mono- and oligonucleosomes in the serum of mice receiving D1L3 therapy (Figure 36F). V Mice administered D1L3 showed only mono- and dinucleosomes. V The hyperactivity of D1L3 is confirmed. DNA isolation from serum of mice receiving D1 therapy showed faint DNA smears of various sizes, whereas no DNA could be isolated from serum of mice injected with vehicle (Figure 36F). Thus, D1L3 may be used not only for prevention but also for acute treatment of NET-related diseases.

[0191] D1L3 in models of ischemia-reperfusion injury VThe therapeutic application of DNase1L3 was further investigated (Figure 37A). Briefly, one testis from male wild-type rats was subjected to testicular torsion as previously described by the inventors (35). This procedure induces ischemic tissue damage. After randomization and detorsion of the testis, rats were treated with vehicle DNase alpha (D1, 1 mg / kg) or purified DNase1L3 variant (SEQ ID NO: 17, D1L3 V D1L3 (1 mg / kg) was injected three times daily. After 7 days, the ischemic and intact testes were harvested. V Treatment with D1L3, but not with saline or D1, significantly reduced testicular atrophy (Figure 37B). V Treatment with D1L3, but not with saline or D1, substantially reduced tissue damage and the majority of animals showed no signs of injury (Figure 37C). Collectively, the data identify D1L3 as a potent therapy against ischemia-reperfusion injury.

[0192] Drug development of DNase1 variants, DNase1-like 3 and variants Nearly 70% of all protein therapeutics are produced using Chinese hamster ovary (CHO) (36). In fact, wild-type DNase1 (dornase α) is produced in CHO cells. Despite the great advantages, cell line development and large-scale production in CHO remains a major challenge due to a significant degree of variability and the lack of reliable methods to predict or model cell growth characteristics (36). Importantly, CHO cells have not been able to stably produce hyperactive variants of D1, thus hindering their clinical production (12). The manufacturing characteristics of D1L3 are unknown. Therefore, we developed stable CHO cell lines producing wild-type D1 (SEQ ID NO:1), hyperactive D1 variant (SEQ ID NO:7), wild-type D1L3 (SEQ ID NO:2), and hyperactive D1L3 variant (SEQ ID NO:17). When the cell lines were cultured in bioreactors, stable protein expression was observed for wild-type D1 and D1 variants, with the latter at significantly increased expression levels (Figure 38), indicating the feasibility of producing hyperactive D1 variants in CHO. Contrary to expectations, only negligible protein levels were observed for wild-type D1L3 and D1L3 variants (Figure 38), pointing to a major challenge for clinical manufacturing of D1L3 and its variants.

[0193] High cell density in large-scale bioreactors causes cells to compete for resources and undergo cellular stress, leading to increased cell death called apoptosis, a cell death program used by multicellular organisms, including mammals (37). D1L3 targets DNA in apoptotic bodies (7). We speculated that the low levels of D1L3 were due to removal of the enzyme by these apoptotic vesicles. To overcome these limitations, we tested the production of D1, D1L3, and their variants using the microbial expression system Pichia pastoris, an established, FDA-approved, and generally recognized as safe (GRAS) organism with protein secretion capabilities (38, 39). An important limitation of this approach is that proteins produced by P. pastoris are often hyperglycosylated, which can lead to enhanced immunogenicity (40). The composition of D1L3 and its variants is unglycosylated and optimal for expression in P. pastoris. The glycosylation sites of D1 and its variants were mutated at N40S and N128S, respectively, to generate deglycosylated proteins (SEQ ID NO: 21, 23). Protein expression in P. pastoris is usually achieved by linking the protein of interest to secretory signal peptides of various origins. This step was omitted to avoid the generation of immunogenic chimeric proteins. We speculated that the native signal peptides of D1 and / or D1L3 are recognized by P. pastoris. After codon optimization, we expressed the cDNAs (SEQ ID NO: 22, 24-26) in P. pastoris. Expression of D1 and D1 variants was achieved (not shown). Importantly, this approach further enabled the expression of D1L3 and D1L3 variants, the latter of which showed increased expression levels (Figure 38). The proteins were purified, and the increased activity of D1L3 was confirmed (Figure 38). In conclusion, the data suggest that non-mammalian expression systems such as P. pastoris can be used for clinical manufacture of D1L3 and its variants.

[0194] Consideration The two DNA-degrading enzymes are widely used therapeutically in experimental models and patients. Streptodornase, a DNase secreted by Streptococcus species, has been tested in disease models of skin allografts, bladder clots, wound debridement, and meningitis. DNase1 (including pancreatic DNase1) has been used therapeutically in experimental models of cancer, cystic fibrosis, lupus, thrombosis, stroke, sepsis, lung injury, atherosclerosis, viral infections, sickle cell disease, myocardial infarction, ear infections, wound healing, liver injury, endocarditis, liver infections, pancreatitis, primary graft dysfunction, limb ischemia-reperfusion injury, kidney injury, blood clotting, asthma, alum-induced inflammation, and hepatic and renal injury. Streptodornase has also been used to treat patients with pleural effusion, hemothorax, intrabiliary clots, post-pneumonic anemia, ulcers, ENT conditions, oral infections, minor wounds, sinusitis, post-operative rhinoplasty, infertility, bladder catheters, wound irrigation, and skin reaction tests. Importantly, DNase1 has been therapeutically tested in patients with pneumococcal meningitis, gout, leg ulcers, cystic fibrosis, Kartegener's syndrome, asthma, lobar atelectasis, chronic bronchitis, bronchiectasis, lupus, primary ciliary dyskinesia, bronchiolitis, empyema, pleural infections, cancer, dry eye disease, lower respiratory tract infections, chronic hematoma, Alzheimer's disease, and obstructive pulmonary disease. In this example, D1L3, its variants, and D1 variants were identified as novel candidates for DNase therapy (Figure 39).

[0195] method Detection of chromatin degrading activity To measure chromatin degradation activity, samples were mixed with nuclei isolated from HEK293 (1,500,000–3,000,000 per reaction), 20 mM Tris-HCl pH 7.4, 2 mM MgCl2, 2 mM CaCl2, 50 mM NaCl and protease inhibitors. After 1 h incubation at 37 °C, the samples were heated to 65 °C for 10 min. DNA isolation was performed using the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer's protocol. The eluate was then loaded onto an agarose gel and DNA fragments were separated by gel electrophoresis. The DNA fluorescence of the gel was recorded with a fluorescence scanner.

[0196] Further methods are described in Example 1. References 1.V. Kumar, AK Abbas, N. Fausto, JC Aster, in Robbins & Cotran Pathologic Basis of Disease. (Elsevier Health Sciences, 2009), chap. 2. 2.V. Brinkmann et al., Neutrophil extracellular traps kill bacteria. Science (New York, NY) 303, 1532-1535 (2004). 3.TA Fuchs, A. Hakkim, CF Urban, in Inflammation: Fundamental Mechanisms, K. Ley, Ed. (World Scientific, 2018), chap. 6. 4.D. Shiokawa, S. Tanuma, Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis. Biochemistry 40, 143-152 (2001). 5.M. Napirei, A. Ricken, D. Eulitz, H. Knoop, H. G. Mannherz, Expression pattern of the deoxyribonuclease 1 gene: lessons from the Dnase1 knockout mouse. Biochem J 380, 929-937 (2004). 6.W. F. Baron et al., Cloning and characterization of an actin-resistant DNase I-like endonuclease secreted by macrophages. Gene 215, 291-301 (1998). 7.V. Sisirak et al., Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell 166, 88-101 (2016). 8.M. Jimenez-Alcazar et al., Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. Journal of thrombosis and haemostasis : JTH 13, 732-742 (2015). 9.M. Napirei, S. Ludwig, J. Mezrhab, T. Klockl, H. G. Mannherz, Murine serum nucleases--contrasting effects of plasmin and heparin on the activities of DNase1 and DNase1-like 3 (DNase1l3). FEBS J 276, 1059-1073 (2009). 10.A. Wilber, M. Lu, M. C. Schneider, Deoxyribonuclease I-like III is an inducible macrophage barrier to liposomal transfection. Mol Ther 6, 35-42 (2002). 11.W. Kabsch, H. G. Mannherz, D. Suck, E. F. Pai, K. C. Holmes, Atomic structure of the actin:DNase I complex. Nature 347, 37-44 (1990). 12.C. Lam et al., Taming hyperactive hDNase I: Stable inducible expression of a hyperactive salt- and actin-resistant variant of human deoxyribonuclease I in CHO cells. Biotechnol Prog 33, 523-533 (2017). 13.C. Q. Pan et al., Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus. J Biol Chem 273, 18374-18381 (1998). 14.D. Shiokawa, Y. Shika, S. Tanuma, Identification of two functional nuclear localization signals in DNase gamma and their roles in its apoptotic DNase activity. Biochem J 376, 377-381 (2003). 15.R. Mizuta et al., DNase gamma is the effector endonuclease for internucleosomal DNA fragmentation in necrosis. PLoS One 8, e80223 (2013). 16.H. J. Fuchs et al., Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 331, 637-642 (1994). 17.N. M. Rahman et al., Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 365, 518-526 (2011). 18.V. Papayannopoulos, D. Staab, A. Zychlinsky, Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy. PLoS One 6, e28526 (2011). 19.M. Napirei, S. Wulf, H. G. Mannherz, Chromatin breakdown during necrosis by serum Dnase1 and the plasminogen system. Arthritis Rheum 50, 1873-1883 (2004). 20.D. D. Wagner et al. (Children’s Medical Center Corporation, Boston, MA (US), United States, 2017), vol. US 9,642,822 B2. 21.R. A. Lazarus, C. Q. Pan. (Genentech Inc., United States, 2002), vol. US 6,391,607 B1. 22.R. A. Lazarus, C. Q. Pan. (Genentech Inc., 2008), vol. US 7,407,785 B2. 23.R. A. Lazarus, S. Shak, J. S. Ulmer. (Genentech Inc., 2001), vol. US 2001 / 0041360 A1. 24.C. Q. Pan, R. A. Lazarus, Hyperactivity of human DNase I variants. Dependence on the number of positively charged residues and concentration, length, and environment of DNA. J Biol Chem 273, 11701-11708 (1998). 25.C. Q. Pan, D. V. Sinicropi, R. A. Lazarus, Engineered properties and assays for human DNase I mutants. Methods Mol Biol 160, 309-321 (2001). 26.C. Q. Pan, J. S. Ulmer, A. Herzka, R. A. Lazarus, Mutational analysis of human DNase I at the DNA binding interface: implications for DNA recognition, catalysis, and metal ion dependence. Protein Sci 7, 628-636 (1998). 27.G. Parsiegla, C. Noguere, L. Santell, R. A. Lazarus, Y. Bourne, The structure of human DNase I bound to magnesium and phosphate ions points to a catalytic mechanism common to members of the DNase I-like superfamily. Biochemistry 51, 10250-10258 (2012). 28.M. C. Schneider, A. Wilber. (United States, 2004), vol. US 2004 / 0138156. 29.J. S. Ulmer et al., Engineering actin-resistant human DNase I for treatment of cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America 93, 8225-8229 (1996). 30.B. T. Bettinger, D. M. Gilbert, D. C. Amberg, Actin up in the nucleus. Nat Rev Mol Cell Biol 5, 410-415 (2004). 31.C. F. Urban et al., Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 5, e1000639 (2009). 32.D. Russell, N. J. Oldham, B. G. Davis, Site-selective chemical protein glycosylation protects from autolysis and proteolytic degradation. Carbohydr Res 344, 1508-1514 (2009). 33.T. A. Fuchs, J. A. Kremer Hovinga, D. Schatzberg, D. D. Wagner, B. Lammle, Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 120, 1157-1164 (2012). 34.M. Jimenez-Alcazar, N. Kim, T. A. Fuchs, Circulating Extracellular DNA: Cause or Consequence of Thrombosis? Semin Thromb Hemost 43, 553-561 (2017). 35.M. Boettcher et al., Degradation of Extracellular DNA by DNase1 Significantly Reduces Testicular Damage After Testicular Torsion in Rats. Urology 109, 223 e221-223 e227 (2017). 36. A. D. Bandaranayake, S. C. Almo, Recent advances in mammalian protein production. FEBS letters 588, 253-260 (2014). 37. Y. K. Han, Y. G. Kim, J. Y. Kim, G. M. Lee, Hyperosmotic stress induces autophagy and apoptosis in recombinant Chinese hamster ovary cell culture. Biotechnology and bioengineering 105, 1187-1192 (2010). 38. J. L. Cereghino, J. M. Cregg, Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS microbiology reviews 24, 45-66 (2000). 39. M. Ahmad, M. Hirz, H. Pichler, H. Schwab, Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Applied microbiology and biotechnology 98, 5301-5317 (2014). 40. R. Daly, M. T. Hearn, Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. Journal of molecular recognition : JMR 18, 119-138 (2005). Sequence of wild-type DNases SEQ ID NO: 1 Human DNase1 (P24855), amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000001.tif38170Sequence number 2 Human DNase1L3 (Q13609), amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000002.tif47170 SEQ ID NO:3 Mouse DNase1 (P49183): Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000003.tif39170 SEQ ID NO:4 Rat DNase1 (P21704), amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000004.tif35170 SEQ ID NO:34 Mouse DNase1L3 (O55070): Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000005.tif48170 SEQ ID NO:35 Rat DNase1L3 (O89107): Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000006.tif44170 SEQ ID NO:36 Chimpanzee DNase1 (H2QAH1): Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000007.tif39170 SEQ ID NO:37 Chimpanzee DNase1L3 (H2QMU7): Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000008.tif45170 SEQ ID NO:38 Human DNase1-like 1 (NM_006730 (underlined)): Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000009.tif47170 SEQ ID NO:39 Human DNase1-like 2 (NM_001374 (underlined)): Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000010.tif45170 C-terminal tail of human DNase1L3 SEQ ID NO:33 Amino acid sequence: SSRAFTNSKKSVTLRKKTKSKRS Sequence of DNase1 variants SEQ ID NO:5 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000011.tif39170 SEQ ID NO:6 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000012.tif39170 SEQ ID NO:7 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000013.tif37170 SEQ ID NO:8 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000014.tif42170 SEQ ID NO:9 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000015.tif37170 SEQ ID NO:10 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000016.tif39170 SEQ ID NO:11 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000017.tif39170 SEQ ID NO:12 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000018.tif40170 SEQ ID NO:13 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000019.tif39170 SEQ ID NO:14 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000020.tif39170 SEQ ID NO:15 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000021.tif39170 SEQ ID NO:16 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000022.tif53170 Sequence of DNase1L3 variants SEQ ID NO:17 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000023.tif37170 SEQ ID NO:18 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000024.tif46170 SEQ ID NO:19 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000025.tif47170 SEQ ID NO:20 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000026.tif47170Sequences used in Pichia pastoris SEQ ID NO:21 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000027.tif40170 SEQ ID NO:22 Codon-optimized cDNA of SEQ ID NO: 21 (start codon (bold, underlined), signal peptide (underlined)): TIFF0007577314000028.tif122170 SEQ ID NO:23 Amino acid sequence (signal peptide (underlined); mature protein): TIFF0007577314000029.tif39170 SEQ ID NO:24 Codon-optimized cDNA of SEQ ID NO: 23 (start codon (bold, underlined), signal peptide (underlined)): TIFF0007577314000030.tif113170 SEQ ID NO:25 Codon-optimized cDNA of SEQ ID NO:2 (start codon (bold, underlined), signal peptide (underlined)): TIFF0007577314000031.tif106170 SEQ ID NO:26 Codon-optimized cDNA of SEQ ID NO: 17 (start codon (bold, underlined), signal peptide (underlined)): TIFF0007577314000032.tif119170

Claims

1. A pharmaceutical composition for treating a subject in need of extracellular chromatin degradation, comprising a DNase 1-like 3 (D1L3) variant comprising an amino acid sequence at least 90% identical to the enzyme defined by SEQ ID NO:2 and truncated by at least 5 amino acid residues of the C-terminal tail defined by SEQ ID NO:33, wherein the D1L3 variant has increased chromatin degradation activity compared to the wild-type D1L3 of SEQ ID NO:

2.

2. 2. The pharmaceutical composition of claim 1, wherein the variant is fused or conjugated to a protein or carrier moiety, optionally the carrier moiety being albumin.

3. The pharmaceutical composition of claim 1 , wherein the variant comprises a deletion of the entire C-terminal tail defined by SEQ ID NO:

33.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the variant comprises an amino acid sequence that is at least 95% identical to the enzyme defined in SEQ ID NO:

2.

5. A pharmaceutical composition for treating a subject in need of extracellular chromatin degradation comprising an isolated polynucleotide encoding a DNase 1-like 3 (D1L3) variant comprising an amino acid sequence at least 90% identical to the enzyme defined in SEQ ID NO:2 and having at least 5 amino acid residues truncated in the C-terminal tail defined in SEQ ID NO:33, wherein the D1L3 variant has increased chromatin degradation activity compared to the wild-type D1L3 of SEQ ID NO:

2.

6. 6. The pharmaceutical composition of claim 5, wherein the variant is fused or conjugated to a protein or carrier moiety, optionally the carrier moiety being albumin.

7. 7. The pharmaceutical composition of claim 5 or 6, wherein the variant comprises a deletion of the entire C-terminal tail defined by SEQ ID NO:

33.

8. The pharmaceutical composition according to any one of claims 5 to 7, wherein the variant comprises an amino acid sequence that is at least 95% identical to the enzyme defined in SEQ ID NO:

2.

9. The pharmaceutical composition according to any one of claims 5 to 8, wherein the polynucleotide is contained in a vector.

10. The pharmaceutical composition of claim 9 , wherein the vector is contained in a host cell.

11. The pharmaceutical composition according to any one of claims 1 to 10, further comprising a pharma- ceutically acceptable carrier.

12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pharmaceutical composition is formulated for parenteral administration.

13. The object is Have a chronic or acute inflammatory disorder; have an acute or chronic infection; or having or at risk of having vascular occlusion involving NETs; A pharmaceutical composition according to any one of claims 1 to 12.

14. The subject is diagnosed with: chronic neutrophilia, neutrophil aggregation or leukostasis; thrombosis or vascular occlusion; ischemia-reperfusion injury selected from intestinal volvulus, testicular torsion, limb ischemia-reperfusion, vital organ ischemia-reperfusion, and organ transplant; surgical or traumatic tissue injury, acute or chronic inflammatory response or disease; autoimmune disease selected from systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis, vasculitis, and systemic sclerosis; cardiovascular disease selected from myocardial infarction, stroke, atherosclerosis, and venous thromboembolism, including thrombolytic therapy; metabolic disease; systemic inflammatory response syndrome (SIRS), sepsis, septic shock, disseminated The pharmaceutical composition according to any one of claims 1 to 13, wherein the patient has a systemic inflammation selected from among disseminated intravascular coagulation (DIC) and thrombotic microangiopathy (TMA); an inflammatory disease of the airways selected from among cystic fibrosis, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), smoking-induced lung injury, transfusion-related acute lung injury (TRALI), acute respiratory distress syndrome (ARDS), asthma, atelectasis, bronchitis, and empyema; a renal inflammatory disease selected from acute and chronic kidney diseases including acute kidney injury (AKI) and chronic kidney disease (CKD); an inflammatory disease associated with transplanted tissue; or a cancer selected from among leukemia, tumor metastasis, and solid tumors.

15. The pharmaceutical composition of any of claims 1 to 11, wherein the subject has or is at risk of having a ductal obstruction in the ductal system.

16. 16. The pharmaceutical composition of any of claims 1 to 15, wherein the subject is suffering from a disease or condition characterised by a deficiency in D1L3, or a deficiency in D1 and D1L3, optionally the subject has a mutation in the Dnase1 and / or Dnase1l3 gene, optionally the subject has an acquired inhibitor of D1 and / or D1L3, and optionally the subject has an autoimmune or inflammatory disease.

17. The pharmaceutical composition of any of claims 1 to 16, wherein the subject has systemic lupus erythematosus (SLE).

18. The pharmaceutical composition according to any one of claims 1 to 16, wherein the subject has a viral infection.

19. The pharmaceutical composition of any one of claims 1 to 15, wherein the subject has acute respiratory distress syndrome (ARDS) or acute lung injury (ALI).

20. The pharmaceutical composition according to any one of claims 1 to 15, wherein the subject has a cancer selected from the group consisting of leukemia and solid tumors.

21. The subject is selected from the group consisting of thrombosis, stroke, sepsis, lung injury, atherosclerosis, viral infection, sickle cell disease, myocardial infarction, ear infection, wound healing, liver injury, endocarditis, liver infection, pancreatitis, primary graft dysfunction, limb ischemia reperfusion injury, kidney injury, blood clotting, alum-induced inflammation, hepatorenal injury, pleural effusion, hemothorax, intrabiliary clot, post-pneumonia anemia, ulcers, ear, nose and throat conditions, oral infections, minor injuries, sinusitis, post-operative rhinoplasty , infertility, bladder catheter, wound irrigation, skin reaction test, pneumococcal meningitis, gout, lower limb ulcer, cystic fibrosis, Kartegener's syndrome, asthma, lobar atelectasis, chronic bronchitis, bronchiectasis, lupus, primary ciliary dyskinesia, bronchiolitis, empyema, pleural infection, cancer, dry eye disease, lower respiratory tract infection, chronic hematoma, Alzheimer's disease, or obstructive pulmonary disease.

22. 22. The pharmaceutical composition of claim 14 or 21, wherein the subject is suffering from or at risk of having a stroke.

23. 22. The pharmaceutical composition of claim 21, wherein the subject has or is at risk for dry eye disease.